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Atherosclerosis
General introduction
Cardiovascular disease is the most common cause of morbidity and mortality in 
the Western world.1 In developing countries, a transition is taking place towards
urbanization, industrialization, and more Western life styles which will inevitably
lead to a further increase in cardiovascular disease.2,3 The term cardiovascular 
disease includes clinical manifestations of arterial atherosclerosis, such as peripheral
artery disease, cerebrovascular disease, and coronary artery disease. Well-established
risk factors are dyslipidemia, smoking, diabetes mellitus, hypertension, and abdomi-
nal obesity.4 The pathogenesis of atherosclerosis is considered to be multifactorial,
i.e. caused by a combination of genetic predisposition, lifestyle, and environmental
influences.
Pathogenesis of atherosclerosis
For decades, atherosclerosis has been considered a disease of the arteries caused 
by excessive cholesterol storage. In recent years, advances have been made in our
understanding of the pathophysiological mechanisms that lead to atherosclerosis.
Accumulating evidence suggests that the atherosclerotic disease process in the
arterial wall is the consequence of an intricate interplay between numerous 
related and interacting processes and pathways. The endothelial cells that line the
luminal vascular surface play a pivotal role in maintaining the hemostatic balance.
Ross5,6 proposed a model for the pathogenesis of atherosclerosis that was based 
on the response to injury. Injury to the endothelium is an initiating event in athero-
genesis. It triggers the immune system and the coagulation cascade. Endothelial
cells (EC) produce adhesion molecules (VCAM-1 and ICAM-1) and monocyte-
chemotactic-protein-1 (MCP-1), but also prostaglandin-2, nitric oxide (NO), endothe-
lium-derived relaxing factor (EDRF) and thromboxane A2, all influencing vascular
tone, vascular structure and hemostatic properties of the vessel wall.7 The main
determinant of the anti-atherosclerotic properties of the endothelium, endothelium-
derived NO, is intimately involved in the regulation of vascular tone, vascular growth
and coagulation.8-11
The immunological and inflammatory response is generated by the adhesion of
leukocytes to the endothelium.8 Adhered monocytes synthesize and express tissue
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Atherosclerosis
factor, factor VII, high-affinity binding sites for fibrinogen and also produce many
cytokines including IL-6 and TNF-α. The adhesion of platelets to leukocytes is media-
ted by P-selectin expressed on the platelet plasma membrane.12 Adhesion is 
followed by migration to the sub-endothelium and differentiation, in appearance of
oxidized low-density lipoprotein (ox-LDL), into macrophages. Monocyte derived
macrophages and T-lymphocytes are observed in all stages of atherosclerosis.13,14
Early lesions, the so-called fatty streaks, consist of isolated groups of macrophages
containing lipid droplets (macrophage foam cells).13 The genesis of fatty streaks 
consists of transport of cholesterol into the arterial wall, reverse cholesterol trans-
port from peripheral tissues back to the liver, oxidation of constituents of these 
lipoproteins which may trigger an inflammatory response in the vessel wall, pro-
inflammatory mediators which may enhance lipoprotein uptake by macrophages
and enhance their pro-inflammatory response, protection against oxidation and
inflammation by enzymes on some lipoproteins, and pro-oxidative enzymes which
may interfere with the reverse cholesterol transport. The arterial inflammatory reac-
tion stimulates proliferation and migration of vascular smooth muscle cells (VSMC)
Figure. Pathophysiology of atherosclerosis
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that become intermixed with the area of inflammation. A continuous inflammation
and the formation of fibrous tissue lead to further progression and enlargement of
the lesion. In advanced atherosclerotic lesions a fibrous cap overlies an atheroma-
tous core of lipid, necrotic and sometimes calcified material. It is now generally
accepted that rupture of a vulnerable plaque due to infiltration of inflammatory
cells rather than gradual occlusion of an artery, often leads to an acute clinical 
manifestation of atherosclerosis.15 In the presence of one or more risk factors for athero-
genesis (e.g. dyslipidemia, diabetes mellitus, hypertension), early atherosclerotic lesions
may progress and become mature atherosclerotic plaques. The dangerous and
potentially lethal consequences of atherosclerosis are the destabilization of the
advanced plaque, which may culminate in sudden disruption of the plaque surface,
triggering luminal thrombosis. Plaque disruption with superimposed thrombosis is
the most frequent pathoanatomic substrate underlying the acute coronary syndro-
mes (unstable angina, acute myocardial infarction, and sudden coronary death) and
ischemic stroke.16
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Vasoreactivity
Endothelium 
Cardiovascular risk factors such as hypercholesterolemia, hypertension, diabetes and
smoking may impair the normal protective function of the vascular endothelium. The
endothelium is a selective barrier located between the circulating blood and the
VSMC. It is a larg organ, which covers an area of approximately 1 to 7m2 and weighs
about 1kg in an adult human. The endothelium is metabolically active and functional
integrity of the endothelium is important for the maintenance of blood-flow and the
prevention of atherothrombosis. The endothelium releases factors that are involved in
both pro-atherogenic actions such as vasoconstriction, platelet aggregation, leukocyte
adhesion, thrombogenesis, and VSMC proliferation and anti-atherogenic actions such
as vasorelaxation, fibrinolysis, inhibition of platelet aggregation, and inhibition of
leukocyte adhesion, in a balanced way.1-3 In endothelial dysfunction, a disturbance of
this balance between vasoconstricting, prothrombotic, and proliferative factors
(endothelin-1 (ET-1), reactive oxygen species (ROS), angiotensin-II (Ang-II), thromboxane
A2) and vasodilating, anti-thrombotic, and anti-proliferative factors (NO, endothelium-
derived hyperpolarizing factor, natriuretic peptides, and prostacyclin) occurs, which
results in a pro-atherogenic state.4-9 Endothelial function in humans can be measured
in several ways and serves as a tool for early assessment of cardiovascular risk.
Old fashioned measurements of endothelial function
Several endothelial factors have been put forward as tools for assessing endothelial
function. Endothelial function can be estimated by measuring endothelium-derived
proteins such as von Willebrand factor (vWF), plasma ET-1, modulators of coagula-
tion such as plasma thrombomodulin, plasma tissue plasminogen activator (tPA),
and plasminogen activator inhibitor-1 (PAI-1), as well as adhesion molecules such as
VCAM-1 and ICAM-1.10,11 It should be recognized that these endothelium-derived 
proteins can be affected by a variety of stimuli. Non-specific confounders limit the
use of vWF and P-selectin as specific markers of endothelial function in subjects
with acute-phase reactions and platelet activation.12 Although some of these mar-
kers are elevated in cardiovascular diseases and correlations with cardiovascular
diseases or other risk factors have been shown, they lack sensitivity and/or specificity
for assessment of endothelial function in individual patients.13
Introduction
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Nitric oxide
NO is an important endothelium-derived vasodilating factor.14,15 Besides vasodilation,
NO also inhibits adhesion of leukocytes to the endothelium,16 inhibits platelet-vessel
wall interaction,17,18 decreases endothelial permeability,(19) inhibits VSMC prolifera-
tion and migration,20,21 and reduces vessel tone.22 NO was originally described as
endothelium-derived relaxing factor (EDRF).14 NO is synthesized by NO synthase from
L-arginine.23 The conversion from L-arginine to NO can be inhibited by false substrates
for the NO synthase, e.g. by NG-monomethyl-L-arginine (L-NMMA) or NG-nitro-L-arginine
methyl ester (L-NAME).24 Two subtypes of NO-synthases may be distinguished: a con-
stitutive NO is produced by endothelial cells in response to shear stress by the enzyme
endothelial nitric oxide synthase (eNOS), and an inducible isoform (iNOS) as an impor-
tant inflammatory mediator released by macrophages in response to immunological
stimuli.25 Different co-factors are necessary, such as calcium, calmodulin, heme,
tetrahydrobiopterin (BH4), and reduced nicotamine adenine dinucleotide phosphate
(NADPH).26,27 NO rapidly diffuses to either the blood or abluminally to the underlying
VSMC, where it activates the enzyme guanylate cyclase, inducing an accumulation of
cyclic guanosine monophosphate (cGMP) in the VSMC.28 NO not only stimulates cGMP
but is also rapidly inactivated by binding to heme and by reacting with oxygen 
radicals, yielding methemoglobin, nitrate and peroxynitrite.29 Therefore, NO-bio-
availability is the result of the balance between NO-synthesis and breakdown. Under
normal, healthy conditions, low concentrations of NO and nanomolar concentrations
of peroxynitrite are produced, both resulting in vasodilative and/or anti-atherosclerotic
actions. However, in pathophysiological situations like diabetes,29-33 hypercholestero-
lemia,34-38 and smoking,39-42 NO-availability in vivo is impaired as a result of reduced
NO-formation, enhanced NO-breakdown or both. Reduced NO-formation can be the
result of decreased availability of L-arginine,34 or co-factors for eNOS.34,40,42
Nevertheless, a major factor of impaired NO-availability may be enhanced degradation
of NO by reactions with oxygen radicals produced by enzymes such as xanthine 
oxidase,44 NADH- and NADPH oxidase.45,46 Moreover, under certain pathophysiological
conditions, eNOS itself can synthesize mainly superoxide instead of NO.47-49 This 
NO-uncoupling phenomenon is characterized by reduced availability of NO and in-
creased production of highly cytotoxic oxidant peroxynitrite. Because of its reactivity,
direct measurement of NO itself in vivo is virtually impossible. Alternatively,
NO-dependent vasodilation is probably one of the most reliable and practically useful
estimations of endothelial function.There are different ways of stimulating or inhibiting
NO-release and different ways to measure this effect in order to assess NO-dependent
vasodilation.
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Coronary endothelial assessment
Coronary angiography is routinely performed to detect stenotic coronary artery
lesions in symptomatic patients. In addition to morphological details of the coronary
arteries, endothelial function of resistance and epicardial conduit vessels can be
simultaneously investigated. The resistance vessels regulate coronary blood flow.
Endothelial function of these resistance vessels can be demonstrated using an intra-
coronary Doppler flow velocity transducer. Endothelial function of coronary conduit
vessels can be demonstrated by measuring the changes in diameter. Intracoronary
infusion of acetylcholine at a dose between 10-8 to 10-4 mmol/l is generally used as a
distinctive agonistic provocation.50-54 In healthy arteries this will result in increased
coronary dilation and flow due to specific stimulation of the muscarinic 1 receptor on
the luminal side of the endothelial cell. Coronary flow decreases and epicardial 
vessels constrict if endothelial function is impaired due to lack of NO availability, thus
allowing a direct effect of acetylcholine on the subendothelial muscarinic 2 receptor
on the VSMC, establishing a paradoxal vasoconstriction.
Determination of forearm blood flow (FBF) using venous occlusion plethysmography
Plethysmography has been used to measure blood flow in resistance vasculature beds
for more than a century. For endothelial function measurements venous occlusion
plethysmography of the forearm is most widely used.30-32,35,55 The mean blood flow of
Introduction
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Figure. Determination of FBF using occlusion plethysmography
FBF: volume changes measured using mercury in elastic strain gauges and the intra-arterial canula for local infusion
of vasoactive compounds.
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the forearm is measured by recording an increase in forearm volume that occurs
during temporary interruption of venous outflow by inflating a pneumatic cuff to 
40 mmHg at the upper arm leaving arterial inflow unimpeded. A wrist cuff, inflated
40 mmHg above systolic blood pressure, excludes flow from the hand, since the latter
reflects thermoregulation rather than a resistance vessel bed. The initial increase in
volume is due to arterial inflow. The volume change can be measured using mercury
in elastic strain gauges wrapped around the forearm at 1/3 of the forearm length 
distal from the olecranon. At this part the forearm contains the largest proportion of
muscle. An intra-arterial canula is placed to allow for local infusion of vasoactive
compounds. The basal blood flow is measured during infusion of 0.9% saline.
Endothelium-dependent vasodilation can be induced using compounds such as sero-
tonin, acetylcholine and bradykinin, which all more or less stimulate NO-formation.
Serotonin, physiologically released by platelets, acts via the luminal serotonin 
receptor and specifically stimulates eNOS. Acetylcholine binds to the muscarinic 
1 receptor on the endothelial cell and activates eNOS as well as endothelium-depen-
dent VSMC-hyperpolarization. In physiologic situations acetylcholine is not a natural
NO-stimulator. Acetylcholine is rapidly degraded by cholinesterase. In many human
studies acetylcholine was used as agonist of NO-release. However, firstly acetyl-
choline has been shown to induce multiple vascular effects such as NO-release,14
release of vasodilative and vasoconstrictive prostaglandins56 and release of EDHF.57
Secondly, since muscarinic receptors on VSMC directly mediate vasoconstriction,
blunting of the acetylcholine-induced vasodilation may be unrelated to a change in
the NO-pathway. Serotonin induces a large initial rise in bloodflow, followed by a
vasodilatation that sustains less. In contrast to the partial inhibition of acetylcholine-
induced vasodilation by the NOS-inhibitor L-NMMA, the sustained vasodilation 
induced by serotonin is completely abolished by co-infusion of L-NMMA.58 Bradykinin
acts via the luminal bradykinin receptor on endothelial cells and stimulates besides
NO also EDHF. Bradykinin causes vasodilation independent of NO, predominantly
through hyperpolarization.59 Therefore, we prefer serotonin to investigate specific
NO-mediated vasodilation. Nitroprusside, serving as exogenous NO-donor, induces
endothelium-independent vasodilation by directly acting on the VSMC. Inhibition of
basal NO-activity is possible with specific NO-blockers such as L-NMMA and L-NAME.
Changes in FBF in the measured arm are the result of vaso-active compounds. Besides
this local reaction, systemic factors such as sympathetic arousal and blood pressure
also can influence FBF. Comparison of flow between the measurement arm and the
contralateral arm (M/C ratio) excludes these systemic factors.
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Non-invasive measurement of flow-mediated dilation (FMD) of the conduit
brachial artery
A non-invasive technique to measure endothelial function is the assessment of FMD
using an ultrasound device.60,61 Assessment of endothelial function is based on
changes in vessel diameter. Endothelium-dependent vasodilation is non-invasively
induced by blood flow increase or shear stress. To induce an increase in blood-flow in
the forearm, a cuff is inflated to 50 mmHg above systolic pressure distal to the trans-
ducer. Deflating this cuff after 4-5 minutes results in hyperemia lasting for approxi-
mately 2 minutes while causing vasodilation for up to 20 minutes.62 In healthy 
subjects, a brachial artery normally dilates approximately 5-10%.60,61 L-NMMA 
abolishes the vasodilative effect of hyperemia in the brachial artery, demonstrating
that NO is the main mediator of FMD.63 The non-endothelium-dependent vaso-
dilative response can be measured using sublingually administrated nitroglycerine.
It is important to be aware of influencing factors like baseline diameter. The vaso-
dilator responses are inversely related to the vessel size. The accuracy and reprodu-
cibility are good. An interobserver variability of 2.9% and a respons variability 
of 1.4% are reported.64 The number of patients required in an intervention trial
depends on the hypothesized improvement in FMD and the type of study; thus,
Introduction
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Figure. FMD of the conduit brachial artery
FMD: measuring endothelial function using an ultrasound device; the ultrasonic view of the brachial artery.
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larger groups are needed for a parallel compared to a cross-over design.65,66 There
is a close relationship of vascular function between the coronary and forearm 
conduit vessels. Patients with coronary artery endothelial dysfunction, manifested
as vasoconstriction in response to intracoronary acetylcholine, had significantly
impaired FMD in the brachial artery compared to patients with normal coronary
endothelial function (FMD 4.8% vs. 10.8%, p<0.01). Also patients with coronary 
artery disease had an attenuated FMD response compared to patients with angio-
graphically smooth coronary arteries (FMD 4.5% vs. 9.7%, p,0.02). Both coronary
endothelial dysfunction and presence of coronary artery disease were strong predic-
tors of reduced FMD responses. The positive predictive value of reduced FMD response
(FMD < 3%) in predicting coronary endothelial dysfunction was 95%.67
Conditions for proper assessment of endothelial function
Noteworthy, different factors affect measurements of endothelial function, which
demand rigid standardization to avoid modulating effects.
The sympathetic nervous system is an important regulator of coronary and 
peripheral vascular tone.68-75 In this respect, FMD was practically abolished during
sympathetic stimulation by baroreceptor unloading which was prevented during
local alpha adrenergic blockade with phentolamine.76 Thus symptomatic treatment
modalities which affect sympathetic outflow (e.g. diuretics, β-blockers) may also
improve FMD secondary to a decreased sympathetic activity.
Circadian rhythm is important in coronary conduit vessels. In coronary segments
with endothelial dysfunction, the constrictor response to acetylcholine or the 
dilator response to nitroglycerine was significantly greater in the morning than in
the afternoon. This suggests a potentially protective role for the endothelium in
modulating variations in coronary tone that may contribute to increased incidence
of cardiovascular events in the early morning.77 According to this phenomenon, FBF
and FMD have found to be markedly reduced in the morning compared to the after-
noon.78,79 Hypercholesterolemia is associated with endothelial dysfunctionand can
be improved by treatment with cholesterol lowering drugs.35-38,80-82 Also high-fat
meals impair endothelial function while several compounds such as vitamin C and E,
folic acid, ACE-inhibition and AT-I receptor blockade, prevent this impairment.83-88
In addition, elevated glucose levels can impair endothelial function as well.89-92
FMD response of the brachial artery is impaired in postmenopausal women and
related to the estradiol level in premenopausal women. This suggests that estrogens
have a protective effect on the endothelium.93-98 Endothelium-mediated vaso-
dilation of coronary and peripheral arteries is inversely correlated to age.99-103
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Several studies revealed impaired endothelial function of the coronary and brachial
conduit vessels and forearm resistance vessels in smokers compared to non-
smokers.39-42 This is probably due to decreased NO-availability by radical stress or
decreased eNOS-activity since the L-NMMA-induced vasoconstrictive effect was
diminished. BH4, an important co-factor for eNOS, improves the endothelial func-
tion in both forearm resistance- and conduit vessels.40-42
As discussed above, some factors improve endothelium-mediated vasodilation,
whereas others deteriorate endothelial relaxation. Thus, for greatest accuracy, it is
important that the patient is investigated in a quiet room at constant room tempe-
rature (20-24°C) in a comfortable position. The patient should have been fasting for
6-12 hours.
Relation between endothelial dysfunction and cardiovascular morbidity
Endothelial dysfunction plays an important role in the pathogenesis of coronary
artery disease and is considered to be an early manifestation of atherosclerosis.
Multiple investigators have clearly demonstrated impaired endothelial function of
coronary conduit and resistance arteries in atherosclerotic patients.53,65,66 In addi-
tion, impairment of peripheral endothelium-dependent vasodilation has been
demonstrated in patients with coronary artery disease.104-106 Moreover, the
progressive impairment of the endothelium correlates with the progression of 
coronary atherosclerosis.107 Even more important, endothelial dysfunction is not
only associated with atherosclerosis and its risk factors but also with cardiovascular
outcome. To identify cardiac events using FMD in the brachial artery in patients with
non-specific chest pain a specificity of 51%, a sensitivity of 86% and a negative 
predicting value of 93% was found.108-109
Introduction
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Insulin resistance
General introduction
The prevalence of type 2 diabetes (DM2) has soared in the past decades because of
changing lifestyles and eating habits. Obesity associated with insulin resistance is
one of the main determinants of the increased incidence of DM2. The major long-
term complications of DM2 are an increased risk of myocardial infarction, stroke and
peripheral vascular disease. Although microvascular complications cause considerable
morbidity in patients with DM2, up to 80% of patients die from macrovascular
pathology.1 Treatment of individual risk factors has been shown to reduce cardiovas-
cular events in DM2. Dysglycemia does not appear to be the major determinant of
cardiovascular disease in DM2, a concept supported by observations in the UK
Prospective Diabetes Study (UKPDS).2 Patients with impaired glucose tolerance 
(IGT) and/or impaired fasting glucose are so called pre-diabetic and are at risk for
developing DM2.3 Although in DM2 elevated plasma glucose concentrations may
induce vascular damage, in pre-diabetic patients the increased cardiovascular risk is
most likely the result of the pathophysiological phenomenon of insulin resistance
which leads to the occurrence of risk factors (e.g. elevated bloodpressure, low HDL-
cholesterol, elevated triglycerides) and causes impaired vasoreactivity.4
Pathophysiology of insulin resistance
Insulin has several physiological functions.This hormone is the most important regulator
for the plasma glucose level by stimulating the disposal of glucose in skeletal muscle- and
adipose tissue and decreasing the hepatic glucose production.Furthermore insulin stimu-
lates the lipogenesis and glycogen- and protein-synthase activity in adipocytes, liver and
skeletal muscle, and inhibits glycogenolysis, lipolysis and protein breakdown. In addition,
insulin plays a role in the regulation of cell growth and differentiation.
Insulin resistance means that when insulin binds to the insulin receptor on the 
cell surface, this stimulation is not strong enough to induce the normal intracellular
signal transduction with the consequence of insufficient reaction of target organs 
on plasma levels of insulin. In case of a sufficient pancreatic β-cell-function, insulin
resistance will lead to a compensatory hyperinsulinemia to maintain normoglycemia.
Hyperglycemia, follows by further increase in insulin resistance and after failing of the
pancreatic β-cell-function. Adipose tissue, especially intra-abdominal obesity, plays an
important role in insulin resistance. Adipose tissue is no longer only a depot, but can
be seen as an endocrine organ.5 Several products of adipose tissue may influence
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development of insulin resistance. Important adipocyte-derived factors are FFA, but
the adipocytokine TNF-α, adiponectin, and leptin. High levels of free fatty acids (FFA)
have been linked to (the induction of) insulin resistance because increased FFA 
production in the liver leads to increased gluconeogenesis and decreased glucose 
metabolism in skeletal muscle.6 Furthermore high levels of FFA will lead to an increase
of very low-density lipoprotein (VLDL) together with an increase of plasma triglycerides.7
In an insulin resistant state there is an attenuated lipoprotein lipase (LPL) acitivity.
Lipoprotein lipase is involved in the lipolysis of VLDL. Decreased breakdown of VLDL 
particles leads to reduced availability of small VLDL fragments and an increase in 
triglyceride-rich high-density lipoprotein (HDL) particles via cholesterolestertransfer-
protein (CETP). Triglyceride-rich HDL particles are faster cleared by the liver resulting in
a decreased HDL plasma concentration and an increased triglyceride concentration.8
The expression of TNF-α by adipose tissue is upregulated in obesity and TNF-α levels
are increased in patients with features of the insulin resistance syndrome (such as
endothelial dysfunction) inducing a higher risk of recurrent coronary events.9,10
Adiponectin is an adipocyte-derived hormone that decreases insulin resistance. A low
adiponectin plasma concentration precedes a decrease in whole-body insulin sensiti-
vity in humans.11-13 The role of leptin in insulin resistance is controversial, but leptin
might interfere with insulin signalling in certain cell types. Hyperinsulinemia also
causes hypertension. Normally insulin has a vasodilating effect, however with insulin
resistance, insulin can cause sympathetic activation, production of the vasoconstrictor
ET-1, and increase of renal salt retention. Together with, or leading to, endothelial 
dysfunction these mechanisms can result in hypertension.14
Figure. Pathophysiology of insulin resistance
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Insulin resistance syndrome
Taken together, insulin resistance is generally regarded as an important feature of a
cluster of risk factors of cardiovascular disease. These risk factors (dyslipidemia,
hypertension, glucose intolerance, hyperinsulinemia, obesity, low-grade inflamma-
tion, endothelial dysfunction and hypercoagulability) often precede clinically mani-
fest DM2. However, the interaction between different cardiovascular risk factors and
defects in insulin signalling is very complex. Most persons with multiple metabolic
risk factors are insulin resistant which leads to the concept that insulin resistance is
the major cause of the cluster metabolic syndrome.15
Metabolic syndrome
The metabolic syndrome, which involves a cluster of cardiovascular risk factors including
hypertension, obesity, glucose intolerance, endothelial dysfunction, dyslipidemia and a
proinflammatory state, is generally considered to be of major importance in the patho-
physiology of DM2 and is associated with an increased risk for cardiovascular complica-
tions.16-18 According to the Adult Treatment Panel III (ATP III) the metabolic syndrome is
diagnosed when 3 or more criteria are present.The ATP III definition of the metabolic syn-
drome is the most commonly used definition and most practical for clinical use:19
1) Abdominal obesity (waist circumference > 102cm in men and >88cm in women).
2) High blood pressure (≥ 130mmHg systolic or ≥ 85mmHg diastolic).
3) Hypertriglyceridemia (serum triglycerides ≥ 1.70mmol/l).
4) Low serum HDL cholesterol (<1.04mmol/l in men and < 1.29mmol/l in women).
5) High fasting serum glucose (≥ 6.1mmol/l).
The increase in prevalence of the metabolic syndrome is of great concern worldwide.
The for age adjusted prevalence of the MS among assumable healthy persons is
around 24% worldwide.20,21 In a French study, using a modified WHO-definition for
the metabolic syndrome, the prevalence for women was 12 % and for men 23%.22 For
patients with manifest arterial disease the prevalence is 45%23 and for patients with
DM2 80%.17 In a population based cohort study the odds ratio (adjusted for age, sex,
and follow-up duration) for the development of diabetes in patients with impaired
fasting glucose was 10.0 (95% CI 6.1-16.5).24 The presence of the metabolic syndrome
at baseline increased the risk for the development of diabetes mellitus almost
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2-fold in American Indians25 and in Finnish men a 4-fold increase was shown.26
Presence of the metabolic syndrome gives a nearly 3-fold increase in cardiovascular
related mortality compared to subjects without the metabolic syndrome.27 In addi-
tion, the metabolic syndrome is associated with advanced vascular damage in
patients with coronary heart disease, stroke, peripheral arterial disease or abdominal
aortic aneurysm28 and untreated essential hypertension.29
It is assumable that the cardiovascular risk for patients with the metabolic syndrome
can just be explained by the sum of the separate cardiovascular risk factors.
However, Scuteri et al. showed that the age-associated increases in vascular thickness
and stiffness was more than expected from the separate cardiovascular risk factors
in relation to the metabolic syndrome.30 Moreover, the increased cardiovascular risk
for patients belonging to the metabolic syndrome can not be completely explained
by the traditional models for risk-scoring like the Framingham-score.31 This increased
cardiovascular risk may be due to the combination of nontraditional markers, which
all have a relation with insulin resistance, together with the separate traditional com-
ponents of the metabolic syndrome (hyperglycemia, hypertension, low plasma HDL
cholesterol, high plasma triglyceride levels, and obesity). The nontraditional markers
are endothelial dysfunction, inflammation, hyperinsulinemia, oxidative stress hyper-
coagulability together with decreased fibrinolysis, and increased small-dense-LDL.32-34
Several studies showed a relation between hyperinsulinemia, increased plasma FFA
levels, and more oxidized small-dense LDL with endothelial dysfunction.35-37 Also
enhanced low-grade inflammation induces endothelial dysfunction by increased
production of cytokines like C-reactive protein (CRP), TNF-α, and IL-6.38-40 In addition,
increased hs-CRP is associated with obesity, insulin resistance, and endothelial dys-
function.41 The more components of the metabolic syndrome are present in the same
person, the higher the plasma CRP concentration.42 Noteworthy is that CRP not only
seems to function as an indicator for cardiovascular disease, but CRP may also play a
role as a risk factor in atherogenesis.43
Endothelial dysfunction, an early step in atherogenesis, is also present in the meta-
bolic syndrome and may be a cause or a consequence of insulin resistance. The
Framingham study already showed that abdominal obesity is the main hyper-
tensinogenic factor.44 Like already mentioned earlier, obesity is also the cause of
insulin resistance, diabetes mellitus type 2, left ventricular hypertrophy, hyper-
lipidemia, and thus related to an increased risk for atherosclerotic diseases. A direct
association between hypertension and BMI has been observed in cross-sectional
and longitudinal population studies from early childhood to old age.45 The mechanism
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by which obesity raises blood pressure is not fully understood, but increased BMI is
associated with an increase in plasma volume and cardiac output. These alterations
and blood pressure can be decreased by weight loss in both normotensive and
hypertensive subjects. Furthermore, blood pressure in obese adolescents is sodium-
sensitive, and fasting insulin is the best predictor of this sensitivity; after weight loss
the blood pressure decreases and the salt sensitivity is reduced.46 The variables that
best predict sodium sensitivity are fasting plasma insulin, plasma aldosterone, and
plasma norepinephrine, supporting the hypothesis that bloodpressure is sensitive
to dietary sodium and that this sensitivity may be due to the combined effect of
hyperinsulinemia, hyperaldosteronism, and increased activity of the sympathetic
nervous system.47 Hyperinsulinemia increases both sympathetic nerve activity and
sodium and water retention and the expected vasodilation, upon binding of insulin
to the endothelial insulin receptor and causing activation of eNOS, is impaired in
insulin resistant states.48 It is also the heterogeneous effect of endogenous NO on
proliferation along the vascular tree that relates to the two different phenomenons
of insulin resistant vascular dysfunction. Endothelial dysfunction exists in conduit
arteries, while elevated vascular resistance of resistance arteries is observed in
essential hypertension.49,50
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Although a pathophysiological construct seems plausible, future research must
unrevel pathophysiology and clinical use before the metabolic syndrome can be
designated as a ‘syndrome’.51 The individual components that make up the syndrome
should be treated coherently. These are the visible mountains of the floating iceberg
above the water. However there are other risk factors underneath the water surface.
Awareness of the underlying disorders is important for understanding the patho-
phyiology and thus coherent treatment: be aware for insulin resistance and its 
associated (non-) traditional risk factors.
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PPAR-γ agonism and Thiazolidinediones
Our understanding of the so-called cardiovascular dysmetabolic syndrome has been
improved by the discovery of nuclear peroxisome proliferator-activated receptors
(PPARs). PPARs are ligand-activated transcription factors belonging to the nuclear recep-
tor superfamily. As transcription factors, PPARs regulate the expression of numerous
genes and affect glycaemic control, lipid metabolism, vascular tone and inflammation.
Activation of the subtype PPAR-γ improves insulin sensitivity. Expression of PPAR-γ is 
present in several cell types involved in the process of atherosclerosis. Thus, modulation
of PPAR-γ activity is an interesting therapeutic approach to reduce cardiovascular events.
Thiazolidinediones are PPAR-γ agonists and constitute a new class of pharmacological
agents for the treatment of type 2 (non-insulin–dependent) diabetes mellitus. Two
such compounds are currently available for clinical use: rosiglitazone and pioglita-
zone. Thiazolidinediones improve insulin sensitivity and glycaemic control in
patients with type 2 diabetes. In addition, improvement in endothelial function, a
decrease in inflammatory conditions, a decrease in plasma levels of free fatty acids
and lower blood pressure have been observed, which may have important beneficial
effects on the vasculature.
Several questions remain to be answered about PPAR-γ agonists, particularly with
respect to the role of PPAR-γ in vascular pathophysiology. More needs to be known
about the adverse effects of Thiazolidinediones, such as hepatotoxicity, increased
low-density lipoprotein cholesterol levels and increased oedema. The paradox of
adipocyte differentiation with weight gain concurring with the insulin-sensitising
effect of Thiazolidinediones is not completely understood. The decrease in blood
pressure induced by Thiazolidinedione treatment seems incompatible with an
increase in the plasma volume, and the discrepancy between the stimulation of the
expression of CD36 and the antiatherogenic effects of the Thiazolidinediones also
needs further explanation. Long-term clinical trials of Thiazolidinediones with 
cardiovascular endpoints are currently in progress.
In conclusion, studying the effects of Thiazolidinediones may shed more light on 
the mechanisms involved in the insulin resistance syndrome. Furthermore, Thia-
zolidinediones could have specific, direct effects on processes involved in the 
development of vascular abnormalities.
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Outline of the thesis
Cardiovascular disease is the leading cause of morbidity and mortality in Western
countries. The term cardiovascular disease comprises clinical manifestations of
arterial atherosclerosis, such as peripheral artery disease, cerebrovascular disease,
and coronary artery disease. Well-established risk factors are dyslipidemia, smoking,
diabetes mellitus, hypertension, and clustered in association with abdominal obesity.
In the pathophysiology of atherosclerosis, based on the respons to injury mechanism,
the pathophysiological phenomenons endothelial dysfunction and inflammation are
playing a pivitol role.
The endothelium has been identified as the central transducer through which risk
factors can cause atherosclerosis and its clinical complications. The central pathway
in this event is the activation of the endothelium. Basically this involves the switch
from a healthy condition with low concentrations of NO resulting in vasodilative
and/or anti-atherosclerotic actions. However, in pathophysiological situations 
NO-availability in vivo is impaired because of redox signalling in the activated
endothelium, as a result of reduced NO-formation, enhanced NO-breakdown or
both. There are two major consequences of this endothelial activation:
First, it will lead to the production of chemokines and expression of adhesion mole-
cules. This will support the recruitment of inflammatory cells into the vessel wall.
Although this system is physiological in the context of host-defense it may become
inappropriate with prolonged periods of endothelial cell activation secondary to
cardiovascular risk factors. As a result, an inflammatory phenotype evolves in the
vessel wall which leads to atherogenesis and plaque rupture.
Second, the loss of NO-bioavailability by the endothelium, due to risk factors, affects
the vessel wall structure. There are some preliminary indications that NO inhibits
VSMC-proliferation in the vascular wall. As a result one could hypothesize that loss
of NO-activity would result in increased VSMC-proliferation. This may accelerate the
development of the atherosclerotic plaque, but may also lead to thicker, remodelled
vessels. As a result these vessels become stiffer and start to produce pressure load
on the heart.
In Chapter 1 we first would like to explore the hypothesis that endothelial function
(in the sense of NO-bioavailability) is an important determinant of vessel wall struc-
ture. In conduit arteries, endothelial dysfunction is initiating atherogenesis. The
other phenomenon of endothelial dysfunction is the elevated vascular resistance 
of resistance arteries (microcirculation) as observed in essential hypertension.
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We addressed this heterogeneity of vascular remodeling along the vascular tree and
postulated that this regional difference may be related to a heterogeneous effect of
eNOS on proliferation in conduit arteries vs. resistance vessels.
In the current thesis we would like to explore several aspects of the described model
of vascular injury in the setting of type 2 diabetes. Type 2 diabetes is emerging as a
worldwide epidemic and currently about 200 million people are affected world-
wide. An important driver for this increased incidence is the associated increase in
patients with insulin resistance (approximately 400 million worldwide right now).
This insulin resistance is driven by obesity and secondary to obesity, free fatty acid
fluxes towards other tissues than adipocytes (like the muscle and liver). However,
genetic factors, particularly in Asian people, seem to play a role as well.
Clinically it would be useful to correlate the severity of insulin resistance to the
severity of alterations in vessel wall structure due to loss of NO-activity. In chapter 2
we investigated in a cross-sectional survey (2105 patients) to determine whether
carotid artery stiffness was increased in (‘pre-diabetic’) patients with the metabolic
syndrome and in patients who developed overt type 2 diabetes.
Because our group extensively studied all kind of other markers of endothelial 
dysfunction in diabetes and obesity (and thus insulin resistance), we did not further
explore these concepts and took the experience already gained, to address possible 
treatment. Thinking about a treatment of the underlying disorders, the discovery of
nuclear peroxisome proliferator-activated receptors (PPARs) and subsequent insight into
their role in several metabolic pathways was a major breakthrough in our understanding
of pathophysiological mechanisms underlying the insulin resistance syndrome.
Thiazolidinediones (like pioglitazone) are clinically available agonists of the PPAR-γ
subtype and constitute a new class of antihyperglycaemic agents. Activation of
PPAR-γ not only improves insulin sensitivity but may also have additional beneficial
vascular effects.
The aim of a main part of this thesis is to focus on the potential role of Thiazolidine-
diones in the pathophysiological mechanisms involved in vascular disease.
Chapter 3 is an overview of the metabolic and additional vascular effects of Thia-
zolidinediones.
In chapter 4 we investigated the direct vascular effects of pioglitazone on the capacity
of the vasculature to maintain its NO-release, in type 2 diabetic patients, in a double
blind and crossover design. As measurement of NO-activity in the vessel wall,
flow-mediated dilation in the conduit brachial artery was used. We focused on rela-
tively short-term application of pioglitazone to tease out direct vascular effects
from its indirect metabolic effects.
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We subsequently investigated whether a beneficial effect of TZDs on NO-bio-
availability in type 2 diabetes also translates into better protection of the vessel wall
from inflammatory stimuli.
To this end we investigated in chapter 5, whether diabetic subjects could maintain
NO dominated endothelial function in the presence of increased concentrations 
of TNF-α. Therefore we first investigated the effect of TNF-α on endothelium-
dependent vasodilation and secondly the effects of short-term pioglitazone treatment
on TNF-α induced endothelial dysfunction in patients with type 2 diabetes mellitus.
In addition, we investigated ex vivo whether TZDs changed the properties of mono-
cytes to adhere to the endothelium, or to produce cytokines.
Therefore, we examined in chapter 6, in a parallel controlled, ex vivo study, the
effects of incubation with TZDs, on monocyte-endothelium-adherence under flow
conditions.
In chapter 7 we studied the cytokine production in whole blood from type 2 diabetes
patients after short-term pioglitazone treatment, in a double blind and crossover
design.
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CHAPTER 1
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nitric oxide synthase inhibition -role of extracellular
signal–regulated kinases 1/2-
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Abstract
Introduction Although conduit arteries develop hypertrophy after chronic NO syn-
thesis blockade, resistance arteries remodel without hypertrophy under the same
conditions. Similar findings have been described in essential hypertension. We 
postulated that this regional difference may be related to a heterogeneous effect of
endogenous NO on proliferation along the vascular tree.
Methods and Results Newly synthesized proteins were radiolabeled in rats with
[3H]L-leucine in basal conditions and during NO synthase inhibition, with or with-
out PD98059 (inhibitor of the extracellular signal–regulated kinases [ERK] 1/2).
Blocking the generation of NO by 3 different L-arginine analogues increased protein
synthesis by an average of 75% in the aorta, in association with enhanced ERK 1/2
phosphorylation. PD98059 significantly reduced L-arginine analogue–induced pro-
tein synthesis and ERK 1/2 phosphorylation, confirming the involvement of ERK 1/2
as an important signaling element. In small arteries, L-arginine analogues did not
influence the extent of protein synthesis, although phosphorylation of ERK 1/2 was
also enhanced. To determine the role of NO in a condition of enhanced protein syn-
thesis, angiotensin-II was infused for 24 hours. Angiotensin-II augmented protein
synthesis in mesenteric arteries and the aorta, and was additive to NO synthase
blockade in the aorta.
Conclusion Endogenous NO exerts a tonic inhibitory influence on aortic growth,
with limited impact on small arteries in basal and hypertrophic conditions. This
heterogeneous role of NO on vascular growth may explain the heterogeneity of 
vascular remodeling observed in essential hypertension, a condition associated with
endothelial dysfunction.
Keywords aorta, arteries, hypertrophy, kinase, nitric oxide, nitric oxide synthase
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Introduction
The endothelium is an important modulator of vascular reactivity and structure,
and NO is one of the main products synthesized and released by endothelial cells.1
Most of the biological effects of NO are mediated by cGMP and include regulation of
vascular tone and endothelial permeability, inhibition of platelet adhesion and
aggregation, and inhibition of leukocyte–endothelial cell interactions.2 In addition,
early studies in vascular smooth muscle cells (VSMCs) in culture have shown that NO
donors inhibit cellular proliferation3-6, which is an important event in the patho-
genesis of atherosclerosis, restenosis, and possibly hypertension.7 Among the 
signaling pathways related to NO inhibition of cell proliferation, inhibition of extra-
cellular signal–regulated kinase (ERK) 1/2 phosphorylation has been proposed to be
important, considering the pivotal role of this signaling event in VSMC growth.6,8
In hypertension, arteries adapt to the pressure-induced elevation in wall stress by
changing their geometry.9,10 Indeed, the elevated vascular resistance observed in
hypertension is associated with an increased media thickness–lumen diameter
ratio (remodeling) of resistance arteries.11,12
In essential hypertension, the amount of material in the vessel wall is not augmen-
ted but appears to be rearranged around a smaller lumen, and the process has been
called eutrophic remodeling.13 In contrast, large arteries undergo mainly hypertrophic
remodeling, because their lumen size is generally not reduced, and wall thickness
increases in an effort to compensate for the increased wall stress.10,14
Chronic inhibition of NO synthesis with NG-nitro-L-arginine methyl ester (L-NAME)
leads to hypertension. Interestingly, in this model, small arteries undergo eutrophic
remodeling in proportion to the elevation of arterial pressure.15,16 In addition, under
conditions of stimulated growth with exogenous angiotensin-II (Ang-II) administration,
chronic NO synthase inhibition does not worsen growth development but blunts it in
cerebral arteries.17 These observations argue against a prominent inhibitory role of NO
on VSMC growth in small arteries in vivo. In the aorta, however, chronic NO inhibition
with L-NAME promotes medial hypertrophy and fibronectin deposition, suggesting a
growth-inhibitory role for NO in large arteries.18 Our postulate is that endogenous NO
exerts growth regulation in large arteries but that there is no such regulation in small
arteries, possibly because of the different influence of signaling along the vascular tree.
To address this issue, the vascular growth response to endogenous NO inhibition was
determined in small and large arteries simultaneously under basal and Ang-II–stimu-
lated conditions in vivo. Furthermore, we tested the potential of ERK 1/2 to represent an
important determinant of the heterogeneity.
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Methods 
Under anesthesia, the left femoral vein and artery of Sprague-Dawley rats (300 to
400 g) were catheterized with a polyethylene tubing that was tunneled subcutane-
ously, exteriorized at the back of the neck, and protected by a tethering system. In
rats treated with Ang-II, an osmotic pump delivering 400 ng/kg per minute was
inserted subcutaneously at the same time.
Twenty hours after surgery, arterial pressure and heart rate were recorded. In the
first series of experiments, a bolus of L-arginine analogues was administered
through the venous catheter to control and Ang II-treated rats. Three different
L-arginine analogues were used: L-NAME, NG-methyl-L-arginine (L-NMMA), and 
NG-nitro-L-arginine (L-NA), all at a dose of 3 mg/kg (n=8 per group). One hour after
this bolus, a 4-hour intravenous infusion of L-(4,5-3H)leucine was started.19 A second
dose of L-arginine analogues was administered intra-arterially 90 minutes after the
start of the infusion. In the second series of experiments, rats received vehicle, L-NA
(as above), PD98059 (10 mg/kg IP, at the time of the first L-NA administration, n=8),
or the combination of L-NA and PD98059 (n=8). L-(4,5-3H)leucine infusion was star-
ted 1 hour after injection of the drugs in half of the animals. The protocols were
approved by the Animal Care Committee of Université de Montréal.
Protein synthesis measurement and autoradiography
Frozen aortas and mesenteric arteries were powdered in liquid nitrogen, and 
proteins were precipitated overnight in trichloroacetic acid (TCA), washed once with
TCA and twice with water, and solubilized in KOH to which the scintillation liquid
was added. The other half of the tissue was also left overnight in TCA, and the 
precipitate was solubilized in NaOH to measure protein concentration by the
method of Lowry et al.20 The final results are expressed as counts per minute per
milligram protein. Slides of paraffin-embedded aortic sections were soaked in an
autoradiography emulsion, dried, and kept at 4°C for 8 weeks in complete darkness.
Slides were then developed, fixed, and counter-stained with hematoxylin to reveal
the nuclei. Images were digitalized at a final magnification of x 400.
Phosphospecific immunoblot of ERK 1/2, cGMP,and plasma renin activity measurements
ERK 1/2 activity was estimated by Western blot, with the use of a phosphospecific
antibody, as previously described by Touyz et al.21 Equal amounts of proteins (20 µg)
were loaded on a 10% SDS–polyacrylamide gel. Proteins were then transferred to a
polyvinylidene difluoride membrane and incubated with a phospho-specific ERK 1/2
Chapter 1
48
proefschrift_Fabrice  21-12-2005  14:21  Pagina 48
49
Heterogeneous growth inhibition by NO
antibody. The membrane was then washed and incubated with a second antibody.
The membrane was incubated with enhanced chemiluminescence (ECL) Western
blotting reagents and exposed on Hyperfilm ECL. Results were normalized to control
values on each gel to account for methodological variation.
cGMP measurements were performed by using the acetylation procedure, as 
suggested by the Biotrak cGMP enzyme immunoassay system. Plasma renin activity
(PRA) was assessed by a commercial radioimmunoassay kit on plasma samples
taken from 6 control rats and 6 rats treated with L-NA (2 injections of 3 mg/kg).
Samples were taken before and 5 hours after the first drug injection. An expanded
Methods section can be found in an online data supplement available at
http://www.hypertensionaha.org.
Results
Hemodynamic measurements
In the first series of experiments, administration of L-arginine analogues in 2 boluses
over a 5-hour period increased mean arterial pressure (MAP) only slightly compared
with preadministration values, with only L-NA having a significant effect (Table). The
dose of Ang II selected did not produce a significant elevation of MAP in 24 hours.
Administered in combination with Ang II, L-NA and L-NAME produced a significant
pressor effect (Table). In the second series of experiments, PD98059 administered
either alone or with L-NA did not modify arterial pressure significantly (Table).
Protein Synthesis and autoradiography
Basal protein synthesis was 406±42 and 276±26 cpm/mg protein in mesenteric 
arteries and in the aorta, respectively (Figure 1). In mesenteric arteries, the admini-
stration of L-arginine analogues 1 hour before labeled L-leucine infusion did not
influence the extent of protein synthesis (Figure 1A). However, in the aorta, the ana-
logues enhanced protein synthesis by 70% to 86% (Figure 1B). Ang II significantly
increased protein synthesis by 70% in small (mesenteric) and by 66% in large 
(aortic) arteries (Figure 1). When endogenous NO production was blocked by 
L-arginine analogues in addition to Ang II, we observed no modification of protein
synthesis in mesenteric arteries (Figure 1C), but we did observe enhanced protein
synthesis ranging from 58% to 72% in the aorta (Figure 1D). The effects of Ang II 
and L-arginine analogues were clearly additive in the aorta. The augmented protein
synthesis found in the aorta did not correlate with mean, systolic, or diastolic 
arterial pressure (data not shown).
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Table. MAP values in awake freely moving rats taken before and averaged during the 5h of drug
administration
Group Predrug Postdrug
MAP (mmHg) MAP (mmHg)
Control 109 ± 4
L-NAME 108 ± 3 113 ± 3
L-NMMA 123 ± 8 122 ± 5
L-NA 112 ± 5 130 ± 4*
Ang II 116 ± 7
Ang II + L-NAME 109 ± 5 140 ± 6*
Ang II + L-NMMA 125 ± 8 121 ± 6
Ang II + L-NA 120 ± 5 138± 4*
Control 98 ± 3
L-NA 101 ± 4 105 ± 2
L-NA + PD98059 102 ± 10 108 ± 7
PD98059 98 ± 6 95 ± 7
Values are mean ± SEM;
In control and Ang II-treated rats, there was no acute drug administration;
* p<0.05 
In our second series of experiments, the effect of L-NA on protein synthesis was
reproduced. Indeed, it amplified protein synthesis in the aorta but not in small 
arteries (Figure 2A and 2B). PD98059, which had no significant effect on its own,
blocked L-NA–induced augmentation of protein synthesis in the aorta by 56%.
Autoradiography of aortic cross sections was performed to localize the enhanced 
protein synthesis in the aortic wall. It revealed that most of protein synthesis occurred
in the media and intima in an evenly distributed fashion, both in control conditions
and after L-NA treatment (Figure 3). Indeed, the number of silver grains in the 
adventitia appears reduced compared with those remaining in the aortic wall.
ERK 1/2 activity
In the aorta, ERK 1/2 phosphorylation increased after L-NA administration (Figure 2C 
and 2D). As expected, this effect was abrogated by PD98059, which even decreased ERK
1/2 phosphorylation below control levels. ERK 1/2 activity was also significantly enhan-
ced in small mesenteric arteries during L-NA administration (165±7% from control).
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Figure 1.
Effect of NOS inhibition on [3H]L-leucine incorporation in proteins from rat mesenteric arteries (A and C) and rat
thoracic aortic segments (B and D) at the basal level (A and B) and after Ang II (ANG) treatment (C and D). CTL indi-
cates control; NAME=L-NAME; NMMA=L-NMMA; and NA=L-NA. Results are expressed as the mean ± SEM in counts
per minute per milligram protein (n=8 per group). *p<0.05 vs respective CTL, and † p<0.05 vs true CTLs
(ANOVA+Bonferroni correction for multiple comparisons).
Figure 2.
A and B: Effect of PD98059 on basal and NOS inhibition–induced [3H]L-leucine incorporation in proteins from small
mesenteric arteries (A) and thoracic aortic segments (B). CTL indicates control; NA=L-NA; NA+PD=L-NA+PD98059.
* p<0.05 vs control (CTL), and † = p<0.05 vs L-NA (ANOVA+Bonferroni correction for multiple comparisons).
C: Representative Western blot for ERK 1/2 (p44/p42), with use of a phospho-specific antibody in aortic protein
extracts from 2 control (Ctl) rats, 2 PD-treated rats, 2 NA-treated rats, and 2 NA+PD–treated rats.
D: Mean corrected optical density of Western blots for 6 to 8 animals per group, performed on 3 separated experiments.
* p<0.05 vs 100 (Ctl value, performed by 1-sample analysis).
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cGMP and plasma renin activity measurements
To confirm that the L-arginine analogues reduced NO production and that Ang II
exerted its effect independently from NO, we measured aortic cGMP levels in control
and in L-NMMA– and Ang II–treated rats. Two and a half hours after the second bolus
injections of L-NMMA, cGMP levels were halved (2.2±0.3 fmol/mg compared with
4.3±0.4 fmol/mg in the control group). In contrast, Ang-II had no significant effect on
vascular cGMP levels (4.0±0.5 fmol/mg).
To rule out any global effect of Ang II on protein synthesis during NOS inhibition,
PRA was measured. In control rats, repeated measurements of PRA were similar at
the beginning and 5 hours later (6.2±1.2 and 7.1±1.1 ng angiotensin I/mL per hour,
respectively). In L-NA–treated animals, however, PRA decreased from 4.3±0.4 to
1.7±0.5 ng angiotensin I/mL per hour after the 2 bolus injections of the drug.
Discussion
Using a model enabling us to measure pharmacological modulation of protein syn-
thesis, we report that endogenous NO exerts tonic inhibition of vascular wall
growth in a vessel-specific manner. In large arteries, NOS blockade stimulated 
protein synthesis by enhancing ERK 1/2 phosphorylation, whereas in small arteries,
NOS blockade did not induce protein synthesis despite elevation of ERK 1/2 phosphory-
lation. These results suggest heterogeneity in vascular growth responses to NOS 
blockade and to ERK 1/2 activation.
Chapter 1
52
Figure 3.
Representative autoradiography of aortic cross sections in a control rat (A) and a rat treated with L-NA for 5 hours
(B). The arrows point to one of the numerous silver grains scattered throughout the aortic wall. It is noteworthy
that the adventitia is poorly labeled. Quantification was performed by use of a more sensitive method (see
Methods and Figure 1). L indicates lumen.
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Although vascular heterogeneity to the relaxing properties of NO has been repor-
ted,22 to the best of our knowledge the concept of vascular heterogeneity to the
antiproliferative action of NO has never been put forward and has never been 
examined directly in the same animals. NOS inhibition did not augment protein
synthesis in small arteries, consistent with previous reports, including ours, showing
that chronic NO deficiency leads to eutrophic remodeling but not to hypertrophy
(no change in cross-sectional area despite an enhanced media/lumen ratio) of small
mesenteric and cerebral arteries.15,16,22,23 During chronic NO deficiency, these 
arteries normally undergo eutrophic remodeling in proportion to the elevation of
arterial pressure.16 One exception may be the coronary circulation, which seems to
have pressure-independent remodeling, possibly related to local Ang II forma-
tion.24,25 Indeed, Ang II leads to a pressure-independent hypertrophic remodeling of
small arteries when it is administered for long periods26-28, and we could measure
a significant increase of protein synthesis after 24 hours of administration in the
present model.
In large arteries, NOS blockade, confirmed by cGMP measurements, enhanced 
protein synthesis and ERK 1/2 phosphorylation, demonstrating that endogenous NO
exerts a tonic inhibition of vascular growth. The involvement of ERK 1/2 in the
growth response was confirmed by the efficacy of PD98059 to reduce it. The partial
effect of PD98059 suggests that other signaling events could also contribute to the
response. Alternatively, higher doses of PD98059 may be required, but 10 mg/kg 
proved to block 100% of Ang II–induced vascular protein synthesis (C. Daigle,
P. Moreau, unpublished data, 2001). The goal of using Ang II was to determine the
modulation, by NOS inhibition, of enhanced vascular protein synthesis (compared
with physiological protein synthesis) and not to specifically look for interactions. In
fact, measurement of PRA shows that acute NOS inhibition decreases the circulating
renin-angiotensin system. It appears quite clear that the 2 treatments had additive
effects in large arteries, suggesting that NO also exerts a modulation of protein 
synthesis in conditions of enhanced growth. One may argue that pressure elevation
secondary to NOS blockade could promote arterial remodeling, thus explaining part
of the enhanced protein synthesis. However, we could not find a correlation
between mean, systolic, and diastolic pressure values and protein synthesis, arguing
against a secondary effect of NOS blockade. In addition, it is quite clear that increased
protein synthesis can occur without elevation of arterial pressure, as we have shown
with the administration of a subpressor dose of Ang II.
The enhanced protein synthesis during NOS inhibition could result directly from the
reduction of NO production, inasmuch as NO has been shown to modulate growth
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in vitro.5,6 However, the in vivo situation is more complex, and numerous molecules
could be recruited and contribute to the enhancement of protein synthesis and the
remodeling process. In that respect, it has been demonstrated that chronic NOS 
inhibition leads to ACE activation and to the formation of a proinflammatory milieu
in the vasculature that could influence VSMC protein synthesis and the develop-
ment of hypertrophy.25,29,30 Thus, the in vivo measurement of protein synthesis 
provides an assessment of the final integration of the tissue to the different circula-
ting and local influences and clearly demonstrates that under NOS inhibition, large
arteries react with a trophic response partly involving ERK 1/2.
The heterogeneous growth response to NOS inhibition between large and small
arteries is not unlikely, because many other vascular functions, including growth
responses, differ between distant segments of the arterial tree.31 In an effort to 
characterize the heterogeneity at the molecular level, ERK 1/2 phosphorylation 
was measured, because it represents a central element of growth signaling.
Furthermore, NO donors have been shown to interact with this element by reducing
its phosphorylation.6 Our in vivo study extends these in vitro findings by showing
that NOS inhibition amplifies ERK 1/2 phosphorylation. However, activation of ERK
1/2 was observed in both small and large arteries, suggesting that it is not its 
activation but its vascular effect that is heterogeneous. We are currently testing 
the role of ERK 1/2 in small-artery vasoconstriction in vivo under NOS inhibition,
because this pathway has been shown to be involved in resistance artery VSMC 
contraction32,33, a condition associated with the attenuation of growth responses.34
The method used in the present study does not allow for the determination of the
nature of the proteins newly synthesized by NOS inhibition or Ang II, although most
of the activity appears to be located in the media and the intima with NOS inhibi-
tion. Kato et al18 have reported that both hypertensive stimuli, administered alone
or in combination, lead to medial thickening of the aorta by cellular hypertrophy
and enhanced matrix deposition in the form of fibronectin. It is also noteworthy
that intimal and adventitial cell division occurred only during the second day of 
Ang II administration and not with NOS inhibition. Thus, although not confirmed in
the present study, previous results suggest that both intracellular and extracellular
proteins account for the elevation of protein synthesis during NOS inhibition and
Ang II administration, at least in large arteries.
It has been suggested that L-NAME exerts NO-independent negative metabolic
effects on protein synthesis that could account for the lack of hypertrophy, at least
in the heart.35 In vessels, we found no evidence that L-NAME is less specific than
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other L-arginine analogues in terms of growth regulation at doses comparable to
that used to induce hypertension (6 mg/kg over 5 hours versus 50 mg/kg per day in
chronic studies). Although we solely measured protein synthesis, it represents a 
prerequisite to the development of vascular hypertrophy, and it appears unlikely
that L-NAME has a nonspecific effect. This does not exclude the possibility that
L-NAME, being a muscarinic antagonist in vitro36, could affect the proliferation of
specific tissues, such as astrocytes and prostate cancer cells, which have been shown
to be modulated by muscarinic interventions.37,38
In conclusion, we report that NO is an endogenous inhibitor of vascular protein 
synthesis in conduit arteries under physiological and Ang II–stimulated conditions,
in part by modulating ERK 1/2 phosphorylation. In contrast, in small arteries from
the mesenteric circulation, endogenous NO does not exert any growth inhibition,
although it also modulates ERK 1/2 activity. Our findings may help to explain the
heterogeneous remodeling of large and small arteries in conditions of endothelial
dysfunction, such as essential hypertension.
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Condensed abstract
We performed a cross-sectional study to determine whether the metabolic syndrome
and type 2 diabetes mellitus are associated with carotid artery stiffness in 2105
patients with manifestations of arterial disease.
We conclude that (increasing number of components of) the metabolic syndrome is
associated with marginally increased carotid artery stiffness, while type 2 diabetes is
associated with a marked increase in carotid artery stiffness, in patients with already
manifestations of arterial disease.
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Abstract
Introduction Insulin resistance is generally considered to be of major importance in
the pathophysiology of the metabolic syndrome and type 2 diabetes mellitus, both
high-risk conditions for cardiovascular complications. Carotid artery stiffness is
increasingly recognized as an important predictor of cardiovascular morbidity 
and mortality. Therefore in the present study we determined whether the metabolic
syndrome (MetSyn) and type 2 diabetes mellitus (DM2) are associated with carotid
artery stiffness in patients with already clinical manifestations of arterial disease.
Methods and Results A cross-sectional study in 2105 patients with manifest arterial
disease (cerebral, coronary or peripheral artery disease, renal artery stenosis or an
aneurysm of the abdominal aorta) was performed. The difference in carotid stiffness
between patients with and without MetSyn and with and without DM2 was studied
with linear regression analysis.
Compared to patients without DM2 (N=1112), patients with DM2 (N=301) had increased
arterial stiffness. Generally, carotid stiffness did not differ as much between patients
with (N=922) or without (N=1112) MetSyn. Excluding the patients with also DM2
(N=230) from the MetSyn-group diminished this relation even more. Furthermore, in
the population as a whole, carotid artery stiffness increases with increasing number 
of components of the metabolic syndrome. In addition, this association is not as 
clear after exclusion of the patients with DM2 from the MetSyn-group. From all 
the components of the MetSyn only high blood pressure and high fasting glucose 
influenced carotid artery stiffness.
Conclusions Increasing number of components of the metabolic syndrome is asso-
ciated with marginally increased carotid artery stiffness, while type 2 diabetes is
associated with largely increased carotid artery stiffness, in patients with already
manifestations of arterial diseases.
Keywords carotid artery stiffness, diabetes mellitus, metabolic syndrome.
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Introduction
The metabolic syndrome (MetSyn), which involves a cluster of cardiovascular risk 
factors including hypertension, obesity, glucose intolerance, endothelial dysfunction,
dyslipidemia and a proinflammatory state, is associated with an increased risk for
cardiovascular complications.1-3 The MetSyn is associated with advanced vascular
damage in patients with coronary heart disease, cardiovascular events after a myo-
cardial infarction,4 stroke, peripheral arterial disease or abdominal aortic aneurysm5
and untreated essential hypertension.6 As insulin resistance is the major underlying
pathophysiological mechanism, the MetSyn often precedes the development of DM2.
The chance of developing DM2 is 10-fold in patients with impaired fasting glucose.7
The presence of the metabolic syndrome increased the risk for the development of
diabetes mellitus almost 2-fold in American Indians8 and in Finnish men a 4-fold
increase was shown.9
Carotid artery stiffness is increasingly recognized as an important predictor of cardio-
vascular morbidity and mortality. While progress in non-invasive ultrasonography has
enabled reliable measurement of carotid intima media-thickness as a strong surro-
gate of coronary atherosclerosis,10 additional functional measurements of carotid
arteries are providing information on viscoelastic properties, such as arterial stiffness.11
Increased arterial stiffness is considered an independent risk factor for cardiovascular
disease12,13 and stroke14,15. Although elasticity of central arteries is influenced by the
aging process per se,16 hemodynamic forces and other cardiovascular risk factors
associated with insulin resistance are also important.17,18 Previous studies already
showed increasing arterial stiffness with deteriorating glucose tolerance status19,20
and with increasing number of risk factors related to the MetSyn in healthy volun-
teers.21,22 Studying the presence of carotid artery stiffness may provide further
insight in cardiovascular risk in patients with MetSyn compared to DM2 patients, in
a group of patients already at high risk for developing cardiovascular diseases.
Therefore in the present study we determined whether the MetSyn and DM2 
are associated with carotid artery stiffness in patients with already clinical mani-
festations of arterial disease.
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Subjects and methods 
Study population
We used data from patients enrolled in the SMART study (Second Manifestations of
ARTerial disease). The SMART study is an ongoing prospective single-center cohort
study in patients with manifest arterial disease or cardiovascular risk factors (cere-
bral, coronary or peripheral artery disease, renal artery stenosis or an aneurysm of
the abdominal aorta). Starting in September 1996, consecutive patients aged 18 to
80 years, referred to the University Medical Center Utrecht (UMCU) with manifest
arterial disease or a cardiovascular risk factor underwent a vascular screening including
a questionnaire, blood chemistry and ultrasonography. Written informed consent
was obtained from all participants. The study was approved by the medical ethics com-
mittee of the University Medical Center Utrecht. The rationale and design of the 
SMART-study have been described in detail elsewhere.23
Carotid stiffness assessment was part of the vascular screening until august 2003
resulting in a study population of 2105 patients. In 2055 of these patients, all 
5 elements of the metabolic syndrome were known.
Vascular screening
Vascular screening was conducted on a single day at the University Medical Center
Utrecht (UMCU). Blood samples were collected after an overnight fast. Glucose, total
cholesterol, triglycerides and HDL-cholesterol were measured by standard enzymatical
laboratory methods (Vitros 250; Johnson/Johnson). LDL-cholesterol was calculated by
use of Friedewald’s formula. Height and weight were measured without shoes and
heavy clothing. Blood pressure was measured in supine position at the right brachial
artery every 4 minutes during the arterial stiffness measurement with a semiautoma-
tic oscillometric device (Omega 1400, Invivo Research Laboratories Inc., Broken Arrow,
OK, USA). Use of current medication was available.23 Common carotid intima-media
thickness (CIMT) was measured at the left and right common carotid arteries with an
ATL Ultramark 9 (Advanced Technology Laboratories, Bethel, WA, USA) equipped with a
10-MHz linear array transducer as previously described elsewhere.23 The mean CIMT
was calculated in each patient.
Carotid artery stiffness
Stiffness was assessed by measurement of distension of the left and right common
carotid arteries. The distension of an artery is the change in diameter in systole relative
to the diastolic diameter during the cardiac cycle. The displacement of the walls of
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the left and right common carotid artery was measured with a Wall Track System
(Scanner 200, Pie Medical, Maastricht, The Netherlands) equipped with a 7.5 MHz
linear array transducer and vessel wall moving detector system. After a rest of at
least 5 minutes in supine position, patients were examined in supine position with
the head turned approximately 45 degrees away from the side examined. The left
and right carotid arteries were examined separately. Measurements were performed
in the distal common carotid artery 2 cm proximal to the origin of the carotid bulb as
described elsewhere.24 In short, at the right carotid artery 5 measurements were per-
formed. Each assessment lasted 4 seconds and comprised several cardiac cycles. First,
the distension of the cardiac cycles within a single measurement was averaged. Next,
the results of the five assessments were averaged. A similar procedure was used for
the left carotid artery. The mean of the left and right carotid artery measurements
was taken as distension measurement for one individual. The same procedure was
followed for lumen diameter measurements. An intra-observer variability study on
distension and end-diastolic lumen diameter measurements showed a coefficient
of variation of 6.2% and 2.1% respectively. Between observers, the coefficient was 
7.3% and 3.5%, respectively.24
Adjusted carotid distension was the primary stiffness measure,11,25 using blood
pressure simultaneously measured at the brachial artery at 4-minute intervals and
adjusting all models for the end-diastolic diameter of the common carotid artery.
In addition, traditional indexes of arterial stiffness were used for comparison.
β stiffness index was determined as ln(SBP/DBP)/(∆D/Dd) with SBP indicating systolic
blood pressure, DPB indicating diastolic blood pressure, ∆D indicating the carotid
distension and Dd the carotid end-diastolic diameter. Distensibility coefficient
(DC) in 10-3*kPa-1 was (2*∆D/Dd)/PP. Cross-sectional compliance coefficient (CC) 
in mm2*kPa-1 was given as (pi*Dd*∆D)/(2*PP) with PP indicating pulse pressure 
(SBP – DBP). Petersons modulus (EP) in kPa *102 was defined as (PP*Dd)/∆D. Young’s
elastic modulus (YEM) in kPa *103 was (PP*Dd2)/(∆D*2*IMT). Increasing distension,
DC and CC imply decreasing stiffness. Distensibility is the relative change in diameter
and compliance is the absolute change in diameter with pressure. Peterson’s (elastic)
modulus is the pressure change required for (theoretic) 100% increase in diameter,
and Young’s modulus is pressure per square millimeter required for (theoretic) 100%
extension.26 If more pressure change is required it implies increasing stiffness.
Metabolic syndrome
The MetSyn was diagnosed according to the Adult Treatment Panel III criteria, including
three or more of the following metabolic abnormalities27:
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1) Abdominal obesity (waist circumference > 102 cm in men and > 88 cm in women).
2) High blood pressure (≥ 130 mmHg systolic or ≥ 85 mmHg diastolic); patients on
anti-hypertensive medication were regarded as having high blood pressure.
3) Hypertriglyceridemia (serum triglycerides ≥ 1.70 mmol/l).
4) Low serum HDL cholesterol (< 1.04 mmol/l in men and < 1.29 mmol/l in women).
5) High fasting serum glucose (≥ 6.1 mmol/l).
Diabetes mellitus
Patients having a fasting glucose ≥ 7.0 mmol/l and/or use of glucose-lowering 
medication or insulin were defined as having DM2.
Data analysis
Baseline characteristics were determined separately for patients with diabetes 
mellitus (DM2), patients with the metabolic syndrome (MetSyn), patients with both
DM2 and MetSyn and patients with neither DM2 nor MetSyn. The relation of MetSyn
and DM2 with the separate parameters of arterial stiffness was studied with linear
regression analysis, using separate models. First, adjustments were made for age 
and sex. Additional adjustments were performed for mean arterial pressure (MAP:
(2*DBP + SBP)/3). MetSyn and DM2 were entered separately and patients without,
respectively, MetSyn and DM2 served as reference groups. Because the categories of
DM2 and MetSyn are not mutually exclusive, both DM2 and MetSyn were adjusted for
age, sex and mean arterial pressure. Patients without DM2 and MetSyn served as refe-
rence group. Our primary stiffness parameter was carotid distension, adjusted for
blood pressure and end-diastolic diameter in the model. Accordingly, adjustments were
made for carotid end-diastolic diameter in all models with carotid distension as
dependent variable. To additionally study the relation of MetSyn and carotid stiffness
independent of DM2, linear regression models were performed, excluding patients
with DM2.
Carotid stiffness in relation to the number of components of the metabolic syndrome
was studied by calculating the mean adjusted carotid stiffness, using analysis of cova-
riance (ANCOVA, general linear model procedure). Adjustments were made for age, sex
and mean arterial pressure. This was repeated after exclusion of patients with DM2.
Finally, the relation of the separate components of the metabolic syndrome with
carotid distension and the different carotid stiffness indexes was studied using linear
regression analysis. The relation was studied univariately and was additionally adjus-
ted for age, sex and mean arterial pressure. The relation between high blood pressure
and carotid stiffness was studied without adjustment for mean arterial pressure.
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Table 1. Baseline characteristics (N=2105)
MetSyn DM2 DM2 No DM2 
(N=922) (N=301) and MetSyn or MetSyn
(230 with DM2) (230 with MetSyn) (N=230) (N=1112)
Male gender (%) 71 69 67 79
Age (years) 60 ± 10 61 ± 10 61 ± 10 60 ± 11
BMI (kg/m-2) 28 ± 4 27 ± 4 28 ± 10 25 ± 3
Ever smoking (%) 82 77 76 84
Total cholesterol (mmol/l) 5.6 ± 1.3 5.4 ± 1.4 5.2 ± 1.2 5.4 ± 1.1
LDL cholesterol (mmol/l) 3.5 ± 1.0 3.2 ± 1.0 3.2 ± 1.1 3.4 ± 1.0
Creatinin (µmol/l) 77 ± 24 77 ± 25 78 ± 28 74 ± 20
Cockroft creatinin 
clearance (µmol/l) 77 ± 24 77 ± 25 78 ± 28 74 ± 20
Albuminuria (%) 18 24 25 11
Homocysteine (Ìmol/l) 15 ± 7 15± 8 15 ± 8 15 ± 8
Cerebral vascular disease (%) 29 37 37 28
Coronary disease (%) 53 53 53 55
Abdominal aneurysm (%) 12 7 7 11
Periferal vascular disease (%) 32 33 33 24
Ras-inhibitors (%) 25 35 40 15
Thrombocyte-aggregation 
inhibitors (%) 60 62 63 64
Calcium-antagonists 25 24 27 20
Diuretics (%) 18 22 24 9
β-blockers (%) 47 41 46 38
Statins (%) 41 47 47 40
Nitrates (%) 18 17 18 20
CCA characteristics:
Distension (Ìm) 423 ± 151 408 ± 145 409 ± 142 429 ± 143
End diastolic diameter (Ìm) 8192 ± 1114 8248 ± 987 8272 ± 1004 7888 ± 1097
β index 12.9 ± 6.3 14.2 ± 6.9 14.1 ± 6.8 11.7 ± 6.4
DC (10-3*kPa-1) 12.9 ± 5.7 11.8 ± 5.5 11.6 ± 5.2 15.1 ± 6.7
CC (mm2*kPa-1) 0.66 ± 0.29 0.62 ± 0.27 0.61 ± 0.26 0.71 ± 0.29
Peterson’s modulus (kPa *102) 1.90 ± 0.99 2.09 ± 1.08 2.08 ± 1.02 1.67 ± 1.02
YEM (kPa *103) 0.83 ± 0.44 0.88 ± 0.48 0.90 ± 0.49 0.74 ± 0.46
Components of the MetSyn:
Waist circumference (cm) 101 ± 10 99 ± 11 101 ± 11 92 ± 9
Systolic blood pressure (mmHg) 145 ± 19 147 ± 21 148 ± 20 138 ± 20
Diastolic blood pressure (mmHg) 80 ± 10 80 ± 10 80 ± 10 79 ± 10
HDL cholesterol (mmol/l) 1.02 ± 0.27 1.11 ± 0.33 1.02 ± 0.28 1.30 ± 0.34
Triglycerides (mmol/l) 2.6 ± 2.2 2.1 ± 1.2 2.4 ± 1.2 1.5 ± 0.9
Fasting serum glucose (mmol/l) 7.2 ± 2.6 9.6 ± 3.4 9.7 ± 3.5 5.6 ± 0.7
Values are mean ± SD;
CCA: common carotid artery; β index: β stiffness index; DC: distensibility coefficient; CC: compliance coefficient;
YEM: Young’s elastic modulus; The groups are not ‘mutually exclusive’
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Anthropometric, hemodynamic and metabolic baseline parameters
The anthropometric, hemodynamic, and metabolic baseline parameters of the study
population (N=2105) are shown in Table 1. All patients had a recent manifestation of
arterial disease and were classified according to have the MetSyn (N=922 of whom
230 also with DM2), DM2 (N=301 of whom 230 also have the MetSyn), or patients with
both DM2 and MetSyn (N=230), and patients with neither DM2 nor MetSyn (N=1112).
Differences in mean carotid artery stiffness in patients with and without MetSyn
and DM2
In Table 2 the difference in carotid artery stiffness between patients with and wit-
hout MetSyn, and patients with and without DM2 is given. A statistical significant
positive relation was observed between carotid artery stiffness and the MetSyn.
Table 2. Differences in mean carotid artery stiffness in patients with and without MetSyn and DM2
MetSyn MetSyn both MetSynand DM2
vs. vs. vs.
MetSyn (N=922): without MetSyn without MetSyn no MetSyn or DM2
adjusted for age and sex additionally adjusted for adjusted for age, sex and
mean arterial pressure mean arterial pressure
Distension (µm) -9.6 (-21.5;2.3) -6.2 (-18.0;5.7) -3.2 (-15.4;9.0)
β index 0.9 (0.4;1.4) 0.6 (0.1;1.1) 0.3 (-0.2;0.8)
DC (10-3*kPa-1) -1.8 (-2.2;-1.4)* -1.1 (-1.5;-0.7)* -0.8 (-1.2;-0.4)*
CC (mm2*kPa-1) -0.02 (-0.05;-0.001)* 0.001 (-0.020;0.023) 0.01 (-0.01;0.03)
Peterson’s (kPa *102) 0.2 (0.1;0.3)* 0.06 (-0.01;0.13) 0.02 (-0.05;0.1)
YEM (kPa *103) 0.08 (0.04;0.12)* 0.03 (-0.004;0.07) 0.02 (-0.02;0.06)
DM2 DM2 both MetSyn and DM2
vs. vs. vs.
DM2 (N=301): without DM2 without DM2 no MetSyn or DM2
adjusted for age and sex additionally adjusted for adjusted for age, sex and
mean arterial pressure mean arterial pressure
Distension (µm) -18.5 (-35.1;-1.9)* -17.3 (-33.8;-0.9)* -16.2 (-33.2;0.8)
β index 1.7 (1.0;2.4)* 1.6 (0.9;2.2)* 1.4 (0.7;2.1)*
DC (10-3*kPa-1) -2.0 (-2.6;-1.4)* -1.6 (-2.2;-1.1)* -1.3 (-1.9;-0.8)*
CC (mm2*kPa-1) -0.05 (-0.09;-0.02)* -0.04 (-0.07;-0.01)* -0.05 (-0.08;-0.01)*
Peterson’s (kPa *102) 0.3 (0.2;0.4)* 0.2 (0.1;0.3)* 0.2 (0.1;0.3)*
YEM (kPa *103) 0.09 (0.04;0.15)* 0.07 (0,02;0.12)* 0.06 (0.01;0.11)*
Values are mean differences with 95% CI
* p <0.05
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Table 3. Differences in mean carotid artery stiffness in patients with and without MetSyn, after
excluding DM2
MetSyn MetSyn 
vs. vs.
MetSyn (N=692): without MetSyn without MetSyn
adjusted for age and sex additionally adjusted for
mean arterial pressure
Distension (µm) -5.7 (-18.8;7.4) -2.7 (-15.6;10.3)
β index 0.3 (-0.3;0.8) 0.1 (0.4;0.6)*
DC (10-3*kPa-1) -1.1 (-1.6;-0.6)* -0.6 (-1.1;-0.2)*
CC (mm2*kPa-1) -0.04 (-0.07;-0.02)* -0.02 (-0.04;-0.001)
Peterson’s (kPa *102) 0.06 (-0.02;0.14) 0.00 (-0.08;0.08)
YEM (kPa *103) 0.02 (-0.02;0.06) -0.01 (-0.04;0.03)
Values are mean differences with 95% CI
* p <0.05
However this association generally disappeared after adjustment for mean arterial
pressure. Patients with DM2 had stiffer arteries than non-diabetic patients, irrespec-
tive of the measured stiffness parameter. Adjustment for mean arterial pressure did
not materially affect this association. Furthermore, excluding DM2 patients from
the MetSyn-group, weakened the observed positive relation of carotid artery stiffness
(Table 3).
Association between carotid artery stiffness and the number of components of the
MetSyn
In Table 4 is shown that increase in the number of components of the metabolic syn-
drome did increase carotid artery stiffness. Patients who had all five criteria consti-
tuting the MetSyn had significantly the highest β index (range 429-408), and
Peterson’s index (range 1.71-1.84). The DC decreased significantly with increasing
number of components of the MetSyn (range 15.8-13.0). In addition, this association
is not as clear after excluding patients with DM2 from the MetSyn-group. (Table 5).
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Table 5. Relation between carotid artery stiffness and the number of MetSyn components, after
excluding DM2 patients
MetSyn Adjusted mean (range)
components Distension β index DC CC Peterson’s YEM
(N) (µm) (10-3*kPa-1) (mm2*kPa-1) (kPa *102) (kPa *103)
0 430 (405-455) 11.3 (10.3-12.3) 15.9 (15.1-16.7) 0.69 (0.64-0.74) 1.69 (1.54-1.84) 0.75 (0.67-0.82)
1 435 (423-448) 11.9 (11.4-12.4) 14.9 (14.4-15.3) 0.70 (0.68-0.73) 1.72 (1.65-1.80) 0.76 (0.72-0.80)
2 425 (413-437) 12.0 (11.5-12.5) 14.3 (13.9-14.7) 0.69 (0.66-0.71) 1.73 (1.66-1.80) 0.76 (0.73-0.79)
3 431 (418-444) 12.2 (11.6-12.7) 14.0 (13.6-14.4) 0.70 (0.67-0.72) 1.75 (1.67-1.83) 0.76 (0.73-0.80)
4 425 (407-443) 12.4 (11.7-13.1) 13.7 (13.2-14.3) 0.70 (0.67-0.74) 1.79 (1.68-1.90) 0.80 (0.75-0.85)
5 405 (372-438) 12.5 (11.2-13.8) 13.3 (12.2-14.4) 0.71 (0.65-0.78) 1.79 (1.59-1.99) 0.77 (0.67-0.86)
p-trend 0.24 0.06 <0.001 0.64 0.20 0.29
Values are means (range)
Mean values are adjusted for age, sex, and mean arterial pressure
Table 4. Relation between carotid artery stiffness and the number of MetSyn components 
MetSyn Adjusted mean (range)
components Distension β index DC CC Peterson’s YEM
(N) (µm) (10-3*kPa-1) (mm2*kPa-1) (kPa *102) (kPa *103)
0 429 (404-454) 11.4 (10.4-12.4) 15.8 (15.0-16.6) 0.68 (0.64-0.73) 1.71 (1.56-1.86) 0.76 (0.68-0.83)
1 434 (422-447) 12.0 (11.5-12.5) 14.7 (14.3-15.2) 0.70 (0.67-0.72) 1.74 (1.67-1.82) 0.79 (0.73-0.80)
2 423 (412-434) 12.3 (11.9-12.8) 14.0 (13.6-14.4) 0.68 (0.66-0.70) 1.79 (1.73-1.86) 0.77 (0.74-0.81)
3 428 (416-440) 12.4 (11.9-12.9) 13.7 (13.3-14.1) 0.69 (0.67-0.71) 1.78 (1.71-1.86) 0.78 (0.75-0.82)
4 418 (403-433) 12.9 (12.3-13.5) 13.1 (12.6-13.6) 0.68 (0.65-0.71) 1.87 (1.78-1.96) 0.83 (0.78-0.87)
5 408 (383-433) 12.8 (11.7-13.8) 13.0 (12.1-13.8) 0.69 (0.64-0.74) 1.84 (1.68-1.98) 0.77 (0.69-0.84)
p-trend 0.08 0.005 <0.001 0.77 0.04 0.11
Values are means (range)
Mean values are adjusted for age, sex, and mean arterial pressure
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Table 6. Difference in mean carotid artery stiffness between absence and presence of separate com-
ponents of the metabolic syndrome
MetSyn Abdominal High blood Hyper- Low serum  High fasting
components: obesity pressure triglyceridemia HDL cholesterol glucose
Distension (µm) -6.0(-20.1;8.1) -21.1(-36.0;-6.1)* -1.8(-14.5;10.9) 3.7(-9.0;16.4) -15.8(-28.7;-2.9)*
adjusted for age,
sex and mean -0.3(-13.7;13.2) 7.2(-7.3;21.7) -11.2(-23.1;0.8) -4.6(-16.5;7.4) -2.8(-15.0;9.4)
arterial pressure
β index 0.25(-0.37;0.87) 3.43(2.80;4.06)* -0.10(-0.65;0.45) 0.05(-0.50;0.61) 1.65(1.09;2.21)*
adjusted for age,
sex and mean -0.08(-0.62;0.47) 1.83(1.25;2.40)* 0.42(-0.06;0.90) 0.57(0.10;1.05)* 0.78(0.29;1.26)*
arterial pressure
DC (10-3*kPa-1) -0.71(-1.32;-0.10)* -6.35(-6.94;-5.77)* -0.34(-0.89;0.21) -0.10(-0.45;0.65) -2.25(-2.80;-1.70)*
adjusted for age,
sex and mean -0.22(-0.65;0.21) -4.52(-5.01;-4.02)* -0.83(-1.21;-0.45)* -0.61(-0.99;-0.23)* -0.99(-1.38;-0.61)*
arterial pressure
CC (mm2*kPa-1) 0.01(-0.03;0.10) -0.17(-0.20;-0.14)* 0.00(-0.02;0.02) 0.01(-0.02;0.04) -0.05(-0.07;-0.02)*
adjusted for age,
sex and mean 0.02(0.0;0.05) -0.11(-0.14;-0.09)* -0.01(-0.03;0.01) -0.01(-0.03;0.02) -0.01(-0.03;0.01)
arterial pressure
Peterson’s (kPa *102) 0.05(-0.05;0.15) 0.74(0.64;0.84)* -0.01(-0.10;0.08) -0.02(-0.10;0.07) 0.27(0.18;0.36)*
adjusted for age,
sex and mean -0.02(-0.1;0.06) 0.50(0.41;0.59)* 0.05(-0.02;0.12) 0.0890.01;0.15)* 0.10(0.03;0.17)*
arterial pressure
YEM (kPa *103) 0.00(-0.04;0.05) 0.28(0.24;0.33)* 0.01(-0.03;0.05) 0.01(-0.03;0.05) 0.09(0.05;0.13)*
adjusted for age,
sex and mean -0.02(-0.06;0.02) 0.21(0.16;0.25)* 0.03(-0.01;0.06) 0.04(0.08;0.10)* 0.03(-0.01;0.06)
arterial pressure
Values are mean differences with 95% CI 
* p<0.05
The relation was studied univariately in a first model and was additionally adjusted for age, sex and mean arterial
pressure; the relation of high blood pressure and carotid stiffness was studied without adjustment for mean arterial
pressure  
Abdominal obesity (waist circumference > 102 cm in men and > 88 cm in women); High blood pressure (≥ 130 mmHg
systolic or ≥ 85 mmHg diastolic); Hypertriglyceridemia (serum triglycerides ≥ 1.70 mmol/l); Low serum HDL cholesterol
(< 1.04 mmol/l in men and < 1.29 mmol/l in women); High fasting serum glucose (≥ 6.1 mmol/l)
Difference in mean carotid artery stiffness between absence and presence of separate
components of the metabolic syndrome
Studying the difference in mean carotid artery stiffness between absence and presence
of separate components of the MetSyn showed that only high blood pressure and high
fasting glucose were associated with increased carotid artery stiffness. Abdominal 
obesity, hypertriglyceridemia, and low serum HDL cholesterol did not influence the
carotid artery stiffness significantly.
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Discussion
The main result of the present study is that (increasing number of components of)
the metabolic syndrome is associated with marginally increased carotid artery stiff-
ness, while type 2 diabetes is associated with a marked increase in carotid artery
stiffness, in patients with already manifestations of arterial disease. High blood
pressure and high fasting glucose are the only components of the metabolic syndrome
that were associated with increased carotid artery stiffness.
The increasing prevalence of clustered risk factors in association with central obesity
is gaining increased attention worldwide. In line with several other studies in different
high-risk populations,2;28;29 the prevalence of the MetSyn in our study population is
nearly 50%. In healthy populations, the presence of the MetSyn is associated with 
a nearly 3-fold increase in cardiovascular related mortality compared to subjects 
without the MetSyn,30 this syndrome calls for a systemic approach to identification
and treatment. The individual components that make up the syndrome could be 
treated separately or with awareness of insulin resistance as the underlying disorder.
Patients with MetSyn are also at risk for the development of vascular abnormalities
that range from endothelial dysfunction, followed by artery stiffness, to evident
atherosclerosis.31 All separate traditional components of the MetSyn (hyperglycemia,
hypertension, low plasma HDL cholesterol, hypertriglyceridemia, and central obesity)
are cardiovascular risk factors and are known to cause endothelial dysfunction.32-34
In DM2 the elevated glucose-levels may add to the development of vascular damage.35
In MetSyn the glucose-levels are lower and therefore the increased cardiovascular risk
is most likely due to metabolic changes associated with insulin resistance causing
impaired vasoreactivity.36 Endothelial dysfunction is a preliminary state causing
remodeling of the vessel wall resulting in increased vascular stiffness and decreased
compliance/elasticity/distensibility. Decreased NO-bioavailability by reactive oxygen
species (ROS) might be a major driving force for instability of atherosclerotic plaques
in patients with the MetSyn.37 Also low-grade inflammation induces endothelial dys-
function by elevated plasma levels of C-reactive protein (CRP), TNF-α, and IL-6.38-40
Carotid artery stiffness is an indicator for the risk of cardiovascular disease12,13 and
stroke.14,15 The results of the present study may conclude that the longer the exposure
of insulin resistance to the vessel wall, the stronger the positive association with
carotid artery stiffness. Compared to patients without DM2, patients with DM2 had
increased arterial stiffness, while carotid stiffness did not differ as much between
Artery stiffness is more increased in type 2 diabetes than in the metabolic syndrome 
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patients with or without MetSyn. Furthermore, although in the population as a
whole, carotid artery stiffness increases with increasing number of components of
the metabolic syndrome, this association is not as clear after exclusion of the
patients with DM2 from the MetSyn-group. High glucose plasma levels, seen in DM2
but not in MetSyn, and longer exposure of the vessel wall to other metabolic changes
associated with insulin resistance  may have contributed to increased arterial stiff-
ness.19,20 MetSyn patients are at high risk for developing type 2 diabetes. The clinical
implication of this finding may be that progression of MetSyn to type 2 diabetes may
lead to an increase in cardiovascular risk. Therefore, preventing MetSyn patients to
develop type 2 diabetes can be an effective strategy to reduce cardiovascular risk.
Increased number of risk factors, as clustered in the MetSyn have been associated
with arterial stiffness in healthy volunteers.21,22 The present study confirms these
results in patients with clinical manifestations of vascular disease. This adds to the
concept of increased vascular risk in MetSyn patients, indicated by advanced vascular
damage as measured by intima media thickness and ankle brachial pressure index,
in a previous study in patients with manifest vascular disease.5 However, supposed
to be an independent predictor for cardiovascular disease12,13 and stroke,14,15, carotid
artery stiffness was no independent risk factor for vascular events in the studied 
population of this present study.41 This could explain the minimal correlation
between carotid artery stiffness and MetSyn.
We acknowledge some limitations of our study. Firstly, there is not a single clinical
definition for the clustering of risk factors associated with abdominal obesity. The
MetSyn can be described by several definitions, which implies that it may be difficult
to compare outcomes of different studies. Most commonly used, because more easy
to measure in daily clinical practice, is the working definition suggested by the ATP
III. Recently also the International Diabetes Federation (IDF) based their MetSyn
definition on modified ATP III criteria.42 Although insulin resistance seems to be a
major underlying disorder, the pathophysiology of MetSyn is not completely clear
yet. Secondly, this survey is a cross-sectional study so only assumptions about possible
etiological relationships can be made without the possibility to draw conclusions 
in terms of causality. Furthermore, adjusted carotid distension, together with other
traditional indexes of arterial stiffness (β index, DC, CC, Peterson’s, and YEM), was used
as stiffness measurements. Although the several different measures can make the
interpretation difficult, it may also give an overview of carotid artery stiffness.
74
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We conclude that (increasing number of components of) the metabolic syndrome is
associated with marginally increased carotid artery stiffness, while type 2 diabetes
is associated with a marked increase in carotid artery stiffness, in patients with already
manifestations of arterial disease. Preventing MetSyn-patients to progress to DM2 may
reduce the cardiovascular risk.
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Introduction
Cardiovascular disease is the number one cause of morbidity and mortality in the
Western world. Several risk factors for the development of cardiovascular disease have
been identified. Some of these risk factors (dyslipidaemia, hypertension, glucose intole-
rance, hyperinsulinaemia, obesity, low-grade inflammation, endothelial dysfunction
and hypercoagulability) have been found to cluster and often precede clinically manifest
type 2 (noninsulin–dependent) diabetes mellitus. Insulin resistance is generally regarded
as an important feature of this cluster of risk factors and therefore the term ‘insulin 
resistance syndrome’ has been coined.1 ‘Cardiovascular dysmetabolic syndrome’,2 or 
‘syndrome X’3 are other terms which have been used to describe this metabolic state.
The prevalence of type 2 diabetes has soared in the past decades because of changing
lifestyles and eating habits. Obesity associated with insulin resistance is one of the
main determinants of the increase in occurrence of type 2 diabetes. Not surprisingly,
the major long-term complications of type 2 diabetes are an increased risk of 
myocardial infarction, stroke and peripheral vascular disease. Although microvascular
complications cause considerable morbidity in patients with type 2 diabetes, up to
80% of patients die from macrovascular pathology.4
Treatment of individual risk factors has been shown to reduce cardiovascular events
in type 2 diabetes. Dysglycaemia does not appear to be the major determinant of
cardiovascular disease in type 2 diabetes, a concept supported by observations in
the UK Prospective Diabetes Study.5 Therefore, targeting the underlying patho-
physiological mechanisms of the insulin resistance syndrome may be a more logical
and beneficial strategy for reduction of cardiovascular morbidity and mortality.
Pharmacological modulation of the insulin resistance syndrome will not only
improve glycaemic control, but may also have beneficial effects on inflammation,
dyslipidaemia and possibly other components of the syndrome independently from
improvements in glucose metabolism.
The discovery of nuclear peroxisome proliferator-activated receptors (PPARs) and
subsequent insight into their role in several metabolic pathways was a major 
breakthrough in our understanding of pathophysiological mechanisms underlying
the insulin resistance syndrome.6
Thiazolidinediones are clinically available agonists of the PPAR-γ subtype and 
constitute a new class of antihyperglycaemic agents. Activation of PPAR-γ not only
improves insulin sensitivity but may also have additional beneficial vascular effects.
The aim of this review is to focus on the potential role of thiazolidinediones in the
pathophysiological mechanisms involved in vascular disease.
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1. Peroxisome Proliferator-Activated Receptors (PPARs)
PPARs are ligand-activated transcription factors belonging to the nuclear receptor
superfamily, which include receptors for steroids, retinoid and thyroid hormones.7-9
Once PPARs are activated by ligand binding, they form heterodimers with the
ligand-activated retinoic acid receptor (RXR). Through its DNA binding domain, this
heterodimer binds to specific DNA sequences, called PPAR-responsive elements
(PPREs), and induces transcriptional activation of specific genes (figure 1).10 PPARs
function as regulators of glucose, lipid and protein metabolism, and influence cellular
proliferation, differentiation and apoptosis. They also play a role in neoplastic prolife-
ration and inflammatory diseases.11
Three subtypes of PPARs are known: PPAR-α, PPAR-γ and PPAR-δ.The tissue distribution
of these subtypes varies considerably.10-12 Whereas PPAR-δ is ubiquitously 
distributed, its function remains to be elucidated. PPAR-α is found in liver, intestine,
kidney, heart, adipose tissue, skeletal muscle and recently in vascular cells.13 PPAR-α
has an important role in lipid metabolism. Its molecular targets include genes for
enzymes that are important for the β-oxidation of fatty acids.14 Synthetic ligands for
this receptor subtype are fibric acid derivatives, which are used in clinical practice as
lipid-lowering agents. PPAR-γ is found in adipose tissue, pancreas, skeletal muscle and
vasculature.10,12,13,15 High levels of expression are found in adipocytes. In addition,
PPAR-γ is also expressed in macrophages, T cells, neutrophils, epithelial cells and
smooth muscle cells.16
Figure 1. Mechanism of action of the peroxisome proliferator-activated receptors (PPARs)
L = ligand; PPRE = PPAR-responsive elements; RXR = retinoic acid receptor; TZD = thiazolidinediones
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The most potent natural ligands are 13-hydroxyoctadecadienoic acid (HODE) 
and 15-deoxy∆-prostaglandin J2 (15d-PGJ2).17 Thiazolidinediones are potent synthetic
ligands for PPAR-γ activation.
2. Thiazolidinediones
Thiazolidinediones are a new class of drugs that act primarily by improving insulin
sensitivity in different target tissues such as liver, skeletal muscle and adipose 
tissue. They have been shown to improve glycaemic control in patients with type 2
diabetes and appear to have favourable direct effects on other components of the
insulin resistance syndrome because of the role of PPAR-γ in vascular physiology
(figure 2).18,19 Thiazolidinediones are chemically and functionally unrelated to other
classes of oral antihyperglycaemic agents. Two compounds in this class are currently
available for clinical use, namely, rosiglitazone, which was approved by the US Food
and Drug Administration (FDA) in May 1999, and pioglitazone, which was approved
in July 1999. Troglitazone, the first drug of this class, was marketed in the US from
March 1997 until it was withdrawn in March 2000, when the FDA decided that the
risk of hepatotoxicity associated with troglitazone therapy outweighed its potential
benefits. The mode of action and magnitude of effects of different thiazolidinediones
show some variation.20-23 Pioglitazone may perhaps also have PPAR-α agonistic
effects, which is of interest with regard to lipid-lowering effects similar to fibric acid
derivatives.
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Figure. 2. The central role of peroxisome proliferator-activated receptor (PPAR)-γ in vascular physiology
HbA1c = glycosylated haemoglobin
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3. Thiazolidinediones and glycaemic control
Several thiazolidinediones have been shown to improve insulin sensitivity by increasing
glucose disposal in skeletal muscle and decreasing hepatic glucose production.
Thiazolidinediones increase glycogen synthase activity and glucose metabolism in 
skeletal muscle but also in adipocytes. They also decrease gluconeogenesis in cultured
hepatocytes.23-25 Stimulation of PPAR-γ normalises glucose uptake associated with 
glucose transporter 4 (GLUT4) expression and stimulates insulin receptor expression
and activation.26-32
Improvement of glycaemic control by thiazolidinediones has been shown in different
animal models of diabetes33-36 and in patients with type 2 diabetes. Although 
troglitazone has been withdrawn from the market, it was very effective in lowering
plasma glucose, insulin and glycosylated haemoglobin (HbA1c) levels in patients
with type 2 diabetes.37-40 Rosiglitazone resulted in significant reductions in fasting
plasma glucose, HbA1c and insulin levels, and was more effective than troglitazone
in maintaining low fasting plasma glucose levels in the long term.41 Rosiglitazone
also improved glycaemic control in patients with type 2 diabetes when administered
in combination with metformin, sulphonylurea derivatives or insulin.42,43 Similar
significant decreases in fasting plasma glucose and HbA1c levels are achieved 
with pioglitazone in monotherapy;44,45 furthermore, combination therapy with
metformin, sulphonylurea derivatives or insulin, improves glycaemic control more
than pioglitazone monotherapy does.45 Unfortunately, studies comparing the 
individual effects of thiazolidinediones with metformin in glycaemic control have
not been published yet. In addition, thiazolidinediones improve insulin sensitivity in
nondiabetic insulin-resistant states, such as obese individuals and individuals with
impaired glucose tolerance.46,47
What mechanisms could be involved in the beneficial effects of thiazolidinediones
on glycaemic control and insulin resistance? Since obesity, causing insulin resistance,
is a main determinant for the development of type 2 diabetes, mechanisms related to
adipocyte function are likely to be involved.
3.1 Differentiation of adipocytes
PPAR-γ is expressed mainly in adipose tissue and is a key factor in the differentiation
of adipocytes and adipogenesis (figure 3).48-49 PPAR stimulation alters adipocyte
metabolism by increasing the expression of specific adipocyte genes involved in 
glucose regulation (e.g. GLUT4, lipoprotein lipase (LPL), fatty acid transporter 
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protein, Acyl CoA synthase and malic enzymes).50 Recent observations in PPAR-γ
knockout mice show that homozygous PPAR-γ-null mice are completely devoid of
adipose tissue and that mice heterozygous for the mutation (PPAR-γ +/- mice) are
characterised by a decreased adipose tissue mass.51 These in vivo results are further
supported by in vitro data showing that embryonic stem cells lacking both copies of
PPAR-γ fail to differentiate into adipocytes after appropriate treatment, whereas
embryonic stem cells expressing PPAR-γ readily differentiate into adipocytes.52
Moreover, forced expression of PPAR-γ in fibroblasts makes them differentiate into
adipocytes.53 Pioglitazone affects the early stage of adipocyte differentiation and
enhances growth arrest, protein synthesis and hypertrophy of 3T3-L1 adipocytes.54
Exposure of 3T3-L1 adipocytes to tumour necrosis factor (TNF)-α, a potent inhibitor
of adipocyte differentiation, results in lipid depletion and a complete reversal of 
adipocyte differentiation.55 Consistent with the opposing effects of PPAR-γ and TNF-α
in adipose tissue, treatment of obese animals with PPAR-γ agonists reduces the 
adipose tissue expression of TNF-α, which contributes to the weight gain.56
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Figure 3. The peroxisome proliferator-activated receptor (PPAR)-γ paradox of increased adipogenesis
and beneficial diabetic treatment TNF-α= tumour necrosis factor-α
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An interesting concept is the ‘lipid-steal hypothesis’.53,57 This hypothesis states that
stimulation of adipose differentiation leads to increased numbers of small adipocytes,
which are thought to be more sensitive to insulin than large adipocytes. These 
smaller adipocytes take up free fatty acids more easily and thus reduce free fatty
acid flux to the muscles or liver. Pioglitazone strongly induces adipocyte differentia-
tion and increases adipocyte glucose utilisation at post-absorptive insulin levels in
vivo.27 However, thiazolidinediones also exert beneficial effects on glucose and lipid
metabolism in the absence of adipose tissue,28 suggesting that an alteration in 
adipocyte differentiation cannot be a sole explanation for the improvement in 
insulin sensitivity.
How can the paradox of beneficial effects of PPAR-γ activation with improvement of
insulin resistance on one hand and stimulation of adipogenesis on the other hand
be explained?
Thiazolidinedione-induced adipogenesis occurs mainly in subcutaneous fat and not
in visceral fat. An increase in visceral fat is associated with a higher cardiovascular
risk. In line with this, levels of mRNA for PPAR-γ and leptin are higher in subcutaneous
fat than in visceral fat.58 Furthermore, 3T3-L1 pre-adipocytes in subcutaneous 
fat become resistant to apoptosis after differentiation into mature adipocytes, a
process stimulated by PPAR-γ activation and resulting in decreased apoptosis in 
subcutaneous fat.59 Finally, the recently identified protein, resistin, a protein that
causes insulin resistance in mice and which is inhibited by PPAR-γ activation, may
also be involved.60 Unfortunately, these results are controversial because resistin is
not found in humans, once again showing the discrepancy between experimental
animal studies and human physiology.
3.2 Modulation of tissue triglyceride content
Improvement in insulin resistance is associated with a decrease in the triglyceride
content of liver and skeletal muscle. Treatment with thiazolidinediones reduces the
triglyceride content in liver and skeletal muscle, which may be an important factor
in the observed improvement in peripheral glucose disposal and decreased hepatic
glucose output.61 In addition, thiazolidinediones also lower the triglyceride content
of β cells, which is associated with an improvement of β cell function.62 Supporting
these data is the clinical observation that the high ratio of proinsulin to insulin 
typically found in patients with type 2 diabetes mellitus is normalised upon thiazol-
idinedione treatment, suggesting an effect of these drugs on β cell function.39,63
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3.3 Effect on adipocyte-derived factors
Other mechanisms of the thiazolidinediones include regulation of storage and release
of adipocyte-derived signaling factors that affect insulin sensitivity of muscle. These
factors include free fatty acids, adiponectin, TNF-α and leptin.
3.3.1 Free fatty acids
Fatty acids are key mediators of the storage or release of adipocyte-derived signa-
ling factors affecting insulin sensitivity. High levels of free fatty acids have been 
linked to the induction of insulin resistance, because increased free fatty acid meta-
bolism in the liver leads to increased gluconeogenesis.64 There is evidence for a
direct regulatory effect of fatty acids on the production of macrophage lipoprotein
lipase (involved in the pathogenesis of atherosclerosis) in the vascular wall.65 It
is well established that increased fatty acid levels decrease glucose metabolism 
in muscle. Because fatty acids are ligands for PPAR-γ, activation of PPARs by thia-
zolidinediones increases fatty acid clearance in adipose tissue with a concomitant
decrease in the uptake of fatty acids in muscle, which potentially improves insulin
sensitivity.66-67
The mechanism underlying these effects may be related to the regulation by PPAR-γ
of the expression of the fatty acid transporter CD36, which is also implicated in the
control of insulin sensitivity.68-70 There is also a correlation between PPAR-γ trans-
activation and intracellular levels of liver fatty acid-binding protein, which could
explain the decrease in plasma levels of free fatty acids.71 Furthermore, PPAR-γ is
required for the expression of adipocyte phosphoenolpyruvate carboxykinase
(PEPCK). PEPCK is the key enzyme in glyceroneogenesis, an important metabolic
pathway that limits the release of non-esterified fatty acids from adipocytes.72
Therefore, PEPCK could be a major target gene for the antidiabetic actions of 
thiazolidinediones. Thus, lowering the elevated plasma levels of non-esterified fatty
acids is likely to be an important mechanism to explain the beneficial metabolic
effects induced by thiazolidinediones.
3.3.2 Adiponectin
Adiponectin is an adipocyte-derived hormone that decreases insulin resistance 
by lowering the triglyceride content of muscle and liver in obese mice. This effect
results from increased expression of molecules involved in fatty-acid combustion 
in muscle. Moreover, insulin resistance in lipoatrophic mice can be completely 
reversed by physiological doses of adiponectin and leptin.73) In addition, adiponectin
suppresses adhesion molecule expression in vascular endothelial cells and inhibits
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cytokine production by macrophages. Recent publications show that thiazolidine-
diones can markedly enhance the expression and secretion of adiponectin in vitro
and in vivo, possibly (partly) mediated by antagonising the suppressive effect of 
TNF-α on the production of adiponectin.74 However, the exact role of adiponectin in
insulin resistance in humans has not been elucidated.
3.3.3 Tumour necrosis factor-α
The expression of TNF-α by adipose tissue is upregulated in obesity and TNF-α levels
are increased in patients with features of the insulin resistance syndrome. This 
cytokine decreases PPAR-γ expression, insulin receptor synthesis and activation, and
glucose uptake in adipose tissue, skeletal muscle and liver by attenuating the
expression of the glucose transporter GLUT4.31,75-77 Chronic hyperglycaemia is asso-
ciated with increased TNF-α production, which may be derived from adipose tissue.78
Thiazolidinediones restore sensitivity to insulin by down-regulating adipose 
cytokines such as TNF-α.6,79,80 Furthermore, it has been shown that pioglitazone
improves TNF-α-induced insulin resistance by improving insulin-stimulated tyrosine
phosphorylation of the insulin receptor and insulin receptor substrate.81
3.3.4 Leptin
Thiazolidinediones have also been implicated in the regulation of leptin expression.
Administration of thiazolidinediones reduces the expression of leptin mRNA and
protein in adipocytes in vivo and in vitro.82 The role of leptin in insulin resistance is
controversial, but some reports indicate that leptin might interfere with insulin 
signalling in certain cell types.
In conclusion, glycaemic control and insulinsensitising properties of thiazolidine-
diones may involve a wide range of inter-related mechanisms in different target
tissues involved in insulin activity and glucose production and uptake.
4. Thiazolidinediones and additional vascular effects
4.1 Improvement of endothelial (dys-)function
Atherosclerotic disease is characterised by endothelial dysfunction. Endothelial 
dysfunction is characterised by decreased availability of endothelium-derived nitric
oxide (NO) and can be assessed clinically by impaired vasoreactivity of the brachial
artery after an ischaemic or other stimulus. Impaired endothelial function has 
proefschrift_Fabrice  21-12-2005  14:21  Pagina 89
prognostic significance for future development of cardiovascular events. All known
cardiovascular risk factors are associated with endothelial dysfunction.83,84
Endothelial dysfunction appears to be an important feature of the insulin resistance
syndrome. Upon binding to the endothelial insulin receptor, insulin activates 
endothelial NO synthase (eNOS), thereby stimulating NO production, resulting in
vasodilation. This vasodilation is impaired in insulin-resistant states, which has
been termed vascular insulin resistance. Patients with insulin-resistant states such
as obesity, hypertension and type 2 diabetes exhibit blunted insulin-mediated 
vasodilation and impaired endothelium-dependent vasodilation.85 Quenching of
NO by decreased NO or an increased inactivation of NO by reactive oxygen species
(ROS) might be a major driving force for instability of atherosclerotic plaques in
patients with diabetes.86
In both obese people and healthy volunteers, it was shown that a single oral dose of
troglitazone improved the ischaemia-induced flow-mediated vasodilatation in the
forearm.87-88 Normalisation of impaired brachial artery vasoreactivity also occurred
during troglitazone therapy in individuals with peripheral vascular disease and
impaired glucose tolerance.89
How can thiazolidinediones improve endothelial function? Improved metabolic 
control will most likely contribute to the effects observed. High levels of glucose and
free fatty acids stimulate ROS production, for example through protein kinase 
C-dependent activation of nicotinamide adenine dinucleotide (phosphate)
[NAD(P)H] oxidase.90 Reduction of the glucose and free fatty acid concentrations by
thiazolidinediones will therefore have beneficial effects. A reduction in formation of
ROS by both polymorphonuclear leukocytes and mononuclear cells after admini-
stration of troglitazone may also contribute to improvement in endothelial 
function.88 Incubation with insulin plus pioglitazone improves vasodilation 
induced by acetylcholine, suggesting that pioglitazone augments the endothelium-
dependent vasodilation mediated by insulin.91
Direct effects of thiazolidinediones on vascular smooth muscle cells have also been
observed. Thiazolidinediones attenuate vasoconstriction as well as inhibit L-type
Ca2+ currents in vascular smooth muscle cells (VSMC) in vitro.92 The vasodilative
action of pioglitazone after removal of the endothelium93 is not yet completely
understood. Pioglitazone appears to act mainly on VSMC rather than the vascular
endothelium. However, expression of PPAR-γ mRNA is very low in VSMC.94
In patient groups with a high incidence of cardiovascular diseases and endothelial
dysfunction (congestive heart failure, diabetes, atherosclerosis) TNF-α levels are
increased. There may be an interesting link between TNF-α and endothelial function
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because of the direct association between TNF-α and NO bioavailability. TNF-α
downregulates mRNA for eNOS by shortening its half-life in human umbilical vein
endothelial cells.96 In a rat model, recombinant TNF-α infusion in vivo depresses
endothelium-dependent relaxation without decreasing mean arterial pressure.96
In addition, brief exposure of the human forearm resistance artery to TNF-α
may increase the basal bioavailability of the vasoconstrictor prostaglandin and
reduce the basal bioavailability of NO. However, in acetylcholine-stimulated endo-
thelium-dependent vasodilatation, TNF-α did not impair the vascular function,
maybe because of an overwhelming NO bioavailability in healthy humans.97 It is
noteworthy to mention that interpretation of these results are difficult in the light
of the effects of TNF-α on the inducible form of NOS (iNOS).
4.2 Decreased inflammatory conditions
Low-grade inflammation plays an important role in the initiation and progression
of cardiovascular diseases.98 Accumulation of monocyte-derived lipid-loaded
macrophages or foam cells, smooth muscle cell proliferation and de novo formation
of extracellular matrix results in the formation of the atherosclerotic plaque.99
Markers of inflammation, such as the acute-phase protein C-reactive protein (CRP),
TNF-α and interleukin (IL)-6, are increased in patients with the insulin resistance 
syndrome.100,101 Elevated serum levels of CRP, which is indicative of a low-grade 
inflammatory state, are associated with a diminished systemic endothelial 
vasodilator function.102
PPARs are mainly expressed in adipocytes and could have an important role in down-
regulation of the inflammatory cytokine TNF-α as discussed in sections 3.3.3 and 4.1.
Expression of PPARs in macrophages, T cells and neutrophils suggests that they may
have an important role in modulating the function of inflammatory cells.16
4.2.1 Modulation of PPAR activity in inflammatory cells
Several studies have reported that PPAR agonists dampen inflammatory responses
in macrophages. PPAR-γ agonists inhibit tissue factor expression in human mono-
cytes and macrophages,103,104 and PPAR-γ agonists reduce macrophage homing to
atherosclerotic plaques.106 PPAR-γ is a negative regulator of macrophage activation
and may limit chronic inflammation by inhibiting the induced expression of 
circulating vascular cell adhesion molecule-1 (VCAM-1) and monocytes without
affecting the acute inflammation mediated by endothelial-leucocyte adhesion
molecule (E-selectin).106,107 In vitro, PPAR-γ agonists suppress the release of 
inflammatory cytokines, such as TNF-α, IL-1 and IL-6, from monocytes at agonist
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concentrations similar to those effective in promoting adipogenesis.108 An 
increased expression of PPAR-γ during the differentiation of monocytes and macro-
phages initially suggested that PPAR-γ may regulate macrophage differentiation.10,109
However, there are also studies, performed with PPAR-γ–deficient stem cells,
suggesting that PPAR-γ is not essential for either myeloid development, or for cer-
tain functions of mature macrophages such as phagocytosis and inflammatory
cytokine production.16,110 Several reports indicate that PPAR-γ agonists dampen
macrophage inflammatory responses by reducing the expression of matrix-
degrading metalloproteinases, cytokines, NO and modified lipoprotein recep-
tors,107,108,110,11 whereas others do not.16,112 Part of this contradiction can be 
explained by the widely varying doses of PPAR-γ agonists used. At high concentra-
tions these agents appear to have PPAR-γ-independent actions, which are as yet
poorly understood.113
4.2.2 CD36 expression in mononuclear cells
PPAR-γ stimulation induces CD36 gene expression.70,110,114 CD36 is a transporter of
longchain fatty acids and is a high-affinity receptor for oxidised low-density lipo-
proteins (oxLDL).115 CD36-deficient mice have a 6-fold reduction in atheroma compa-
red with controls,116 probably because of a reduced uptake of oxLDL, which results in
diminished foam cell formation.109 Since PPAR-γ increases the expression of CD36,
there is concern about the overall antiatherogenic effect of thiazolidinediones.
Some investigators have reported that PPAR activation leads to an induction of foam
cell formation from macrophages,70,109,110 whereas others have reported suppression
of inflammatory cytokines and induction of cholesterol efflux from macrophages as
antiatherogenic effects of PPAR activation.114,117 However, overall results indicate
that foam cell development can occur in the absence of PPAR-γ and that PPAR-γ
agonists decrease atherosclerosis in animal models of LDL receptor and apolipopro-
tein E deficiency.118 The induction by PPAR of cholesterol efflux through the adenosine
triphosphate (ATP)-binding cassette transporter 1 (ABCA1) may be a counter-
balancing mechanism. The liver X receptor-α (LXRα) and the scavenger receptor A
(SRA) may have a central role in this concept of cholesterol efflux induced by PPAR
activation.60,110,117
Recently, CD36-deficient humans were found to have an increased insulin resistance,
including higher plasma triglyceride and glucose levels, lower plasma high-density
lipoprotein (HDL) cholesterol levels and much higher blood pressure than controls.69
So far, most studies show a net antiatherogenic effect of thiazolidinediones, but
the major mechanisms for this still have to be clarified.80;119 Agonists of PPAR-α 
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and PPAR-γ inhibit the cardiac expression of TNF-α, in part by antagonising nuclear 
factor-κB activity.120
Taken together, these complex observations suggest that thiazolidinediones may
have beneficial effects in modulating the inflammatory state and thus atherogenesis.
4.3 Effects on the lipid profile
Dyslipidaemia is a well-established risk factor for the formation of atherosclerotic
plaques. Insulin resistance and type 2 diabetes are associated with a characteristic
pattern of lipid abnormalities, including an increased number of small dense 
LDL particles, elevated plasma triglyceride levels, and low plasma high density 
lipoprotein (HDL) levels.121 The disturbance of lipid metabolism may not be the
result of insulin resistance alone, but may also be directly involved in the metabolic
abnormalities observed. Evidence obtained from obese animal models (eg. rats fed
high-fat diets) shows excess accumulation of muscle triglyceride together with the
development of insulin resistance.122 Several studies demonstrate an increased
muscle triglyceride content in insulin-resistant states in humans as well.123-125 The
factors leading to this accumulation are not clear yet, but it could well be a result of
elevated circulating free fatty acids associated with impaired triglyceride clearance,
or reduced muscle free fatty acid oxidation.
4.3.1 Reduction of plasma triglycerides
In humans, troglitazone4,22 and pioglitazone126,127 lower triglyceride levels by
approximately 9 to 20%. In contrast, mean triglyceride levels were increased after
rosiglitazone treatment by 38.4%.128 The exact mechanism by which thiazolidine-
diones affect triglyceride levels is currently not known. Pioglitazone has been 
reported to increase the expression of lipoprotein lipase and to decrease the expres-
sion of apolipoprotein C-III (key players in plasma triglyceride metabolism), indicating
that pioglitazone has PPAR-α agonistic activity.129 The triglyceride-lowering action 
of PPAR-γ activation may be the result of a reduction in fatty acid and triglyceride 
synthesis, and consequently a decrease in the production of very-lowdensity lipo-
protein (VLDL).
4.3.2 Effects on lipoprotein metabolism
Several trials have been conducted to study the effects of thiazolidinediones on
plasma lipoproteins. In general there appears to be an increase in HDL (up to
≈20%).130 The increase in HDL levels is likely to be explained by the decrease in 
triglyceride levels.
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LDL levels tend to increase (≈10%),130 are unaffected or are lowered (≈15%) by thia-
zolidinedione treatment.128,131,132 However, the concomitant changes in plasma HDL
and LDL levels resulted in unaltered LDL to HDL ratios.4,130 The increase in total 
cholesterol and LDL cholesterol levels observed in several studies is cause for 
concern. This increase may be predominantly caused by larger, buoyant LDL particles.
Larger LDL particles are less prone to oxidative modification and are therefore
thought to be less atherogenic.133,134 Support for this hypothesis comes from a study
showing that troglitazone increases the resistance of LDL cholesterol to oxidation.135;136
Recent studies reported a decrease in LDL levels after pioglitazone treatment.128,131,132
There appears to be a differential effect of thiazolidinediones: LDL levels apparently
increase more during rosiglitazone than pioglitazone treatment.127,137 In a head to
head comparison, treatment with pioglitazone was associated with overall greater
beneficial effects on blood lipid levels (total cholesterol, HDL, LDL and triglycerides)
than treatment with rosiglitazone, while similar effects were demonstrated in
respect to weight gain and glycaemic control.131,132 A possible reason is that pioglita-
zone may perhaps also have PPAR-α agonistic effects, which is in line with lipid-lowering
effects of fibric acid derivatives. The different effects of the various thiazolidinediones
on lipid metabolism need further investigation, but considering its central role in lipid
metabolism, pharmacological modulation of PPAR-γ activity by thiazolidinediones may
result in an overall improvement of the dyslipidaemic phenotype.127,138,139
4.4 Lowering blood pressure
Troglitazone and rosiglitazone decrease blood pressure by ≈10%. This effect has been
observed in patients with hypertension and type 2 diabetes,140,141 individuals with
normal blood pressure and type 2 diabetes,141,142 and obese individuals without
diabetes.47,143 Pioglitazone therapy decreased arterial pressure in rat models of hyper-
tension92,93 and prevented the development of hypertension.144 Other animal and
human studies have shown that thiazolidinediones decrease blood pressure associa-
ted with decreased insulin levels and improvement of endothelial function.91,145,146
However, the exact role of decreased insulin levels on the thiazolidinedione-mediated
regulation of blood pressure is debated because some reports show insulin- and gluco-
se-independent blood pressure–lowering mechanisms.87,147 It has also been suggested
that thiazolidinediones may lower blood pressure by a direct vascular effect involving
decreased calcium uptake into vascular cells.93,148,149 Alternatively, a thiazolidinedione-
induced decrease in the activity of the renin-angiotensin system and of the sympathe-
tic system may also play an important role in the modulation of blood pressure.91
In conclusion, thiazolidinediones lower blood pressure by multiple mechanisms,
including a decrease in plasma insulin levels.
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4.5 Additional antiatherogenic effects
4.5.1 Intimal hyperplasia
The proliferation and migration of vascular smooth muscle cells play a role in the
pathogenesis and progression of atherosclerosis. Troglitazone has been shown 
to inhibit VSMC growth and intimal hyperplasia.150 In clinical trials, troglitazone redu-
ced intimal hyperplasia in patients with type 2 diabetes, with and without coronary
stent implants.151,152 Pioglitazone shows similar effects; a significant decrease in the
intima-media thickness of the carotid arteries was observed as early as 3 and 6 months
after its administration in patients with type 2 diabetes.153 Pioglitazone also reduced
the VSMC density of rat carotid arterial intima induced by balloon catheterisation and
had vasculo-protective effects against neointimal thickening and hypertensive vascu-
lar hypertrophy.154,155 New insights show that pioglitazone is a potent inducer of
apoptosis in vascular lesions. Furthermore, thiazolidinediones inhibit VSMC migration
mediated by multiple chemoattractants and attenuate the development of intimal
hyperplasia in animal models of balloon catheter vascular injury.156 The underlying
mechanism of a reduction in intimal hyperplasia by thiazolidinediones is not known
but improved insulin sensitivity may play an important role.157
4.5.2 Effects on the prothrombotic state
Increased levels of the inhibitor of fibrinolysis, plasminogen activator inhibitor-1 (PAI-1),
create a prothrombotic state. Levels of PAI-1 are increased in patients with type 2 dia-
betes and are strongly correlated with body mass index, insulin resistance and fasting
levels of insulin, triglycerides and HDL cholesterol. So far, only troglitazone has been
shown to reduce PAI-1 to near-normal levels in patients with diabetes.158 Pioglitazone
decreases PAI-1 production in cultured human umbilical vein endothelial cells in vitro.159
Thus, thiazolidinediones may have favourable effects on cardiovascular events by
improvement of the prothrombotic state.
5. Special considerations
Thiazolidinedione treatment is associated with some undesirable effects. Some of
these adverse effects need further consideration.
5.1 Increase in bodyweight
Gain of bodyweight is a dose-dependent adverse effect of thiazolidinediones,
whether administered alone or in combination with other antihyperglycaemic
agents, especially sulphonylureas.160 The weight gain, 4kg on average, plateaus
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after 6 months. Despite the weight gain, thiazolidinediones clearly decrease insulin
resistance as discussed in section 3. An increased fat mass consisting of small adipocytes
and increased plasma volume have been proposed to explain these observations.
5.1.1 Increased fat mass
It is believed that the thiazolidinedione-induced differentiation of adipocytes and
adipogenesis, as discussed in section 3.1, may be partly responsible for the increase
in bodyweight seen in humans and animals.161,162
In humans, long-term troglitazone treatment results in increased accumulation of
subcutaneous fat without a change in the total amount of visceral fat, probably
because of the activation of PPAR-γ subcutaneously.163 Thus, troglitazone appears to
promote fat accumulation in subcutaneous adipose tissue rather than in visceral
adipose tissue, which may have little impact on atherogenesis.164 One study even
shows that troglitazone treatment of patients with type 2 diabetes decreases the
intra-abdominal fat mass but does not affect the total body fat mass or bodyweight.165
Thus, increased adipocyte differentiation associated with increased bodyweight
may not be as harmful as first thought, but the clinical significance of this modest
weight change will require further evaluation in long-term studies.
5.1.2 Increase in plasma volume
The weight gain caused by thiazolidinedione treatment is also associated with an
increase in the plasma volume, which occurs whether thiazolidinediones are
administered alone or in combination with metformin or sulphonylureas. Again,
there is a paradox because thiazolidinediones cause a substantial decrease in blood
pressure while increasing plasma volume. An explanation could be the effects of
thiazolidinediones on downregulation of endothelin-1, a potent vasoconstrictor.166
As a consequence of an increased plasma volume, haemoglobin and haematocrit
levels are decreased. These haematological alterations are observed during the first
weeks of therapy but do not change further thereafter.
Because of this plasma volume expansion, thiazolidinediones are not recommended
for patients with heart failure (New York Heart Association class III or IV).
5.2 Hepatotoxicity
As mentioned in section 2, troglitazone was withdrawn from the market because of
an increased risk of idiosyncratic hepatic toxicity. Three cases of severe hepatotoxi-
city have recently been reported with rosiglitazone.167,168 It is uncertain whether the
drug directly induces these hepatic disturbances. All patients recovered fully after
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discontinuing treatment. Currently, no cases of pioglitazone-induced severe hepato-
toxicity have been reported but it must be realised that there is considerably less 
clinical experience with rosiglitazone and pioglitazone than with troglitazone. The
largest study conducted so far shows no evidence of hepatotoxic effects observed 
in studies that involved 5006 patients taking rosiglitazone as monotherapy or 
combination therapy for 5508 person-years.169 These findings suggest that the 
idiosyncratic liver toxicity observed with troglitazone is unlikely to be a thiazolidine-
dione class effect.
Patients with poorly controlled type 2 diabetes may have moderate elevations of
serum alanine transferase (ALT) that will decrease with improved glycaemic control
during treatment with rosiglitazone or other antihyperglycaemic agents.
Thiazolidinediones should not be given to patients with signs of serious hepatic 
dysfunction. However, in patients with non-alcoholic steatohepatitis and small
increases in plasma transaminases, thiazolidinediones may be particularly useful
because of their beneficial effects on visceral fat accumulation; regular monitoring
of plasma transaminases is recommended in these patients.
5.3 Effects on gonadal function in women
Since the increased insulin sensitivity induced by thiazolidinediones is associated
with an improvement of ovulation and fertility in woman with polycystic ovary 
syndrome (PCOS) and with an increased estrogen clearance in pre- and postmeno-
pausal women, caution should be taken in women receiving oral contraceptives or
hormone replacement therapy. Medications with a higher estrogen content may be
beneficial to avoid the possibility of reduced effectiveness. Thiazolidinediones
should not be administered to women during pregnancy and breast-feeding since it
is not known whether these drugs have teratogenic effects or are secreted in human
breast milk.
5.4 Drug interactions
According to the 1B-text, pioglitazone is metabolised in the liver by hydroxylation of
aliphatic methyl groups, mainly through the cytochrome P450 (CYP) isoenzymes
CYP3A4 and CYP2C9. In vitro studies have suggested that xenobiotic oxidations by
CYP enzymes are more substantially affected by troglitazone and its metabolites
than pioglitazone or rosiglitazone.170 Troglitazone directly and competitively inhibits
the steroidogenic enzyme P450c17, whereas rosiglitazone and pioglitazone exert a
direct but weaker inhibitory effect on P450c17.171 Indeed the results of further in vitro
studies indicate that pioglitazone has a low potential for drug interactions and
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there is no evidence to date that pioglitazone induces the hepatic CYP isoform
CYP3A4 system. However, to our knowledge no in vivo studies have been published
to further establish the effects of pioglitazone on drug metabolism regarding inter-
ference with the CYP3A4 isoform. An article by Prueksaritanont et al. studied the
interactions between simvastatin and troglitazone or pioglitazone in healthy indivi-
duals and concluded that the modest effect of troglitazone on simvastatin pharma-
cokinetics was in agreement with the suggestion that troglitazone is an inducer 
of CYP3A4, while the lack of pharmacokinetic effect of pioglitazone on simvastatin
supported the expectation that this combination may be used safely.172 To date
there are more published clinical trials investigating pioglitazone and, even though
it is circumstantial evidence, there is indeed no evidence that pioglitazone induces
the hepatic CYP isoform CYP3A4 system.132,169 However, until more long-term data
are available regular monitoring of liver enzymes is still recommended.
6. Conclusion
The co-occurrence of metabolic disorders such as type 2 diabetes, dyslipidaemia,
hypertension, hypercoagulability, vasculopathy, obesity and atherosclerotic disease,
and the central role of insulin resistance in this cluster, provide a target to potentially
reduce vascular incidents. Until now these vascular risk factors have been treated
separately and thus patients often need polypharmacy. Obviously, insulin resistance
plays a key role and pharmacological intervention aimed at the insulin resistance
syndrome may therefore have beneficial effects on several cardiovascular risk factors,
resulting in a decreased risk of future cardiovascular disease.
Thiazolidinediones are uniquely able to exert direct beneficial effects on insulin
resistance by binding to PPAR-γ and probably to PPAR-α. As transcription factors,
PPARs regulate the expression of numerous genes with key roles in glucose and lipid
metabolism. In addition, activation of PPARs could improve vascular function and
inflammatory processes resulting in additional vascular effects.
Several issues are yet to be resolved.The apparent paradox of adipocyte differentiation
with weight gain concurring with the insulin-sensitising effects of thiazolidinediones
is not completely understood. The thiazolidinedione-induced decrease in blood 
pressure accompanied by an increase in the plasma volume has not been fully
explained. The discrepancy of the stimulation of expression of CD36 and the anti-
atherogenic effect of the thiazolidinediones also needs to be further explained. It
would be interesting to know whether thiazolidinediones act directly by activating
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PPAR-γ or stimulate PPAR-α activity at the same time, which could also explain the
broad metabolic and additional vascular effects of thiazolidinediones. An important
issue that needs to be resolved is the importance of raised cholesterol levels, in 
particular raised LDL levels, caused by some thiazolidinediones. Future research may
provide answers to these questions, particularly with respect to the role of PPAR-γ
in vascular pathophysiology. Although the concept of thiazolidinediones is very 
promising, long-term clinical trials concerning cardiovascular end points are needed.
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Short-term pioglitazone treatment improves vascular
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Fabrice M.A.C. Martens, MD1, Frank L.J. Visseren, MD, PhD1, Eelco J.P.
de Koning, MD, PhD2,3 and Ton J. Rabelink, MD, PhD2
1 Department of Internal Medicine, Section of Vascular Medicine and
Diabetology, University Medical Center Utrecht, The Netherlands
2 Department of Medicine, Division of Nephrology, Leiden University Medical
Center, The Netherlands
3 Department of Medicine, Division of Endocrinology and Metabolism, Leiden
University Medical Center, The Netherlands
J Cardiovasc Pharmacol 2005;46(6):773-778
proefschrift_Fabrice  21-12-2005  14:21  Pagina 113
Condensed abstract
To determine whether pioglitazone influences endothelial function directly we 
examined in a randomised, cross-over, placebo-controlled, double blind trial, the
effects of 4 weeks pioglitazone treatment in 20 male type 2 diabetic patients.
We conclude that short-term pioglitazone treatment ameliorates endothelial dys-
function in conduit arteries irrespective of significant beneficial changes in plasma
levels of insulin, FFA, adiponectin or CRP in type 2 diabetics.
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Abstract
Objective Pioglitazone, a PPAR-γ agonist, does not only improve insulin resistance
and glycemic control but may also have additional beneficial vascular effects 
in patients with type 2 diabetes. Low-grade inflammation, free fatty acids and 
adiponectin may play a role in modulation of vascular function. We studied the
effect of 4 week pioglitazone treatment on endothelial function, metabolic changes
and C-reactive protein in patients with type 2 diabetes.
Methods and Results A randomised, cross-over, placebo-controlled, double blind
trial was performed in which pioglitazone 30 mg once daily was administered in 
20 patients with type 2 diabetes on oral anti-hyperglycemic agents for 4 weeks.
Shear stress-induced flow mediated dilation (FMD) of the brachial artery was used
as outcome parameter for vascular function.
Brachial artery endothelial function was significantly increased by pioglitazone 
treatment compared to placebo (FMD 5.4±0.5 vs. 3.1±0.5 %, p=0.001). Endothelium-
independent vasodilation was not different between the two study periods.
Pioglitazone treatment reduced insulin, FFA and C-reactive protein concentrations
compared to placebo (18.3±2.4 vs. 14.8±2.1 mU/l; p=0.03, 641±46 vs. 542±33 µmol/l;
p=0.04 and 3.5±0.6 mg/l vs. 2.6±0.5; p= 0.01, respectively). A significant increase in
plasma adiponectin concentration (3.95±0.57µg/ml vs. 7.59±0.95; p=0.002) was also
observed. No correlations were found between these metabolic changes and the
improvement of conduit artery endothelial function.
Conclusions Short-term pioglitazone treatment ameliorates endothelial dysfunction
in conduit arteries irrespective of changes in insulin, FFA, adiponectin or CRP in type
2 diabetics.
Keywords adiponectin, C-reactive protein, diabetes mellitus, endothelial function,
nitric oxide, pioglitazone.
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Introduction
Patients with type 2 diabetes have a high risk to develop micro- and macrovascular
complications.1 Insulin resistance, which drives hypertension, glucose intolerance,
endothelial dysfunction, dyslipidemia and a proinflammatory state, is generally
considered to be of major importance in the pathophysiology of type 2 diabetes and
cardiovascular complications. A therapeutic strategy that targets insulin resistance
in type 2 diabetes may have beneficial effects on the cardiovascular risk.
Thiazolidinediones (TZDs) are a class of oral anti-hyperglycemic agents that can
improve insulin resistance. TZDs such as pioglitazone and rosiglitazone are ligands
for peroxisome proliferator-activated receptors (PPARs), in particular PPAR-γ. These
nuclear transcription factors are involved in glucose homeostasis, lipid and lipo-
protein metabolism and adipogenesis. TZDs improve glycemic control by increasing
insulin sensitivity and have also been shown to favorably modulate other compo-
nents of the metabolic syndrome.2 In addition, pparγ-agonists may have direct
effects on vessel wall structure, inflammation and endothelial function.
Endothelial dysfunction, metabolic abnormalities related to insulin resistance and a
proinflammatory state, are characteristic of patients with type 2 diabetes.
Endothelial dysfunction is characterised by decreased availability of endothelium-
derived nitric oxide (NO) and can be assessed clinically by impaired vasoreactivity of
the brachial artery after an ischemic stimulus with flow-mediated dilation.3
Previous studies showed already improvement of endothelial vasoreactivity in 
insulin resistant patients (obesity, polycystic ovary syndrome and type 2 diabetes)
with TZD treatment. However many studies were done with troglitazone, now with-
drawn from the market, and/or with long treatment periods.4-7 In a non-randomised,
open-label study, pioglitazone treatment for 3 months resulted in improvement
of endothelial function in type 2 diabetic patients.8 In this study pioglitazone 
treatment also significantly reduced the metabolic abnormalities associated with
type 2 diabetes. To tease out a direct vascular effect on vascular function of pioglita-
zone from its indirect metabolic effects we studied, double blind and crossover,
the direct vascular effect of short-term (4 weeks) treatment with pioglitazone on
endothelial function in patients with type 2 diabetes.
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Subjects and methods 
Subjects
Twenty male, non-smoking patients with type 2 diabetes were recruited. All patients
were treated with oral anti-hyperglycemic agents (9 patients with sulphonylurea
derivates, 4 patients with metformin and 7 patients with a combination of metformin
and sulphonylurea derivates) which continued during the study. Subjects with poor
glycemic control (HbA1c> 9%) were not included. Other relevant exclusion criteria
were presence of macro- or microvascular disease and use of vasoactive medication
(e.g. beta-blockers, calcium entry blockers, ACE-inhibitors, angiotensin type 1 receptor
blockers, statins, aspirin, non-steroidal inflammatory drugs).
The protocol was approved by the ethical review board of the University Medical
Center Utrecht (UMCU). All subjects gave written informed consent. Measurements
were carried out in accordance with local institutional guidelines in a Good Clinical
Practice-certified unit.
Study design
The study was designed as a prospective, randomised, crossover, placebo-controlled,
double blind trial. Patients eligible to take part in the study were randomised to
receive pioglitazone 30 mg once daily (Eli Lilly, Indianapolis, U.S.A.) or placebo for 
4 weeks in addition to their oral anti-hyperglycemic agents. Forearm vascular 
function was performed after four weeks followed by a washout period of six weeks.
Crossover of therapy occurred at the end of the washout period with reanalysis of
vascular function at 4 weeks. At the beginning and at the end of each 4-week treat-
ment period laboratory parameters were determined. Patients were instructed to
fast for at least 10 hours prior to the tests. No study medication or other medication
was used on the morning of the study days.
Methods
Assessment of vascular function
Experiments were performed in a temperature-controlled room (22-24°C) in the 
morning. Vascular function tests after pioglitazone and placebo treatment were 
performed at the same time for each individual in order to exclude daytime variability.
Upon arrival after an overnight fast, patients were asked to rest ina supine position for
20 minutes before ultrasonographic assessment of post-ischemic flow-mediated vaso-
dilation (FMD) of the brachial artery. This procedure was followed by blood withdrawal
for laboratory measurements.
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For assessment of post-ischemic NO-dependent FMD of the brachial artery, ultra-
sound measurements were performed at the elbow of the right arm using a vessel
wall-movement system (Wall Track System, Pie Medical) that consists of a 10 MHz
linear array transducer connected to a data acquisition system and a personal com-
puter.9 In order to optimize quality of the ultrasound images of the arterial wall,
ultrasound gel, a 200 ml water bag (as conductive medium), and a fixed probe 
holder were used. An optimal two-dimensional B-mode image of the brachial 
artery was obtained. An M-line perpendicular to the vessel was selected and the
ultrasound system was switched to M-mode. The vessel-movement detector system
registers the end-diastolic vessel diameter repeatedly during a period of 12 seconds.
The first three measurements were averaged to provide a baseline arterial diameter.
By inflation of a blood pressure cuff for 5 minutes at a pressure of 200 mmHg,
ischemia was applied to the forearm distal to the location of the transducer.
Ultrasonographic measurements continued for 4 minutes after cuff release at
30-second intervals. The widest lumen diameter was taken as a measure for maximal
post-ischemic vasodilation. In eight patients sublingual nitroglycerine spray (400µg)
was administered after a 15-minute rest in order to allow the arterial diameter to return
to its baseline value. After 2, 3, 4 and 5 minutes the vasodilatory respons to nitrogly-
cerine was assessed as previously described. FMD and nitroglycerine-induced vasodila-
tion were calculated as the percentage change relative to the baseline diameter.
Laboratory assessment
Fasting blood was drawn and plasma was frozen at –20°C until further analysis.
Glucose, creatinine, serum alanine transferase (ALT), serum aspartate transferase
(AST), total cholesterol, triglycerides and high-density lipoprotein cholesterol 
(HDL-C) were measured by standard enzymatical laboratory methods (Vitros 250;
Johnson/Johnson). Low-density lipoprotein cholesterol (LDL-C) was calculated with
the Friedewald formula. HbA1c and free fatty acids (FFA) were photometrically per-
formed (Hitachi 911; Roche). Insulin levels were determined with an immunological
method (Immulite 2000; Diagnostic Prod Corp.). Measurements of plasma 
adiponectin, interleukin-6 (IL-6) and high-sensitive C-reactive protein (hs-CRP) were
performed with a commercially available kit (ELISA; R&D Systems Inc.).
Statistical analysis
Results from vascular function tests and laboratory analysis are expressed as mean 
+ standard error. Differences in FMD and metabolic parameters between pioglitazone
and placebo treatment were analysed with a paired t-test (95% confidence interval).
In case of non-normal distribution the Wilcoxon Signed Rank test was used. Statistical
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significance was taken at the 5% level. Correlations between the change in FMD and the
change in metabolic or inflammatory parameters were analysed by linear regresion.
Results 
All subjects completed the study. The demographic, clinical and laboratory characte-
ristics are shown in Table 1. No carry-over effects between the two treatment periods
were observed for any parameter.
Table 1. Clinical characteristics at baseline and cross-over  
Baseline values Baseline values Baseline values Baseline values
at study start at crossover at study start at crossover 
with placebo to pioglitazone with pioglitazone to placebo
(N=10) (N=10) (N=10) (N=10)
Age (yrs) 58±2 58±2 55±3 55±3
Weight (kg) 86.6±5.2 89.0±5.2 98.2±5.7 99.0±5.7
BMI (kg/m2) 28.8±1.6 29.3±1.6 29.9±1.6 30.2±1.6
Waist (cm) 104.6±2.8 104.6±2.8 111.8±4.2 111.8±4.2
SBP (mmHg) 159±4 148±5 138±7 142±7 
DBP (mmHg) 92±2 90±2 85±3 90±3
Fasting glucose (mmol/l) 7.9±0.8 6.3±0.5 9.1±0.5 8.1±0.6 
Insulin (mU/l) 18.3±5.0 14.1±2.4 23.5±4. 20.6±3.3
HOMA-R 7.5±2.7 7.7±2.7 10.2±2.2 7.6±1.4 
HbA1c (%) 7.0±0.4 6.6±0.4 7.1±0.3 6.9±0.3 
Total cholesterol (mmol/l) 5.7±0.3 5.2±0.2 5.8±0.3 5.6±0.3 
HDL cholesterol (mmol/l) 1.21±0.08 1.20±0.08 1.14±0.06 1.10±0.09 
LDL cholesterol (mmol/l) 3.4±0.28 3.2±0.2 3.8±0.19 3.7±0.19 
Triglycerides (mmol/l) 2.24±0.43 1.75±0.25 1.84±0.32 1.80±0.27
Free fatty acids (µmol/l) 656±80 615±62 699±101 654±77
Adiponectin (ng/ml) 5073±954 4143±648 4759±926 3497±657
ASAT (U/l) 35±3 32±3 27±3 27±5 
ALAT (U/l) 40±7 34±4 37±8 39±10 
Creatinine (µmol/l) 79±4 78±4 74±1 76±2 
Hematocriet (l/l) 0.45±0.01 0.44±0.01 0.46±0.01 0.46±0.01 
hs-CRP (mg/l) 3.3±0.5 4.3±0.8 4.2±1.1 4.2±0.9 
Interleukin-6 (pg/ml) 2.18±0.60 2.43±0.41 1.99±0.39 2.17±0.33
Values are mean ±SEM
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Influence of pioglitazone on anthropometric, hemodynamic and metabolic parameters 
Table 2 reports the outcome of pioglitazone- or placebo treatment on anthropometric,
hemodynamic and metabolic parameters.
Short-term pioglitazone treatment for 4 weeks already reduced insulin and FFA 
concentrations compared to placebo (18.3±2.4 vs. 14.8±2.1 mU/l; p=0.03 and 641±46
vs. 542±33 µmol/l; p=0.04, respectively).
A significant increase in adiponectin plasma levels was observed during pioglitazone
treatment compared to placebo after only 4 weeks (3948±573 vs. 7591±953 ng/ml,
p=0.002).
Table 2. Clinical characteristics after treatment
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Placebo Pioglitazone p-value
(N=20) (N=20)
Weight (kg) 94.4±4.1 94.6±3.9 0.68
SBP (mmHg) 136±4 135±3 0.94
DBP (mmHg) 91±2 87±2 0.89
Fasting plasma glucose (mmol/l) 7.1±0.4 6.7±0.4 0.19
Insulin (mU/l) 18.3±2.4 14.8±2.1 0.03* 
HOMA-R 6.1±1.1 4.9±0.9 0.06
HbA1c (%) 6.8±0.2 6.7±0.2 0.50
Total cholesterol (mmol/l) 4.9±0.2 5.0±0.2 0.38
HDL cholesterol (mmol/l) 1.02±0.04 1.04±0.05 0.36
LDL cholesterol (mmol/l) 3.1±0.14 3.2±0.16 0.69
Triglycerides (mmol/l) 1.60±0.12 1.59±0.17 0.60
Free fatty acids (µmol/l) 641±46 542±33 0.04*
Adiponectin (ng/ml) 3948±573 7591±953 0.002*
ASAT (U/l) 27±2 28±3 0.88
ALAT (U/l) 34±5 35±5 0.65
Creatinine(µmol/l) 72±2 69±2 0.09
Hematocriet (l/l) 0.43±0.01 0.41±0.01 0.08
CRP (mg/l) 3.5±0.6 2.6±0.5 0.01*
Interleukin-6 (pg/ml) 1.71±0.21 1.62±0.22 0.17
Values are mean ±SEM;
p-values are reported for comparison between placebo and pioglitazone 
* p-values < 0.05
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Furthermore a significant decrease in CRP concentration was observed during
pioglitazone treatment compared to placebo after only 4 weeks (3.5±0.6 vs. 2.6±0.5
mg/l, p=0.01) while IL-6 plasma concentrations did not change significantly.
We did not observe a difference in the effects of pioglitazone between patients
using metformin or a combination of metformin and sulphonylurea derivates 
and the group of patients only treated with sulphonylurea derivates (data not
shown). No change in weight or blood pressure was observed during pioglitazone
treatment. Fasting glucose concentrations and lipids were not different between
the pioglitazone and placebo treatment periods. Edema did not occur in any patient
on pioglitazone treatment. Pioglitazone treatment was not associated with liver
enzyme abnormalities.
Effects of pioglitazone on brachial artery vasoreactivity
The baseline arterial diameter was similar during pioglitazone and placebo treat-
ment (Table 3).
Table 3. Ultrasound assessment of brachial artery vasoreactivity
Flow-mediated vasodilation (FMD) was significantly increased by pioglitazone
(3.08±0.53% vs. 5.38±0.46, p=0.001) (Table 3). As ultrasound recordings of the 
post-ischemic arterial diameter were performed every 30 seconds during 5 minutes
in our protocol, a difference between post-ischemic vasoreactivity at all time points
between pioglitazone and placebo treatment could be observed (Figure 1).
Placebo Pioglitazone p-value
Baseline diameter (mm) 4.45±0.10 4.44±0.10 0.39
Post-ischemic maximum diameter (mm) 4.59±0.11 4.68±0.11 0.01*
FMD after ischemia (%) 3.08±0.53 5.38±0.46 0.001*
Nitroglycerin-induced maximum diameter (mm) 5.14±0.10 5.24±0.10 0.17
Nitroglycerin-induced vasodilation (%) 12.04±1.09 14.49±1.36 0.09
Values are mean ±SEM;
p-values are reported for difference between placebo and pioglitazone after 4 weeks of treatment.
* p-values < 0.05
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Figure 1. Post-ischemic flow-mediated vasodilation
Figure 2. Relationship between the change in FMD and the change in insulin, free fatty acids, CRP
and adiponectin after short-term pioglitazone treatment
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There were no significant differences in the effects of pioglitazone between the
group of patients using metformin or a combination of metformin and sulphonylurea
derivates and the group of patients only treated with sulphonylurea derivates.
Nitroglycerin-induced endothelium-independent vasodilation of the brachial artery
was not significantly different between both treatments (12.04±1.09% vs. 14.49±1.36,
p=0.09) indicating that there seemed to be no alteration of large vessel vascular
smooth muscle cell (VSMC) responsiveness to NO (Table 3).
Correlation between endothelial function, metabolic and inflammatory changes
We used a study-design with short-term pioglitazone treatment to avoid known
long-term metabolic improvement of insulin sensitivity to investigate direct vascular
effects of pioglitazone. Although already after treatment for 4 weeks, significant
beneficial changes in insulin, free fatty acids, adiponectin and CRP were observed in
our study no correlation was present between the beneficial changes in insulin, FFA,
adiponectin or CRP, and the improvement of FMD (Figure 2).
Discussion
In the current study we demonstrate that short-term pioglitazone treatment amelio-
rates endothelial dysfunction in conduit arteries irrespective of significant beneficial
changes in plasma levels of insulin, FFA, adiponectin or CRP in type 2 diabetics.
To tease out metabolic effects from direct vascular effects we aimed to study 
relatively short-term actions of pioglitazone rather than long-term effects. Long-
term TZD treatment has been shown to significantly change body composition and
to have profound effects on the glycemic and lipid profile. The first metabolic effects
were found as early as the 2-4th week of therapy but maximal decreases occurred
after 10-14 weeks10-12. Most clinical studies observed substantial improvements in
metabolic parameters by TZDs after 8- or more weeks of treatment.13 These long-
term anthropometric and metabolic alterations are likely to significantly modulate
vascular function and inflammatory parameters. Using a 4-week treatment period
we did not observe significant differences in fasting lipids and glucose between the
pioglitazone and placebo treatment period. Nevertheless, insulin, FFA, adiponectin
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and CRP concentrations were beneficially changed already. No relation was found
between the changes in insulin, FFA, adiponectin or CRP, and the improvement of
FMD. However, in view of the limited number of patients studied, such a relation can
also not be entirely excluded.
Our results are in line with previous studies showing antiatherogenic effects 
of pioglitazone in type 2 diabetic patients independent of its antidiabetic effect.8,14
An explanation could be the direct effects on the vascular wall of TZDs. PPAR-γ mRNA
is expressed in endothelial and vascular smooth muscle cells.15 TZDs increase NO
release from endothelial cells without altering expression of endothelial nitric oxide
synthase.16 A direct effect on NO availability by pioglitazone may have contributed
to the increase in FMD.
Other direct effects of pioglitazone on vascular smooth muscle cells in vitro have also
been observed. These actions include attenuation of vasoconstriction as well as inhi-
bition of L-type Ca2+ currents in VSMC.17,18 In order to study vascular smooth muscle
responsiveness to NO we administered nitroglycerin, a nitric oxide donor, before
ultrasound assessment of brachial artery diameter. No significant difference was
observed in endothelium-independent vasodilation between placebo and 
pioglitazone treatment indicating that pioglitazone does not seem to alter large
vessel VSMC responsiveness to NO.
Interestingly, pioglitazone also significantly decreased C-reactive protein (CRP)
after only four weeks of therapy. Concentrations of CRP are increased in patients
with type 2 diabetes. This is considered to reflect a low-grade inflammatory state
that is likely to contribute to the increased cardiovascular morbidity and mortality
in patients with type 2 diabetes. CRP concentrations correlate with several compo-
nents of the metabolic syndrome19 and CRP is considered a strong predictor of 
cardiovascular events. Our results are in accordance with a study by Haffner et al.
who showed a reduction in CRP after 26 weeks of treatment with another TZD,
rosiglitazone.20
Although our data suggest no major role for adiponectin, FFA or insulin in improve-
ment of conduit artery endothelial function during pioglitazone, the sample size is
a limiting factor to more reliably assess the possible existence of a relationship
between these parameters and endothelial function. An increase in adiponectin by
pioglitazone has previously been shown8 and adiponectin can directly stimulate 
NO production by phosphorylating eNOS by AMP-activated protein kinase in 
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endothelial cells in vitro.21 High levels of FFA impair NO production by generation of
reactive oxygen species (ROS).22 In addition, FFA decrease insulin sensitivity in peri-
pheral tissues. We included subjects who were only using oral anti-hyperglycemic
agents. Since insulin could have profound effects on the vasculature, caution should
be taken to extrapolate our results to patients with type 2 diabetes who use combi-
nation treatment consisting of pioglitazone and insulin. In addition, our patients
did not use vasoactive medication. Many patients with type 2 diabetes use pharma-
cologic agents such as angiotensin-converting enzym blockers, angiotensin-II 
antagonists and statins improve endothelial function. It remains to be determined
whether pioglitazone has additional benefits on endothelial function in these
patients.
In conclusion, 4-weeks pioglitazone treatment improves conduit artery endothelial
function, independent of metabolic changes in patients with type 2 diabetes. This
may contribute to decreased cardiovascular risk in these patients.
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Condensed abstract
To determine whether pioglitazone influences TNF-α induced endothelial dys-
function we examined in a randomised, parallel, placebo-controlled, double blind
trial, the effects of 4 weeks pioglitazone treatment in 16 male type 2 diabetic patients.
We conclude that intra-arterial TNF-α induces impairment of endothelial function in
type 2 diabetes. Short-term pioglitazone treatment blocks this impairment.
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Abstract
Introduction Inflammation contributes to the pathogenesis of cardiovascular disease.
Tumor necrosis factor (TNF)-α in particular, is a key mediator of inflammation and 
vascular dysfunction and progression of atherosclerotic disease. Pioglitazone, a PPAR-γ
agonist, not only improves insulin sensitivity, but may also have anti-inflammatory
effects. The aims of this study were to investigate the acute effects of local intra-
arterial infusion with low-dose TNF-α on resistance vessel endothelial function in type
2 diabetes and to determine whether short-term pioglitazone treatment protects
against vascular dysfunction induced by this inflammatory stimulus.
Methods and Results A randomised, parallel, placebo-controlled, double blind trial
with 30 mg pioglitazone once daily for 4 weeks was performed in 16 male patients
with type 2 diabetes. Forearm plethysmography (FBF) was used to evaluate the 
effect on resistance vessel responses of intra-arterial administration of seroton
in (NO-dependent vasodilation) and nitroprusside (endothelium-independent
vasodilation) followed by another FBF-measurement during the second hour of
intra-arterial infusion with TNF-α (10ng/100 ml FAV/min for 2h). Endothelial-
dependent FBF of type 2 diabetic patients was significantly impaired (25.4%) by
intra-arterial TNF-α infusion (p <0.02), while nitroprusside-induced vasodilation 
did not change. Treatment with pioglitazone for 4 weeks completely blocked 
TNF-α-induced impairment of endothelial-dependent FBF compared to placebo. No
significant changes in plasma concentrations of TNF-α, IL-6, soluble TNF-α-receptors
or CD40L were observed.
Conclusions Pioglitazone treatment can convey direct protection against cytokine
(TNF-α)-induced endothelial dysfunction in humans with an increased cardiovascular
risk due to type 2 diabetes.
Keywords diabetes mellitus, endothelial function, inflammation, pioglitazone,
tumour necrosis factor-α.
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Introduction
The metabolic syndrome, which involves a cluster of cardiovascular risk factors
including hypertension, obesity, glucose intolerance, endothelial dysfunction,
dyslipidemia and a proinflammatory state, is generally considered to be of major
importance in the pathophysiology of type 2 diabetes and cardiovascular compli-
cations.1 Endothelial activation is considered the transducer by which risk factors
lead to progression of atherosclerosis. It is present in patients with increased cardio-
vascular risk including the metabolic syndrome2 and is a predictor for development
of cardiovascular events.3 Endothelial activation is characterised by decreased 
availability of endothelium-derived nitric oxide (NO) and can be assessed clinically
by impaired forearm blood flow (FBF) to NO-agonists.
Low-grade chronic vascular inflammation contributes to the pathogenesis of cardio-
vascular disease. Elevated levels of proinflammatory proteins are predictive for both
cardiovascular disease and type 2 diabetes.4 The proinflammatory cytokines,
tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) in particular, are elevated 
in patients with endothelial dysfunction and ischemic heart disease.5,6 TNF-α
downregulates mRNA for endothelial nitric oxide synthase (eNOS) by shortening its 
half-life in endothelial cells.7 In addition in vivo intra-arterial TNF-α causes an 
acute local vascular inflammation that is associated with impaired endothelium-
dependent vasomotion in young healthy non smoking men because of an acute
local vascular-wall inflammation confirmed by the local rise of IL-6.8 Another recent
study in healthy lean male volunteers showed impairment of endothelium-
dependent vasodilation upon intra-arterial TNF-α infusion.9
Thiazolidinediones (TZDs), such as pioglitazone and troglitazone, are a class of oral
anti-hyperglycemic agents and ligands for peroxisome proliferator-activated recep-
tors (PPARs), in particular PPAR-γ. These nuclear transcription factors are involved 
in glucose homeostasis, lipid and lipoprotein metabolism and adipogenesis.
TZDs improve glycemic control by increasing insulin sensitivity, but may also have
potential anti-inflammatory effects.10
Therefore in the present study we first investigated the effect of TNF-α on endothelium-
dependent vasodilation and secondly the effects of short-term pioglitazone treatment
on TNF-α induced endothelial dysfunction in patients with type 2 diabetes mellitus.
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Subjects and methods 
Subjects 
Sixteen male, non-smoking patients with type 2 diabetes were recruited. All patients
were treated with oral anti-hyperglycemic agents (7 patients with sulphonylurea deri-
vates, 3 patients with metformin only and 6 patients with a combination of metformin
and sulphonylurea derivates) which was continued during the study. Subjects with
very poor glycemic control (HbA1c >9%) were excluded. Other exclusion criteria were
presence of macro- or microvascular disease and the use of vasoactive medication (e.g.
beta-blockers, calcium entry blockers, ACE-inhibitors, angiotensin type 1 receptor 
blockers, statins, aspirin, non-steroidal inflammatory drugs). The protocol was appro-
ved by the ethical review board of the University Medical Center Utrecht (UMCU).
All subjects gave written informed consent. Measurements were carried out in accor-
dance with local institutional guidelines in a Good Clinical Practice-certified unit.
Study design
The study was a prospective, randomised, parallel, placebo-controlled, double blind trial.
Patients eligible to take part in the study were randomised in two patient-groups:
8 patients received placebo in addition to their current oral anti-hyperglycemic agents
for 4 weeks first followed by measurement of forearm vascular function without intra-
arterial TNF-α infusion and secondly directly followed by measurement of forearm 
vascular function during the second hour of intra-arterial TNF-α infusion (10ng/100 ml
forearm volume (FAV)/min for 2h); 8 patients received pioglitazone 30mg once daily 
(Eli Lilly, Indianapolis, U.S.A.) in addition to their current oral anti-hyperglycemic agents
for 4 weeks first followed by measurement of forearm vascular function without intra-
arterial TNF-α infusion and secondly directly followed by measurement of forearm 
vascular function during the second hour of intra-arterial TNF-α infusion (10ng/100 ml
FAV/min for 2h). At the end of each 4-week treatment period laboratory parameters
were determined. Patients were instructed to fast for at least 10 hours prior to the tests.
No study medication or other medication was used on the morning of the study day.
Methods
Assessment of vascular function
Experiments were performed in a temperature-controlled room (22-24°C) in the
morning. All vascular function tests after pioglitazone and placebo treatment were
performed at the same time for each individual in order to exclude daytime variabi-
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lity. Upon arrival, patients were asked to rest in a supine position for 20 minutes
before insertion of intra-arterial and intravenous cannula, blood withdrawal for
laboratory measurements and determination of forearm blood flow (FBF) using
venous occlusion plethysmography.
For assessment of FBF by venous occlusion plethymography (Hokanson EC-4,
Bellevue, Wash., USA), both forearms were supported above heart level. The brachial
artery of the non-dominant arm was cannulated with a 20-gauge catheter (Arrow
International, USA) after local anaesthesia. Bilateral forearm blood flow was deter-
mined using mercury-in-silastic strain gauges and a microcomputer based, R-wave
triggered system for online monitoring according to established methods.11
Intra-arterial blood pressure was continuously monitored. Baseline measurements
were performed at least 45 minutes after cannulation of the brachial artery in order
to allow stabilisation of baseline blood flow. Vasoactive agents were dissolved in
NaCl 0.9% and infused at a constant rate of 90 ml/h. All infusates were prepared in
our hospitals pharmacy department in accordance to GMP guidelines.
Sequential infusions of vasoactive agents were performed. Serotonin (5-HT, Sigma
Chemicals, St. Louis, Mo., USA) was infused into the brachial artery at increasing
doses of 0.6, 1.8, 6.0 ng/100 ml FAV/min. This protocol has previously been shown to
cause a dose-dependent increase in endothelium-dependent, NO-mediated vaso-
dilation.12 Sodium nitroprusside (SNP, Merck, Germany) was infused at increasing
doses of 20, 60, 180 and 600 ng/100 ml FAV/min to assess endothelium-independent
vasodilation. Serotonin- and SNP infusions were performed in random order in
order to avoid any bias related to the order of drug infusion. Each dose was infused
for 5-7 minutes and only during the last 2 to 3 min FBF was recorded. Five-minute
intervals were applied between each dose. In order to allow recovery of forearm
blood flow after administration of a vasoactive agent, a 20-minute rest between
infusions of different vasoactive agents was applied. Average values of FBF of the
cannulated and control arm were obtained from the last four to six consecutive
recordings of each infusion period. The ratio of flow in the cannulated measure-
ment (M) and non-cannulated control (C) arm was calculated for each recording
(M:C ratio). The FBF for each dose is expressed as the percentage change of M:C ratio
from baseline M:C ratio (M:C%).
TNF-α infusion
Human recombinant TNF-α (10ng/100 ml FAV/min Tasonermin, Boehringer-
Ingelheim, Germany; 1/8 of dosis used in healthy young volunteers13) was infused in
the cannulated brachial artery for 2 hours. During the second hour of TNF-α infusion
Chapter 5
134
proefschrift_Fabrice  21-12-2005  14:21  Pagina 134
135
TNF-α induces endothelial dysfunction in diabetics, an effect reversible by pioglitazone
serotonin- and SNP infusions were performed as well as FBF measurements. Blood
was drawn from the infused arm, 60- and 120 minutes after start of intra-arterial
TNF-α infusion, for measurements of TNF-α and IL-6 concentrations. Blinded sham
control with an intra-arterial salt infusion was not performed due to the invasive
nature of the procedure.
Laboratory assessment
At the end of each 4-week treatment period fasting blood was drawn before the
start of FBF measurements and plasma was frozen at –20°C until further analysis.
Glucose, creatinine, serum alanine transferase (ALT), serum aspartate transferase
(AST), total cholesterol, triglycerides and high-density lipoprotein cholesterol (HDL-C)
were measured by standard enzymatical laboratory methods (Vitros 250;
Johnson/Johnson). Low-density lipoprotein cholesterol (LDL-C) was calculated with
the Friedewald formula. HbA1c and free fatty acids (FFA) were photometrically per-
formed (Hitachi 911; Roche). Insulin levels were determined with an immunological
method (Immulite 2000; Diagnostic Prod Corp.). HOMA-R was calculated (fasting
glucose (mmol/L) x fasting insulin (mU/mL)/22.5). Measurements of plasma TNF-α,
soluble TNF-α receptors 60kD and 80kD and IL-6 were performed with commercially
available high-sensitive kits (ELISA; R&D Systems Inc./ minimum detectable doses
resp.: 0.06 pg/ml, 0.2 pg/ml, 0.43 pg/ml, and 0.016 pg/ml). Measurement of circula-
ting sCD40L was also performed with a commercially available high-sensitive kit
(ELISA; BenderMed Systems/ minimum detectable dose: 0.005 ng/ml).
Statistical analysis
Results from vascular function tests and laboratory analysis are expressed as 
mean + standard error. Differences in metabolic parameters as well as in FBF (for
each vasoactive agent on different concentration/time-points) between both treat-
ments were analysed with (un-)paired t-tests (95% confidence interval). In case 
of non-normal distribution the Wilcoxon Signed Rank test was used. Statistical 
significance was taken at the 5% level.
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Results
Anthropometric, hemodynamic and metabolic baseline parameters
Table 1 shows the anthropometric, hemodynamic, inflammatory and metabolic
baseline parameters of both groups.
Table 1. Baseline characteristics
During TNF-α-infusion the intra-arterial TNF-α-concentration increased. No signifi-
cant changes were observed in anthropometric, hemodynamic, metabolic and 
inflammatory parameters after 4 weeks of pioglitazone- or placebo treatment
(Table 2). In addition we did not observe a difference in the effects of pioglitazone
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Placebo  Pioglitazone
(N=8) (N=8)
Age 55 ± 3 57 ± 2
Weight (kg) 89 ± 9 95 ± 4
BMI 28 ± 2 30 ± 1
RRsyst (mmHg) 151 ± 8 144 ± 6
RRdiast (mmHg) 90 ± 3 86 ± 5
Fasting plasma glucose (mmol/l) 7.8 ± 0.8 7.6 ± 0.6 
Insulin (mU/l) 19.2 ± 6.4 18.8 ± 4.0
HOMA-R 8.3 ± 3.9 6.7 ± 1.6
HbA1c (%) 7.4 ± 0.4 7.0 ± 0.5 
Total cholesterol (mmol/l) 5.9± 0.3 5.6± 0.3
HDL cholesterol (mmol/l) 1.10 ± 0.06 1.20 ± 0.09
LDL cholesterol (mmol/l) 3.7 ± 0.2 3.7 ± 0.3
Triglycerides (mmol/l) 2.1 ± 0.5 1.6 ± 0.2
Free fatty acids (µmol/l) 591 ± 85 553 ± 41
Adiponectin (mg/l) 3.7 ± 0.1 2.1 ± 0.2
ASAT (U/l) 32 ± 4 26 ± 2
ALAT (U/l) 35 ± 8 32 ± 4
Creatinin (µmol/l) 74 ± 2 78 ± 5
Hematocrite (l/l) 0.45 ± 0.01 0.44 ± 0.01
CRP (mg/l) 3.4 ± 0.4 4.5 ± 1.2
Interleukin-6 (ng/l) 1.8 ± 0.3 1.8 ± 0.3
TNF-α (ng/l) 2.2 ± 0.2 2.7 ± 0.3
Values are mean ± SEM
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between the group of patients using metformin alone or a combination of 
metformin and sulphonylurea derivates and the group of patients only treated with
sulphonylurea derivates. Edema did not occur in any patient on pioglitazone treat-
ment. Pioglitazone treatment was not associated with liver enzyme abnormalities.
Table 2. Clinical characteristics after treatment
Placebo  Pioglitazone p-values
(N=8) (N=8)
Weight (kg) 90 ± 8 96 ± 5 0.53
BMI 28 ± 2 30 ± 1 0.33
RRsyst (mmHg) 138 ± 5 139 ± 4 0.77
RRdiast (mmHg) 80 ± 4 82 ± 5 0.74
Fasting plasma glucose (mmol/l) 6.7 ± 0.4 6.3 ± 0.5 0.55
Insulin (mU/l) 16.0 ± 2.6 12.0 ± 2.9 0.44
HOMA-R 5.4 ± 1.0 3.8 ± 1.3 0.50
HbA1c (%) 6.9 ± 0.2 6.9 ± 0.4 0.97
Total cholesterol (mmol/l) 5.2 ± 0.3 5.1 ± 0.3 0.69
HDL cholesterol (mmol/l) 1.04 ± 0.04 1.06 ± 0.09 0.83
LDL cholesterol (mmol/l) 3.2 ± 0.2 3.3 ± 0.2 0.75
Triglycerides (mmol/l) 1.7 ± 0.2 1.4 ± 0.1 0.33
Free fatty acids (Ìmol/l) 536 ± 90 487 ± 32 0.64
Adiponectin (mg/l) 2.9 ± 0.7 5.5 ± 0.1 0.10
ASAT (U/l) 30 ± 4 24 ± 3 0.24
ALAT (U/l) 30 ± 6 32 ± 4 0.75
Creatinin (µmol/l) 69 ± 2 71 ± 5 0.67
Hematocrite (l/l) 0.41 ± 0.01 0.40 ± 0.01 0.37
CRP (mg/l) 2.7 ± 0.6 3.3 ± 0.8 0.57
Interleukin-6 (ng/l) 1.7 ± 0.3 1.5 ± 0.2 0.53
TNF-α (ng/l) 2.3 ± 0.2 2.7 ± 0.3 0.25
sTNFr 60kD (µg/l) 2.1 ± 0.1 2.5 ± 0.3 0.23
sTNFr 80kD (µg/l) 5.7 ± 0.3 9.5 ± 2.7 0.18
CD40L (µg/l) 8.5 ± 1.3 7.3 ± 0.8 0.45
IL-6 after 60min infusion (ng/l) 2.0 ± 0.6 1.6 ± 0.2 0.57+
IL-6 after 120min infusion (ng/l) 3.4 ± 1.2 2.9 ± 0.9 0.77+
TNF-α after 60min infusion (ng/l) 9.4 ± 1.5 8.8 ± 1.6 0.81+
TNF-α after 120min infusion (ng/l) 22.1 ± 5.7 14.2 ± 1.6 0.21+
Values are mean ± SEM;
p-values are reported for comparison between placebo and pioglitazone;
+: p-values are reported for comparison between with- or without TNF-α-infusion
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Figure 1a. Endothelial-dependent serotonin-induced vasodilation of the forearm
Figure 1b. Endothelial-independent nitroprusside-induced vasodilation of the forearm
Values are mean±SEM;
-u-: placebo, N=8;
-n-: pioglitazone, N=8;
-5-: placebo + TNF-α infusion (10ng/min for 2h), N=8;
-s-: pioglitazone + TNF-α infusion (10ng/min for 2h), N=8;
*: p-value 0.01 is reported for comparison of intra-arterial TNF-α infusion vs. no TNF-α infusion in the placebo
group; p-value 0.02 is reported for comparison of pioglitazone + intra-arterial TNF-α infusion vs. placebo + intra-
arterial TNF-α infusion; Analyses by (un-)paired t-tests on different concentration/time-points.
Values are mean±SEM;
-u-: placebo, N=8;
-n-: pioglitazone, N=8;
-5-: placebo + TNF-α infusion (10ng/min for 2h), N=8;
-s-: pioglitazone + TNF-α infusion (10ng/min for 2h), N=8;
NS: no comparisons are significant; Analyses by (un-)paired t-tests on different concentration/time-points.
*
*
*
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Influence of intra-arterial TNF-α infusion on forearm blood flow
Intra-arterial TNF-α infusion had no effects on heart rate or blood pressure. Basal
forearm blood flow was similar in all groups.
The serotonin-induced endothelial-dependent FBF of patients treated with placebo
for 4 weeks was impaired by intra-arterial TNF-α infusion (p<0.02) (Figure 1a).
Effects of pioglitazone and intra-arterial TNF-α infusion on forearm blood flow
Basal forearm blood flow was similar in the placebo- and pioglitazone-treated
patients. After treatment with pioglitazone for 4 weeks followed by an intra-arterial
TNF-α infusion the serotonin-induced endothelium-dependent vasodilation in the
forearm vascular bed stayed at the level of the serotonin-induced endothelium-
dependent vasodilation of the placebo group- or the pioglitazone group- without
intra-arterial TNF-α infusion. Compared to the serotonin-induced endothelium-
dependent vasodilation in the forearm vascular bed of the placebo treated patients
with intra-arterial TNF-α infusion, the serotonin-induced endothelium-dependent
vasodilation in the forearm vascular bed of the pioglitazone treated patients 
improved significantly (p<0.02) (Figure 1a). Administration of the endothelium-
independent vasodilator nitroprusside caused an increase in FBF that was at the
same level in the pioglitazone group as it was in the placebo group, indicating that
there was no alteration in large vessel VSMC responsiveness to NO (Figure 1b).
Furthermore the endothelial-independent nitroprusside-induced vasodilation did
not change indicating that there was no alteration of large vessel vascular smooth
muscle cell (VSMC) responsiveness to NO (Figure 1b).
Discussion
Inflammation contributes to the pathogenesis of cardiovascular disease and 
elevated levels of pro-inflammatory proteins are predictive of both cardiovascular
disease and type 2 diabetes.14 Especially in obese individuals TNF-α is elevated and
is associated with ischemic heart disease and endothelial dysfunction.15,16 The main
outcome of the present study is that low dose intra-arterial TNF-α infusion induces
an acute impairment of endothelial function in type 2 diabetes and that (short-
term) pioglitazone treatment blocks this impairment completely independently of
metabolic changes.
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In vitro TNF-α plays a role in acute coronary syndromes by increasing expression of
adhesion molecules on the endothelial cell surface and the ensuing recruitment of
inflammatory cells, and by decreasing vascular smooth muscle cells viability. In
agreement with such mechanisms TNF-α levels have been associated with plaque
instability by decreasing VSMC viability.13 In vivo previous studies showed impair-
ment of endothelium-dependent vasodilation in healthy subjects by low dose 
intra-arterial TNF-α infusion.8 Type 2 diabetic patients already have endothelial 
dysfunction and it could therefore be hypothesized that inflammatory stimuli like
TNF-α do not further affect endothelial function. However, in our study we now
show that raising the intra-arterial TNF-α concentration in type 2 diabetes locally, to
levels that are towards the range of the levels found in conditions such as congestive
heart failure14 and acute coronary syndromes15, further impairs endothelium-
dependent vasodilation. This effect appeared to be endothelium specific as vaso-
dilation to nitroprusside was unaltered. Treatment with pioglitazone for 4 weeks 
completely protected against TNF-α induced depression of endothelium-dependent
vasodilation. It should be noticed that baseline levels of cytokines and TNF-α were
not affected by pioglitazone treatment nor was there any change in metabolic 
indices in this short term study. This is not unexpected as usually the metabolic
effects of TZD treatment only become apparent after 8 weeks of treatment.16,17
Nevertheless, basal endothelial function was also restored to normal values (Figure 1a).
These data indicate that pioglitazone specifically and directly changed endothelial
function, and in particular the endothelial responsiveness to TNF-α. Indeed,
the PPAR-γ isoform is expressed in endothelial cells and its activation has been 
associated with enhanced NO availability18-20 and a reduced potential of endo-
thelial cells to switch to an inflammatory phenotype.21-23 There appears to be a
generalized repression of NF-κB, CCAAT/enhancer-binding protein, and activator
protein-1– mediated transcription of inflammatory genes.24-25 The exact mecha-
nism is still unknown, but probably involves increased levels of co-repressor molecu-
les or transcriptional superregu¬lation, for example by chromatin remodeling, as
has been described for activation of other nuclear hormone receptors.30 In addition
endothelial release of the vasoconstrictor peptide endothelin-1 is suppressed by
TZD’s.27
The direct vascular anti-inflammatory properties of TZD’s have previously been
demonstrated in animal models. For example Angiotensin-II (Ang-II) infusion in rats
resulted in endothelial dysfunction, increased medio/lumen ration and vascular 
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inflammation. All these changes where abrogated by TZD treatment independently
of metabolic effects suggesting direct interference of TZD’s with signaling cascades
that lead to these events.28 Our current study extends these properties of TZD’s 
to humans with increased cardiovascular risk. These observations may provide an
explanation for some of the recent findings where TZD treatment could reduce the
progression of intima-media thickness29, a proxy for atherosclerotic burden and 
cardiovascular risk30, in patients with coronary artery disease but without diabetes.
In these studies only minimal changes in metabolic parameters were observed.
We only included subjects using oral anti-hyperglycemic agents. Since insulin has
profound effects on the vasculature, caution should be taken to extrapolate our
results to patients with type 2 diabetes using pioglitazone in combination with
insulin. In addition, patients using vasoactive medication were excluded from 
our study while it would also be interesting to study the additional benefits of 
pioglitazone in these patients.
In conclusion, pioglitazone treatment can convey direct protection against cytokine
(TNF-α)-induced endothelial dysfunction in humans with an increased cardiovascular
risk due to type 2 diabetes.
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CHAPTER 6
Monocyte-endothelium adhesion (under flow 
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be reduced by PPAR-γ agonists pioglitazone and 
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Condensed abstract
To determine whether PPAR-γ agonists pioglitazone and troglitazone modify mono-
cyte-endothelium- adhesion we examined in an ex vivo study the effects of incubated
monocytes and HUVEC in 6 male type 2 diabetic patients and 6 matched male healthy
volunteers. Monocyte-endothelium-adhesion was studied under flow conditions.
We conclude that monocytes from patients with type 2 diabetes adhere more 
to endothelium compared to monocytes from healthy volunteers. Pioglitazone- or
troglitazone pre-treatment of monocytes reduce monocyt adhesion.
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Abstract
Introduction Monocytes are involved in atherosclerotic lesion development, desta-
bilization and plaque rupture. PPAR-γ agonists, like pioglitazone and troglitazone,
regulate glucose homeostasis, lipid metabolism and may have anti-inflammatory
effects, which may influence atherogenesis. In this study we determined the effect
of PPAR-γ agonism on adhesion of monocytes from patients with type 2 diabetes vs
healthy volunteers to endothelial cells under flow conditions ex vivo.
Methods and Results Monocytes were isolated from 6 male patients with type 2 
diabetes and 6 age-matched male healthy volunteers. The isolated monocytes were
incubated with pioglitazone, troglitazone, DMSO and RPMI and added to confluent
HUVEC. The adherence capacity of the monocytes in a small volume perfusion
chamber was measured by realtime video microscopy.
Monocyte-adhesion under flow conditions showed significant more monocyte
adhesion in type 2 diabetic patients compared to healthy controls: 212 counts per
mm2±17 vs 158 counts per mm2±9 (p=0.018). Incubation with pioglitazone (1µM)
lowered monocyte-adhesion in type 2 diabetic patients: 162 counts per mm2±16
(p=0.07). Troglitazone (1µM) did lower adhesion of monocytes from type 2 diabetic
patients significantly: 147 counts per mm2±11 (p=0.008). Any differences in expres-
sion of (adhesion-)surface-antigens CD14, CD11b/CD18, CD62L and CD36 could not be
observed.
Conclusions Monocyte-endothelium-adhesion is increased in type 2 diabetes and
can be reduced by PPAR-γ agonists pioglitazone and troglitazone without changes in
CD14, CD11b/18, CD62L and CD36 expression on monocytes.
Keywords diabetes mellitus, monocyt-endothelium adhesion, inflammation, pioglita-
zone, troglitazone.
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Introduction
Atherosclerotic disease in large vessels is the major cause of morbidity and mortality
in patients with type 2 diabetes (DM2).1 The early phase of atherosclerosis involves the
recruitment of inflammatory cells from the circulation, adhesion to the endothelium
and transendothelial migration. This process is predominantly mediated by cellular
adhesion molecules which are expressed on the vascular endothelium in response to
several inflammatory stimuli.2,3 The first step in adhesion, the rolling of monocytes
along the endothelial surface is mediated by selectines. For firm adhesion of mono-
cytes to the endothelium, integrins, vascular cell adhesion molecule (VCAM)-1 and 
intracellular adhesion molecule (ICAM)-1, all expressed on the surface of vascular
endothelial cells, are involved.4 The progression of the atherosclerotic plaque even-
tually leading to plaque rupture is to view upon as an chronic inflammatory process.5
Elevated plasma levels of endothelial adhesion molecules6 and enhanced monocyte-
adhesion to endothelium under static conditions7,8 have already been documented
in patients with type 2 diabetes. It would be important to know whether these results
are similar under, physiologically more relevant, flow conditions and whether this
process can be pharmacologically influenced.
Thiazolidinediones (TZDs), such as pioglitazone and troglitazone, are a class of oral
anti-diabetic agents and are ligands for peroxisome proliferator-activated receptors
(PPARs), in particular PPAR-γ. These nuclear transcription factors are involved in 
glucose homeostasis, lipid and lipoprotein metabolism and adipogenesis. TZDs
improve glycemic control by increasing insulin sensitivity, but may also have poten-
tial anti-inflammatory effects.9 Pioglitazone treatment leads to a 16% reduction in
cardiovascular events.10 PPAR-γ agonists may limit chronic inflammation by inhibi-
ting VCAM-1 induction11-13 and reduce macrophage homing to atherosclerotic 
plaques.14 Because of conflicting findings the consequences of PPAR-γ activation on
monocyt/macrophage inflammatory responses have led to much debate regarding
the role of PPAR in atherosclerosis.
In the present study we investigated the effects of PPAR-γ agonists on the adhesion
to endothelium and the expression of surface proteins of monocytes from healthy
volunteers compared to monocytes derived from patients with type 2 diabetes.
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Subjects and methods 
Subjects 
Six male, non-smoking patients with type 2 diabetes were recruited. All patients
were treated with oral anti-hyperglycemic agents (3 patients with sulphonylurea
derivates, 1 patient with metformin and 2 patients with a combination of metformin
and sulphonylurea derivates). Subjects with very poor glycemic control (HbA1c> 9%)
were excluded. Other relevant exclusion criteria were presence of macro- or micro-
vascular disease and use of vasoactive medication (e.g. beta-blockers, calcium entry
blockers, ACE-inhibitors, angiotensin type 1 receptor blockers, statins, aspirin, non-
steroidal inflammatory drugs). Six healthy male volunteers were age-matched .
Methods
Reagents
Trypsine; Gelatine 2% solution type B from bovine skin G1393; EDTA:
C10H14N2O8Na2.2H20, molmassa : 372,2 (E-4884); Histopaque-1077 (Sigma, St. Louis
MO); RPMI-1640 containing 25mM hepes buffer-glutamine and L-glutamine (Gibco,
Grand Island NY); Dimethyl sulfoxide (DMSO); M199 medium with Earle’s Salt, 2,2g/L
NaHCO3, L-glutamine, without L-amino-acids (Gibco-BRL/Invitrogen 31150-022); Fetal
Calf Serum (FCS); Penicillin/Streptomycine; Heparin 5000E/ml (Leo 5 ml, RVG 01372);
Bovine Pituitary Extract (BPE) (Gibco-BRL/Invitrogen 13028-014); PBS (our own hospital
pharmacy); Ficoll Paque Tm Plus (Amersham Biosciences 17-1440-03); CD14, CD11b/CD18,
CD62L and CD36 microbeats (Miltenyi Biotec); Carboxylfluorescentmarker CFDA-SE.
IL-1‚ (Peprotech Inc); Propidium Iodide/ Annexin V-FITC staining solution (BD Biosiences);
Pioglitazone powder (Takeda Pharmaceuticals); Troglitazone powder (Sankyo Pharma
GmbH).
HUVEC preparation
HUVEC (±10.000) were seeded in each well of gelatin-coated 96-well plates 3-4 days
before experiments. Only confluent monolayers, as confirmed by microscopic
inspection the day before the assay, were used for experiments. Confluent cultures
of HUVEC were incubated with pioglitazone (1µM), troglitazone (1µM), DMSO 10-5
and RPMI for 20h, all with medium and stimulated with TNF-α for 9h at 37°C.
CD14+ MNC preparation
The mononuclear cell (MNC) fraction was prepared by dilution with an equal volume
of PBS with 2 % EDTA at room temperature and layered over a solution containing 3ml
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Ficoll-Histopaque per 10ml and centrifuged at 2000rpm for 20 min. The mononuclear
cell layer was harvested and transferred to a fresh tube, mixed with 3 volumes of PBS,
and centrifuged at 2000 rpm for 5 min. The supernatant was removed and the pellet
was resuspended in buffer. Magnetically labelled CD14 antibodies (20µl) per 1x107
cells were added and incubated for 15 min. Monocytes were separated using
Magnetic Cell Sorting (MACS). After purification, monocytes were labelled with 
the fluorescent marker CFDA-SE by incubating the monocytes in PBS containing 
0.2 µl/ml of the CFDA-SE at 37°C for 20 min, and centrifuged at 1500 rpm for 5 min.
Fluorescent cells were pelleted and resuspended (1x106/ml) in RPMI 1640, and 
incubated at 37°C for 15 min to wash out excess of CFDA-SE. Cells were pelleted and
resuspended in RPMI and divided in fresh tubes. Tubes were centrifuged at
3000rpm, 3 min and supernatant was removed. Incubation at 37°C with pioglitazone
(1µM), troglitazone (1µM), DMSO 10-5 and RPMI, all with 10% autologe serum, was 
performed for 20h.
Cells were washed once with RPMI and resuspended at 1x106 cells/ml. The cells
expressed CD14 as determined by FACS analysis (>95%).
Monocyte-adhesion assay under flow conditions
For measurement of monocyte-endothelium-adhesion under flow conditions the
isolated monocytes (1x105 in 50µl/well) were incubated with pioglitazone (1µM),
troglitazone (1µM), DMSO 10-5 and RPMI, all with 10% autologe serum for 20h and
were added to confluent and TNF-α pre-stimulated HUVEC. HUVEC was also incubated
with pioglitazone (1µM), troglitazone (1µM), DMSO 10-5 and RPMI, all with medium for
20h.
Perfusions under steady flow were performed in a modified form of transparent
parallel plate perfusion chamber as previously described by van Zanten et al.15 This
micro-chamber has a slit height of 0.2 mm and width of 2 mm. The chamber contains
a circular plug on which a coverslip (18 mm x 18 mm) with HUVEC was mounted.
Monocytes (1x106 cells/ml) were suspended in perfusion buffer (20 mM Hepes,
132 mM NaCl, 6 mM KCL, 1 mM MgSO4, 1.2 mM KH4PO4, 5 mM glucose, 1 mM CaCl2,
0.5 % human serum albumin, pH 7.4) and were aspirated from a reservoir through
the perfusion chamber. Monocyte perfusions were performed as individual runs at
37ºC for 5 minutes at shear stress 1.0 dyn/cm2 to obtain firmly adhering cells on the
endothelial surface.16 Shear stress was increased to 2 dyn/cm2 and recording of the
images on video was started. During the perfusion, the flow chamber was mounted
on a microscope stage (DM RXE, Leica, Weitzlar, Germany) equipped with a B/W CCD-
video-camera (Sanyo, Osaka, Japan), coupled to a VHS video recorder. The monocytes
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in contact with the surface, appeared as bright white-centered cells after proper
adjustment of the microscope during recording. Twentyfive video images were 
evaluated for the number of adhered cells per mm2 of endothelial cell surface using
dedicated routines made in the image-analysis software Optimas 6.1 (Media
Cybernetics systems, Silverspring, MD).
Laboratory assessment
Fasting blood was drawn to obtain peripheral blood mononuclear cells and plasma
was frozen at –20°C until further analysis. Glucose was measured by standard 
enzymatical laboratory methods (Vitros 250; Johnson/Johnson). HbA1c was photo-
metrically performed (Hitachi 911; Roche). Expression of CD14, CD11b/CD18, CD62L
and CD36 (Miltenyi Biotec) on mononuclear cells were determined by FACS analysis.
Viability of the mononuclear cells were quantitatively determined by the percentage
of cells undergoing apoptosis by Annexin V-FITC and Propidium Iodide (BD
Biosciences).
Statistical analysis
Results are expressed as mean + standard error. Differences in parameters between
the different groups were analysed with one-way ANOVA analysis followed by an
unpaired t-test (95% confidence interval). In case of non-normal distribution the
Wilcoxon Signed Rank test was used. Statistical significance was taken at the 5% level.
Results 
Monocyte-endothelium adhesion in DM2 patients compared to healthy controls
In table 1. the differences between the 6 male healthy volunteers and the 6 age-and
sex-matched DM2 patients are shown. The body mass index (BMI), fasting plasma
glucose concentrations and HbA1c levels are elevated in the DM2 patients as expected.
The total white bloodcell count and the plasma concentration of monocytes were 
similar in both groups.
Monocyte-adhesion under flow conditions was significant higher in monocytes
derived from DM2 patients compared to healthy controls: 212±17 vs 158±9 counts 
per mm2 (p=0.018) (see also figure 2). Differences in expression of the (adhesion-)
surface-antigens CD14, CD11b/CD18, CD62L and CD36 on monocytes could not be
observed (see also Table 3).
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Table 1. Healthy volunteers- or type 2 diabetes patients-characteristics 
Control DM2 p-value
(N=6) (N=6)
Age (y) 52±3 54±3 0.55
BMI 24.5±0.4 28.0±1.9 0.11
Fasting plasma glucose (mmol/l) 4.7±0.2 8.6±1.3 0.03*
HbA1c (%) 5.5±0.1 6.9±0.4 0.04*
White Bloodcell Count (exp9) 5.5±0.6 5.9±0.8 0.72
Monocytes in WBC (%) 8.8±0.4 8.5±0.8 0.81
Adhesion (counts per mm2) 158±9 212±17 0.018*
CD14 (mean effluoresence) 263±46 372±107 0.37
CD11b/CD18 (mean effluoresence) 2746±508 2820±629 0.93
CD62L (mean effluoresence) 23±25 80±43 0.31
CD36 (mean effluoresence) 1417±294 1478±200 0.87
Values are mean ±SEM;
p-values are reported for comparison between healthy volunteers vs patients with type 2 diabetes.
*  p-values < 0.05
Table 2. Effects of pioglitazone- or troglitazone treatment in type 2 diabetes
Control=DMSO Pioglitazone 1µM Troglitazone 1µM p-value
(N=6) (N=6) (N=6)
Pio/Tro
Viability (% cell death) 6.6±1.7 4.3±0.9 5.0±0.9 0.27/0.43
Adhesion (counts per mm2) 206±14 162±16 147±11 0.07/0.008*
CD14 (mean effluoresence) 339±115 319±85 312±87 0.89/0.86
CD11b/CD18 (mean effluoresence) 2633±572 2561±653 2430±663 0.94/0.83
CD62L (mean effluoresence) 20±67 96±60 5±26 0.42/0.85
CD36 (mean effluoresence) 1451±245 1467±336 1439±341 0.97/0.98
Values are mean ±SEM;
p-values are reported for comparison between pioglitazone treatment vs vehicle DMSO and troglitazone treat-
ment vs vehicle DMSO, in patients with type 2 diabetes.
* p-values < 0.05
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Effect of pioglitazone and troglitazone on monocyte-endothelium adhesion
In table 2. the effects of monocyte incubation with pioglitazone or troglitazone are
shown. Because both PPAR-γ agonists needed to be dissolved in DMSO, the effects of
pioglitazone- or troglitazone treatment are compared with the effects caused by
DMSO alone. While DMSO can be harmful for the cells together with viability-checks
also RPMI-controls were performed in all experiments. The percentage of cell death
as measured by the propidium iodide/ annexin V-FITC staining-method did not
exceed the 9.5% in any experiment and there were no differences in cell death
observed between all groups.
Adhesion of monocytes from DM2 patients was lowered by incubation with 
pioglitazone (1µM) compared to the vehicle DMSO: 206±14 vs 162±16 counts per mm2
(p=0.07) and incubation with troglitazone (1µM) did lower adhesion in type 2 diabetic
patients significantly compared to the vehicle DMSO: 206±14 vs 147 ±11 counts per
mm2 (p=0.008) (see figure 1).
Differences in expression of the (adhesion-) surface-antigens CD14, CD11b/CD18,
CD62L and CD36 on monocytes could not be observed (see also Table 3).
Figure 1. Monocyte-endothelium-adhesion under flow conditions 
Values are mean±SEM;
p-value 0.018 is reported for comparison between patients with type 2 diabetes vs healthy volunteers;
p-value 0.07 is reported for comparison between pioglitazone treatment 1ÌM vs vehicle DMSO in patients with type
2 diabetes;
p-value 0.008 is reported for comparison between troglitazone treatment 1µM vs vehicle DMSO in patients with
type 2 diabetes.
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Discussion
The main outcome of our study is that monocyte-endothelium-adhesion is increased
in monocytes derived from DM2 patients. Furthermore this monocyte-endothelium-
adhesion can be reduced by PPAR-γ agonists pioglitazone and troglitazone without
changes in CD14, CD11b/18, CD62L and CD36 expression on monocytes.
Enhanced monocyte-endothelium adhesion in type 2 diabetic patients
Increased adherence of mononuclear cells from patients with type 2 diabetes mellitus
to cultured endothelium in vitro may explain why accelerated atherosclerosis occurs in
Chapter 6
156
Table 3. Expression of surface-antigens on monocytes (mean effluoresence) 
Control DM2 p-value
(N=6) (N=6)
CD14 (RPMI) 263±46 372±107 0.37
CD14 (DMSO 10-5) 260±73 339±115 0.97/0.84
CD14 (Pioglitazone 1µM) 291±85 319±85 0.60/0.89
CD14 (Troglitazone 1µM) 209±40 312±87 0.58/0.86
CD11b/CD18 (RPMI) 2746±508 2820±629 0.93
CD11b/CD18 (DMSO 10-5) 2490±326 2633±572 0.68/0.83
CD11b/CD18 (Pioglitazone 1µM) 2199±433 2561±653 0.60/0.94
CD11b/CD18 (Troglitazone 1µM) 2525±520 2430±663 0.96/0.83
CD62L (RPMI) 23±25 80±43 0.31
CD62L (DMSO 10-5) 4±20 20±67 0.61/0.47
CD62L (Pioglitazone 1µM) 47±45 96±60 0.44/0.42
CD62L (Troglitazone 1µM) 0±45 5±26 0.83/0.85
CD36 (RPMI) 1417±294 1478±200 0.87
CD36 (DMSO 10-5) 1213±238 1451±245 0.60/0.93
CD36 (Pioglitazone 1µM) 1400±312 1467±336 0.64/0.97
CD36 (Troglitazone 1µM) 1294±322 1439±341 0.85/0.98
Values are mean ± SEM;
p-values are reported for:
In case of RPMI: comparison between healthy volunteers vs patients with type 2 diabetes;
In case of DMSO: comparison between RPMI incubation vs incubation with vehicle DMSO in healthy
volunteers/patients with type 2 diabetes;
In case of pioglitazone and troglitazone: comparison between pioglitazone-or troglitazone incubation vs their
vehicle DMSO in healthy volunteers/patients with type 2 diabetes.
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patients with DM2 since the adherence of mononuclear cells to the endothelium repre-
sents the earliest step in atherosclerosis.7 Increased adhesiveness of diabetic monocytes
to endothelial cells, but under static conditions and with cultured bovine aortic endo-
thelial cells (BAEC) has been shown.8 However, in the present study we showed under,
physiologically more relevant, flow conditions significantly more adhesion to endo-
thelium of monocytes derived from DM2 patients compared to healthy volunteers.
Potential determinants of increased monocyte-endothelial cell adhesion in type 2
diabetes include oxidative stress and advanced glycation end products (AGEs).
Glycoxidation products accumulate in tissue collagen with age and at an accelerated
rate in diabetes. Possible sources of oxidative stress and damage to proteins in 
diabetes include free radicals generated by autoxidation reactions of sugars, sugar
adducts to protein, and by autoxidation of unsaturated lipids in plasma and mem-
brane proteins.17 Furthermore elevated plasma concentrations of the adhesion
molecules ICAM-1 and VCAM-1 are seen in patients with DM16 or DM2.18 In the 
present study we did not use diabetic endothelium but focussed on differences in
adhesiveness of monocytes from type 2 diabetics compared to monocytes form
healthy volunteers. Activated monocytes can activate endothelial cells resulting in
production of CAMs and cytokines like interleukin-6 and interleukin-8, and mono-
cyte chemoattractant protein-1 (MCP-1). These effects combined will lead to recruit-
ment and activation of monocytes, as expressed by increased selectins and integrins
on the outer membrane, causing eventually firm adhesion to the vessel wall.16 From
in vitro studies it is known that acute stimulation of monocytes results in rapid shed-
ding of CD62L19,20 or translocation of stored receptors like CD11b.25 However, in this
study no differences in the adhesion-surface antigens CD14, CD11b/18, CD62L and
CD36 were observed. An alternative activator route for monocytes may be 
elevated levels of glucose, lipoproteins, and free fatty acids (FFA). Furthermore, these
directly activated monocytes can activate the endothelium or destabilize atheros-
clerotic lesions by the production of ROS, tumor necrosis factor-α (TNF-α), and 
degradative enzymes like collagenase and gelatinase.22
Incubation with pioglitazone or troglitazone reduced adhesion in type 2 diabetics
The exact mechanism of a PPAR-γ induced decrease in monocyte-adhesion is likely
to be a combination of anti-inflammatory effects upon the endothelium as well as
an effect upon the monocytes. It is assumable that the inhibitory effect of PPAR-γ
activation on NF-κB, STAT1 and AP-123,24 leads to decreased expression of adhesion
molecule expression on monocytes and endothelium (like VCAM-1 and ICAM-1),
eventually leading to decreased adhesion11-13 and thus reducing the formation 
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of atherosclerotic plaques.14 PPAR-γ agonism has an important anti-atherogenic 
influence on the endothelium and will therefore also reduce monocyte-endothelium-
adhesion. Unfortunately we were not able to perform a unilateral incubation of
monocytes or HUVEC alone to differentiate between the effects of PPAR-γ agonism
directly on the endothelium, and the effects of PPAR-γ agonism directly on the
monocytes. But, to exclude at least different effects of PPAR-γ agonism on endo-
thelium, only HUVEC of non-diabetic subjects was used in all experiments to get
proof of principle in the present study.
The observed reduction of monocyte-endothelium-adhesion by the PPAR-γ agonists
pioglitazone and troglitazone under physiological flow-conditions means an inhibi-
tion in the early step of atherogenesis. In another study pioglitazone inhibited the
expression of adhesion molecules on the endothelium but also decreased
CD11b/CD18 expression on stimulated leukocytes.11 However in the present study we
did not find any difference in CD11b/CD18 expression on monocytes in DM2 patients
compared to healthy volunteers. Incubation with pioglitazone or troglitazone did
not affect CD11b/CD18 and other (adhesion-) surface-antigens like CD14, CD62L and
CD36 expression on monocytes. These results are in line with a in vitro study by
Toriumi et al. showing a reduction of monocyte-adhesion from a U937 cell line to
HUVEC under flow by pre-incubation with pioglitazone. Also in that study the
expression levels of CD11a, CD18, and CD49d were not affected after treatment but
they found a reduction of actin filament and a decrease in RhoA GTPase activity.25
Probably diabetic monocytes are in a more inflammatory activated state and thus
more sensitive for PPAR-γ agonism. In the present set of experiments it is possible
that monocytes already become activated. However this should implicate an under-
estimation of the results. Staels et al. found that whereas PPAR-α is already present
in undifferentiated monocytes, PPAR-γ expression is yet induced upon differentiation
into macrophages.26
In conclusion, monocyte-endothelium-adhesion is increased in monocytes derived
from DM2 patients and this increased monocyte-endothelium-adhesion can be
reduced by PPAR-γ agonists pioglitazone and troglitazone without changes in CD14,
CD11b/18, CD62L and CD36 expression on monocytes. PPAR-γ agonists may be beneficial
in the prevention of atherosclerosis in type 2 diabetes patients.
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Condensed abstract
To determine whether PPAR-γ agonism influences cytokine production directly we
examined, in a randomised, cross-over, placebo-controlled, double blind trial, the
effects of 4 weeks pioglitazone treatment on TNF-α, IL-6, and IL-10 production in
with LPS-stimulated whole blood from 20 male type 2 diabetic patients ex vivo. The
effects of pioglitazone on isolated monocytes are compared with the natural PPAR-γ
ligand prostaglandin J2 (PGJ2) in vitro.
We conclude that short-term pioglitazone treatment does not affect TNF-α, IL-6, and
IL-10 production of monocytes in contrast with the natural PPAR-γ ligand PGJ2.
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Abstract
Introduction Monocyte derived lipid-loaded macrophages are involved in athero-
sclerotic lesion development, destabilization and plaque-rupture. PPAR-γ agonists,
like pioglitazone, are regulators of glucose homeostasis, lipid metabolism and 
appear to have anti-inflammatory effects, which may influence atherogenesis. In
this study we determined the effect of PPAR-γ agonism on cytokine production 
in whole blood from type 2 diabetics with pioglitazone ex vivo. The effects of 
pioglitazone on isolated monocytes are compared with the natural PPAR-γ ligand
prostaglandin J2 (PGJ2) in vitro.
Methods and Results A randomised, cross-over, placebo-controlled, double blind
trial was performed in which pioglitazone 30 mg once daily was administered in 
20 patients with type 2 diabetes for 4 weeks. Whole blood was stimulated ex vivo
with different concentrations LPS (0, 0.6, and 6 ng/ml stimulated for 15min, and 4h).
No differences were observed between the pioglitazone- vs. the placebo-group in
LPS-stimulated TNF-α, IL-6, and IL-10 production.
Peripheral blood mononuclear cells and isolated monocytes (1x104 in 200 µl/well)
from 4 healthy volunteers, stimulated for 20h with lipopolysaccharides (LPS) (100
pg/ml), phorbol myristate acetate (PMA) (10 ng/ml) and okadaic acid (40 ng/ml)
have been incubated with various concentrations of pioglitazone (0, 11, 33 and 
100 µM) in vitro. Pioglitazone did not affect TNF-α, and IL-6 production. The natural
PPAR-γ ligand PGJ2 (0, 5.6, 16.7 and 50 µM) inhibited the cytokine production.
Conclusions Short-term pioglitazone treatment does not affect TNF-α, IL-6, and 
IL-10 production of monocytes in contrast with the natural PPAR-γ ligand PGJ2.
Keywords cytokine production, diabetes mellitus, IL-6, pioglitazone, TNF-α.
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Introduction
Low-grade chronic vascular inflammation contributes to the pathogenesis of cardio-
vascular disease. Elevated levels of proinflammatory proteins are predictive for both
cardiovascular disease and type 2 diabetes.1 The proinflammatory cytokines, tumor
necrosis factor-α (TNF-α) and interleukin-6 (IL-6) in particular, are elevated in
patients with endothelial dysfunction and ischemic heart disease.2,3 In contrast,
serum levels of the potent anti-inflammatory cytokine IL-10 have been shown to 
be decreased in patients with acute coronary syndromes,4 thus suggesting that
reduced levels of IL-10 may favour plaque instability and accelerate the development
of acute coronary syndromes. The progression of the atherosclerotic plaque even-
tually leading to plaque rupture is to view upon as an chronic inflammatory 
process.5 Atherosclerotic disease in large vessels is the major cause of morbidity and
mortality in patients with type 2 diabetes (DM2).6
Thiazolidinediones (TZDs), such as pioglitazone, are a class of oral anti-diabetic
agents and are ligands for peroxisome proliferator-activated receptors (PPARs), in
particular PPAR-γ. These nuclear transcription factors are involved in glucose home-
ostasis, lipid and lipoprotein metabolism and adipogenesis. TZDs improve glycemic
control by increasing insulin sensitivity, but may also have potential anti-inflamma-
tory effects.7 Several lines of evidence suggest that PPAR-γ ligands may influence 
the development of atherosclerosis due to anti-inflammatory effects of monocytes
by potent inhibition of nuclear factor-κB (NF-κB)-dependent transcription.8-11 In
contrast to these data, others report that IL-6 and TNF-α levels were not affected 
by TZD treatment.12,13 Because of these conflicting results we investigated the direct
effects of pioglitazone on cytokine production of human-monocytes ex vivo and 
in comparison with the natural PPAR-γ ligand PGJ2 in vitro.
Subjects and methods 
Subjects
Twenty male, non-smoking patients with type 2 diabetes were recruited. All patients
were treated with oral anti-hyperglycemic agents (9 patients with sulphonylurea
derivates, 4 patients with metformin and 7 patients with a combination of metformin
Chapter 7
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and sulphonylurea derivates) which continued during the study. Subjects with poor
glycemic control (HbA1c >9%) were not included. Other relevant exclusion criteria
were presence of macro- or microvascular disease and use of vasoactive medication
(e.g. beta-blockers, calcium entry blockers, ACE-inhibitors, angiotensin type 1 receptor
blockers, statins, aspirin, non-steroidal inflammatory drugs).
The protocol was approved by the ethical review board of the University Medical
Center Utrecht (UMCU). All subjects gave written informed consent. Measurements
were carried out in accordance with local institutional guidelines in a Good Clinical
Practice-certified unit.
Study design
The original study was designed as a prospective, randomised, crossover, placebo-
controlled, double blind trial.14 Patients eligible to take part in the study were 
randomised to receive pioglitazone 30 mg once daily (Eli Lilly, Indianapolis, U.S.A.) 
or placebo for 4 weeks in addition to their oral anti-hyperglycemic agents. Blood
sampling for cytokine-production measurements was performed after four weeks
followed by a washout period of six weeks. Crossover of therapy occurred at the end
of the washout period with reanalysis of the cytokine-production at 4 weeks. At the
beginning and at the end of each 4-week treatment period laboratory parameters were
determined. Patients were instructed to fast for at least 10 hours prior to the tests. No
study medication or other medication was used on the morning of the study days.
Methods
LPS stimulation of whole blood ex vivo
Whole blood samples of 4.5 ml were collected using sterile endotoxin-free blood 
collection tubes containing heparin. Venapuncture and transportation were perfor-
med uniformly in all experiments without agitating the samples. Samples were
directly divided into 0.3 ml aliquots to be stimulated with different concentrations
LPS (Boivin method, Difco Laboratories, Detroit). Obtained LPS final concentrations
were 0, 0.6, and 6 ng/ml (RPMI-diluted: Gibco, Grand Island, NY). Stimulation was
directly performed for 15min and 4h at 20°C. After stimulation the aliquots were 
centrifuged twice at 600xg and the supernatants were directly stored at -80°C.
Measurements of plasma TNF-α, IL-6, and IL-10 were performed with commercially
available kits (ELISA; R&D Systems Inc./ minimum detectable doses resp.: 0.5, 0.7 and
3.9 pg/ml).
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Other laboratory assessments
Glucose, creatinine, serum alanine transferase (ALT), serum aspartate transferase
(AST), total cholesterol, triglycerides and high-density lipoprotein cholesterol 
(HDL-C) were measured by standard enzymatical laboratory methods (Vitros 250;
Johnson/Johnson). Low-density lipoprotein cholesterol (LDL-C) was calculated with
the Friedewald formula. HbA1c and free fatty acids (FFA) were photometrically per-
formed (Hitachi 911; Roche). Insulin levels were determined with an immunological
method (Immulite 2000; Diagnostic Prod Corp.).
LPS stimulation of peripheral blood mononuclear cells and isolated monocytes in vitro 
Confirmation was provided by pilot-measurements of TNF-α, and IL-6 production
from peripheral blood mononuclear cells (MNC) or isolated monocytes (1x104 in 200
µl/well) from 4 healthy volunteers, stimulated for 20h with LPS (100 pg/ml), PMA 
(10 ng/ml; Sigma-Aldrich) and okadaic acid (40 ng/ml; Sigma-Aldrich), in the presence
of various concentrations of pioglitazone (0, 11, 33 and 100 µM) and the natural 
PPAR-γ ligand PGJ2 (0, 5.6, 16.7 and 50 µM; Sigma-Aldrich).
The MNC fraction was prepared by dilution with an equal volume of PBS with 
2 % EDTA at 20°C and layered over a solution containing 3ml Ficoll-Histopaque per
10ml and centrifuged at 2000rpm for 20 min.
Isolated monocytes were obtained by harvesting the mononuclear cell layer,
transfered to a fresh tube, mixed with 3 times the volume of PBS, and centrifuged at
2000 rpm for 5 min. The supernatant was removed and the pellet was resuspended.
Metal beats coated with CD14 antibodies (20µl; 0.01M; Sigma-Aldrich) per 1x107 cells
were added and incubated for 15 min. Monocytes were separated using Magnetic
Cell Sorting (MACS).
Statistical analysis
Results from laboratory analyses are expressed as mean + standard error.
Differences in metabolic parameters between pioglitazone and placebo treatment
were analysed with a paired t-test (95% confidence interval). In case of non-normal
distribution the Wilcoxon Signed Rank test was used. Statistical significance was
taken at the 5% level.
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Results 
All subjects completed the study. The demographic, clinical and laboratory characte-
ristics are shown in Table 1. No carry-over effects between the two treatment periods
were observed for any parameter.
Table 1. Clinical characteristics at baseline and cross-over  
Baseline values Baseline values Baseline values Baseline values
at study start at crossover at study start at crossover 
with placebo to pioglitazone with pioglitazone to placebo
(N=10) (N=10) (N=10) (N=10)
Age (yrs) 58±2 58±2 55±3 55±3
Weight (kg) 86.6±5.2 89.0±5.2 98.2±5.7 99.0±5.7
BMI 28.8±1.6 29.3±1.6 29.9±1.6 30.2±1.6
Waist (cm) 104.6±2.8 104.6±2.8 111.8±4.2 111.8±4.2
SBP (mmHg) 159±4 148±5 138±7 142±7 
DBP (mmHg) 92±2 90±2 85±3 90±3
Fasting glucose (mmol/l) 7.9±0.8 6.3±0.5 9.1±0.5 8.1±0.6 
Insulin (mU/l) 18.3±5.0 14.1±2.4 23.5±4. 20.6±3.3
HOMA-R 7.5±2.7 7.7±2.7 10.2±2.2 7.6±1.4 
HbA1c (%) 7.0±0.4 6.6±0.4 7.1±0.3 6.9±0.3 
Total cholesterol (mmol/l) 5.7±0.3 5.2±0.2 5.8±0.3 5.6±0.3 
HDL cholesterol (mmol/l) 1.21±0.08 1.20±0.08 1.14±0.06 1.10±0.09 
LDL cholesterol (mmol/l) 3.4±0.28 3.2±0.2 3.8±0.19 3.7±0.19 
Triglycerides (mmol/l) 2.24±0.43 1.75±0.25 1.84±0.32 1.80±0.27
Free fatty acids (µmol/l) 656±80 615±62 699±101 654±77
ASAT (U/l) 35±3 32±3 27±3 27±5 
ALAT (U/l) 40±7 34±4 37±8 39±10 
Creatinine (µmol/l) 79±4 78±4 74±1 76±2 
Hematocriet (l/l) 0.45±0.01 0.44±0.01 0.46±0.01 0.46±0.01 
hs-CRP (mg/l) 3.3±0.5 4.3±0.8 4.2±1.1 4.2±0.9 
Values are mean ±SEM
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Influence of pioglitazone on anthropometric, hemodynamic and metabolic parameters 
Table 2. reports the outcome of pioglitazone- or placebo treatment on anthropome-
tric, hemodynamic and metabolic parameters. Short-term pioglitazone treatment for
4 weeks already reduced insulin and FFA concentrations compared to placebo
(18.3±2.4 vs. 14.8±2.1 mU/l; p=0.03 and 641±46 vs. 542±33 µmol/l; p=0.04, respectively).
Furthermore a significant decrease in CRP concentration was observed during pioglita-
zone treatment compared to placebo after only 4 weeks (3.5±0.6 vs. 2.6±0.5 mg/l, p=0.01).
We did not observe a difference in the effects of pioglitazone between patients using
metformin or a combination of metformin and sulphonylurea derivates and the group
of patients only treated with sulphonylurea derivates (data not shown). No change in
weight or blood pressure was observed during pioglitazone treatment. Fasting glucose
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Table 2. Clinical characteristics after treatment
Placebo Pioglitazone p-value
(N=20) (N=20)
Weight (kg) 94.4±4.1 94.6±3.9 0.68
SBP (mmHg) 136±4 135±3 0.94
DBP (mmHg) 91±2 87±2 0.89
Fasting plasma glucose (mmol/l) 7.1±0.4 6.7±0.4 0.19
Insulin (mU/l) 18.3±2.4 14.8±2.1 0.03* 
HOMA-R 6.1±1.1 4.9±0.9 0.06
HbA1c (%) 6.8±0.2 6.7±0.2 0.50
Total cholesterol (mmol/l) 4.9±0.2 5.0±0.2 0.38
HDL cholesterol (mmol/l) 1.02±0.04 1.04±0.05 0.36
LDL cholesterol (mmol/l) 3.1±0.14 3.2±0.16 0.69
Triglycerides (mmol/l) 1.60±0.12 1.59±0.17 0.60
Free fatty acids (µmol/l) 641±46 542±33 0.04*
ASAT (U/l) 27±2 28±3 0.88
ALAT (U/l) 34±5 35±5 0.65
Creatinine(µmol/l) 72±2 69±2 0.09
Hematocriet (l/l) 0.43±0.01 0.41±0.01 0.08
CRP (mg/l) 3.5±0.6 2.6±0.5 0.01*
Values are mean ±SEM;
p-values are reported for comparison between placebo and pioglitazone 
* p-values < 0.05
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concentrations and lipids were not different between the pioglitazone and placebo
treatment periods. Edema did not occur in any patient on pioglitazone treatment.
Pioglitazone treatment was not associated with liver enzyme abnormalities.
Effects of pioglitazone on TNF-α, IL-6, and IL-10 production in LPS-stimulated whole
blood from type 2 diabetic patients ex vivo
In table 3. the production of TNF-α, IL-6, and IL-10 in whole blood from type 2 diabetic
patients after treatment with pioglitazone or placebo for 4 weeks is shown. The
effects of different concentrations and different incubation times of LPS-stimulation
of whole blood are also shown. No significant differences were observed between the
pioglitazone- vs. the placebo-group in TNF-α, IL-6, and IL-10 production.
Table 3. Cytokine production in LPS-stimulated whole blood system after treatment
Placebo Pioglitazone p-value
(N=20) (N=20)
TNF-α (pg/ml) Plasma 4.7±0.9 3.9±0.7 0.24
LPS 0.6 ng/ml for 15min 4.8±0.8 4.1±0.8 0.37
LPS 0.6 ng/ml for 4h 356±78 354±57 0.97
LPS 6 ng/ml for 15 min 5.0±0.9 5.1±1.3 0.92
LPS 6 ng/ml for 4h 724±153 648±128 0.55
IL-6 (pg/ml) Plasma 13.6±1.4 11.4±2.7 0.43
LPS 0.6 ng/ml for 15 min 12.5±3.6 10.4±1.6 0.55
LPS 0.6 ng/ml for 4h 1336±296 1169±276 0.46
LPS 6 ng/ml for 15 min 12.1±2.1 14.4±2.5 0.34
LPS 6 ng/ml for 4h 2830±396 3184±410 0.44
IL-10 (pg/ml) Plasma 6.0±2.2 3.7±1.0 0.25
LPS 0.6 ng/ml for 15 min 14.3±8.1 7.8±4.5 0.11
LPS 0.6 ng/ml for 4h 14.5±7.5 11.5±5.9 0.17
LPS 6 ng/ml for 15 min 11.8±7.3 6.1±3.5 0.16
LPS 6 ng/ml for 4h 12.8±6.1 9.8±3.8 0.32
Values are mean ±SEM;
p-values are reported for comparison between placebo and pioglitazone
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Effects of pioglitazone on TNF-α and IL-6 production by MNC and isolated monocytes
from healthy volunteers in vitro
Incubation with various concentrations of pioglitazone (0, 11, 33 and 100 µM) for 20h
did not affect TNF-α (Figure 1a + 1b) or IL-6 (Figure 1c + 1d) production in peripheral
blood mononuclear cells (Figure 1a + 1c) or isolated monocytes (Figure 1b + 1d) from
healthy volunteers stimulated with LPS (100 pg/ml) or PMA (10 ng/ml) or okadaic
acid (40 ng/ml) for 20h.
Figure 1. Effects of pioglitazone on TNF-α and IL-6 production by MNC and isolated monocytes from
healthy volunteers in vitro
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Effects of PGJ2 on TNF-α and IL-6 production by MNC and isolated monocytes from
healthy volunteers in vitro
Incubation with various concentrations of the natural PPAR-γ ligand PGJ2 (0, 5.6, 16.7
and 50 µM) for 20h resulted in a decrease in TNF-α (Figure 2a + 2b) and IL-6 (Figure
2c + 2d) production by peripheral blood mononuclear cells (Figure 2a + 2c) and isolated
monocytes (Figure 2b + 2d) from healthy volunteers stimulated with LPS (100 pg/ml)
and okadeic acid (40 ng/ml).
Figure 2. Effects of PGJ2 on TNF-α and IL-6 production by MNC and isolated monocytes from healthy
volunteers in vitro
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Discussion
In the current study we demonstrated that pioglitazone did not affect cytokine pro-
duction directly. Neither in LPS-stimulated whole blood ex vivo after short-term
pioglitazone treatment for 4 weeks in type 2 diabetics, nor after incubation for 20h
with various concentrations of pioglitazone in peripheral blood MNC or isolated
monocytes from healthy volunteers in vitro. In contrast, the natural PPAR-γ ligand
PGJ2 did decrease TNF-α, and IL-6 production in peripheral blood MNC and isolated
monocytes from healthy volunteers in vitro.
In the present study we focused on the potential direct effects of the PPAR-γ agonist
pioglitazone on monocytes. The hypothesis is that PPAR-γ agonism can bring mono-
cytes in a less active state resulting in reduced cytokine production after stimulation.
Several lines of evidence suggest that PPAR-γ ligands may beneficially influence 
the development of atherosclerosis due to anti-inflammatory effects of monocytes 
by potent inhibition of NF-κB-dependent transcription.8,15 Incubation of human
monocytes with synthetic PPAR-γ ligands inhibits the production of inflammatory
cytokines.9,14 The original report of this effect by Jiang et al suggested that troglita-
zone and the natural PPAR-γ ligand PGJ2 selectively abrogate cytokine production
(TNF-α and IL-6) by PMA stimulation of human monocytes, but not by LPS.10 In a
mouse model of atherosclerosis, Li et al. demonstrated that TZDs reduce TNF-α
expression in the aortic root.11 We and others previously demonstrated anti-inflam-
matory effects of pioglitazone in diabetic patients as measured by attenuation of
the postprandial increase of neutrophils, IL-6 and IL-817, and a decrease in systemic
low-grade plasma levels of C-reactive protein (CRP) after only 4 weeks of pioglitazo-
ne therapy.14 Also after 26 weeks of treatment with another TZD, rosiglitazone, a
reduction in CRP has been shown.18 In contrast to these data, other reports indica-
ted that IL-6 and TNF-α levels were not affected by TZD treatment in db/db mice 
in response to LPS challenge.12 Another study, performed in rat peritoneal macro-
phages, also reported an increase in LPS-stimulated TNF-α production after rosiglita-
zone treatment.13 The IL-6 plasma level, a strong inducer of CRP, was expected to
decrease too after 4 weeks of pioglitazone treatment, but this was not the case.14
In line with the results of the present study, Staels et al. found that whereas PPAR-α
is already present in undifferentiated monocytes, PPAR-γ expression is yet induced
upon differentiation into macrophages.19 This may also explain the observed 
inhibition of cytokine production by the putative endogenous PPAR-γ ligand PGJ2.
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That PGJ2 is stronger in its inhibition may be explained by differences in PPAR-α
agonistic activities by PPAR-γ-agonists.20 Furthermore PGJ2 has shown pronounced
inhibition of inflammatory cytokines production by inhibition of nuclear factor-κB
(NF-κB)-dependent transcription although this is not very selective for PPAR-γ and
also acts via PPAR-independent mechanisms.21-23
Another reason for the variety in anti-inflammatory effects of PPAR-γ agonism on
monocytes may be the difficulty to study monocytes in vitro. We determined 
the cytokine production in a whole blood stimulation system to reduce the risk of
activation of monocytes to a minimum. It is known that monocytes can already be
activated when removed from their environment. Although cytokine production
induced by LPS in whole blood samples ex vivo varies in healthy subjects by 60 to
75% on the basis of heritability alone.24 In combination with a small laboratory 
error and small intra-individual variation makes whole blood stimulation a reliable
system for cytokine production measurements.25 It is clear that there are many 
conflicting findings on the effects of PPAR-γ activation on monocyte/macrophage
inflammatory responses and many studies are being revisited using different PPAR-
ligands at various concentrations. It appears likely that the anti-inflammatory
effects of several PPAR-γ agonists may vary depending on the source (e.g. primary 
vs. transformed cells, mouse vs. human), the state of differentiation/activation of
monocytes/macrophages studied, and the selectivity of the PPAR-γ agonists used.
We conclude that short-term pioglitazone treatment does not affect TNF-α, IL-6, and
IL-10 production of monocytes directly in contrast to the natural PPAR-γ ligand PGJ2.
The present study provides evidence that systemic anti-inflammatory effects of
pioglitazone are not due to direct effects on monocytes but probably because of
general inhibition of the NF-κB pathway, improvement of adipocyte function, and a
decrease of endothelial cell activation. These changes may in turn affect monocyte
function.
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CHAPTER 8
General discussion, summary and conclusions
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Cardiovascular disease is the leading cause of morbidity and mortality in Western
countries. The term cardiovascular disease comprises clinical manifestations of
arterial atherosclerosis, such as peripheral artery disease, cerebrovascular disease,
and coronary artery disease. Well-established risk factors are dyslipidemia, smoking,
diabetes mellitus, hypertension, and clustered in association with abdominal obesity.
In the pathophysiology of atherosclerosis, based on the respons to injury mechanism,
the pathophysiological phenomenons endothelial dysfunction and inflammation are
playing a pivitol role.
The endothelium has been identified as the central transducer through which risk
factors can cause atherosclerosis and its complications. The central pathway is 
the activation of the endothelium causing endothelial dysfunction. Endothelial 
dysfunction is characterized by a shift towards reduced vasodilation, a pro-inflam-
matory state, and pro-thrombic properties. Mechanisms that participate in the
reduced vasodilatory responses include reduced NO generation, oxidative stress,
and reduced production of hyperpolarizing factor. Vasoactive peptides (such as Ang-
II and ET-1), hypercholesterolemia, altered insulin signalling, and hyperglycemia,
together with upregulation of adhesion molecules, generation of chemokines (such
as MCP-1), and production of PAI-1, participate in these reduced vasodilatory responses,
the inflammatory response, and contribute to a pro-thrombic state. Basically this
involves the switch from a healthy condition, with concentrations of NO resulting 
in vasodilative and/or anti-atherosclerotic actions, to a situation of vasoactive 
dysfunction. Besides vasodilation, NO inhibits adhesion of leukocytes to the endo-
thelium, inhibits platelet-vessel wall interaction, decreases endothelial permeability,
inhibits VSMC proliferation and migration, and reduces vessel tone. However, in
pathophysiological situations NO-availability in vivo is impaired because of redox
signalling in the activated endothelium, as a result of reduced NO-formation,
enhanced NO-breakdown or both. Summarized there are two major consequences
of this endothelial activation:
First it will lead to the production of chemokines and expression of adhesion mole-
cules. This will support the recruitment of inflammatory cells into the vessel wall.
Although this system is physiological in the context of host-defense it may become
inappropriate with prolonged periods of endothelial cell activation secondary 
to cardiovascular risk factors. As result, an inflammatory phenotype evolves in the
vessel wall which leads to atherogenesis and plaque rupture. Evidence that athero-
sclerosis is a chronic inflammatory disease emerged when pathologic studies
showed that T-lymphocytes and macrophages are present in the shoulder regions of
atherosclerotic plaques in individuals who died from acute myocardial events.
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Subsequent studies implicated a multitude of pro-inflammatory targets that appear
to be involved in atherogenesis, atherosclerosis and plaque rupture. Atherosclerosis
starts with the entry of monocytes into the vessel wall. This occurs as a result of
monocytes following a chemical gradient of chemoattractant cytokines, produced
by an injured endothelium. However the pathogenic mechanism accounting for 
this relation is yet unclear. It has been shown that inflammation is a contributor to
atherosclerosis and its complications implicating that inflammation itself may
represent a therapeutic target.
Second, the loss of NO-bioavailability by the endothelium, due to risk factors, affects
the vessel wall structure. There are some preliminary data showing that NO inhibits
VSMC proliferation in the vascular wall. As a result one could hypothesize that loss
of NO-activity would result in increased VSMC-proliferation. This may accelerate the
development of the atherosclerotic plaque, but may also lead to thicker, remodelled
vessels. As a result these vessels become stiffer and start to produce pressure load
on the heart.
Endothelial dysfunction is associated with most forms of cardiovascular disease such
as hypertension, coronary artery disease, chronic heart failure, peripheral artery 
disease, diabetes, and chronic renal failure. Furthermore the severity of endothelial
dysfunction has been shown to have prognostic value for cardiovascular events.
Endothelial dysfunction is not only associated with cardiovascular disease but may
also precede its development. In contrast, correction of endothelial dysfunction may
be associated with reduced cardiovascular risk. Treatment of the causes of endo-
thelial activation may restore endothelial function.
In Chapter 1 we explored the hypothesis that endothelial function (in the sense of
NO-bioavailability) is an important determinant of vessel wall structure. In conduit
arteries, endothelial dysfunction is initiating atherogenesis. The other phenomenon
of endothelial dysfunction is the elevated vascular resistance of resistance arteries
(microcirculation) as observed in essential hypertension. We addressed this hetero-
geneity of vascular remodeling along the vascular tree and postulated that this
regional difference may be related to a heterogeneous effect of eNOS on prolifera-
tion in conduit arteries vs. resistance vessels. We found that eNOS exerts a tonic
inhibitory influence on aortic growth, with limited impact on small arteries, in basal
and hyperthrophic conditions. This heterogeneous role of NO on vascular growth
may explain the heterogeneity of vascular remodeling due to endothelial activation.
These results may also explain the various effects of a stimulus on endothelial 
function, measured in the conduit brachial artery with FMD vs. measurements in
the resistance vascular bed with FBF (chapter 4 and 5).
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In the current thesis we explored several aspects of the described model of vascular
injury in the setting of type 2 diabetes. Type 2 diabetes is emerging as a worldwide
epidemic and currently about 200 million people are affected worldwide. An impor-
tant cause for this increased incidence is the associated increase in patients with
insulin resistance (approximately 400 million worldwide right now). Insulin 
resistance is driven by central obesity and is secondary to free fatty acid fluxes
towards muscle and liver. However, genetic factors, particularly in Asian people,
seem to play a role as well. Several risk factors such as glucose intolerance, hyperin-
sulinemia, obesity, dyslipidemia, hypertension, but also endothelial dysfunction and
inflammation, have been found to cluster and often precede type 2 diabetes 
mellitus. Seeing the importance for primary prevention of early identification,
the National Cholesterol Education Program (NCEP) of the US created in 2001 a
readily applicable definition for daily clinical practice for this cluster of metabolic
abnormalities, often referred to as the metabolic syndrome. It is assumable that the
cardiovascular risk for patients belonging to the metabolic syndrome can just be
calculated out of the sum of the separate cardiovascular risk factors. However, there
are also data pointing towards a higher risk than expected from the separate cardio-
vascular risk factors (high triglycerides, low HDL, hyperglycemia, and high blood
pressure) in relation to the metabolic syndrome. Treatment of these risk factors
decreases the risk for cardiovascular events. Although it is difficult to distinguish
between the relative effects of insulin resistance, it induces clearly a significantly
increased cardiovascular and cerebrovascular risk. This effect is consistent across 
the spectrum of worsening glycemic control, from the onset of impaired glucose
tolerance to the development of clinical diabetes.
Although a pathophysiological construct seems plausible, future research must
unrevel pathophysiology and clinical use before the metabolic syndrome can be
designated as a ‘syndrome’. The individual components that make up the syndrome
should be treated coherently. These are the end-sites of the vascular tree. However
other risk factors act like trunk of this vascular tree. Awareness of the underlying
disorders is important for understanding the pathophysiology and thus coherent
treatment: be aware for insulin resistance and its associated (non-) traditional risk
factors like endothelial dysfunction and inflammation.
Clinically it would be useful to correlate the severity of insulin resistance to the
severity of alterations in vessel wall structure due to loss of NO-activity. In chapter 2
we investigated a cross-sectional survey (2105 patients) and showed that the meta-
bolic syndrome (and increasing number of components of the metabolic syndrome)
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is associated with marginally increased carotid artery stiffness, while type 2 diabetes
is associated with a marked increase in carotid artery stiffness. The increase in artery
stiffness seemed consistent across the spectrum of worsening glycemic control.
Despite the extensive data analyzing the connections between diabetes mellitus 
and atherosclerosis, it remains unclear whether diabetic atherosclerosis is merely a
similar but accelerated process recapitulating non-diabetic atherosclerosis. Certainly
hyperglycemia itself may be a unique aspect of diabetes. Accelerated atherosclerosis
may be due to hyperglycemia, resulting in elevated formation of advanced glycation
endproducts (AGEs). In addition, insulin resistance leads to hypertension, hypertri-
glyceridemia, low HDL, small dense LDL, diminished fibrinolysis, and increased
thrombogenicity. Since dysglycemia does not appear to be the major determinant
of cardiovascular disease in type 2 diabetes, targeting the underlying pathophysio-
logical mechanisms of the insulin resistance syndrome may be a more logical and
beneficial strategy for reduction of cardiovascular morbidity and mortality.
Pharmacological modulation of insulin resistance will not only improve glycemic
control, but may also have beneficial effects on inflammation, endothelial dysfunction,
dyslipidaemia and possibly other components of the syndrome independently from
improvements in glucose metabolism.
The discovery of nuclear peroxisome proliferator-activated receptors (PPARs) and
subsequent insight into their role in several metabolic pathways was a major break-
through in the understanding of pathophysiological mechanisms underlying the
insulin resistance syndrome. The Thiazolidinediones (TZDs) as a drug subclass are
PPAR-γ agonists that have been exhaustively shown to improve peripheral (predomi-
nantly skeletal muscle) insulin sensitivity in both animals and humans. Two agents
from this class, rosiglitazone and pioglitazone, are currently approved for use in
patients with type 2 diabetes mellitus. An earlier TZD, troglitazone, was found to
have similar effects on insulin sensitivity but was withdrawn from commercial use
because of hepatotoxicitiy. Available TZDs improve insulin sensitivity predomin
antly at the adipose level, with smaller hepatic effects. The increase in adipocyte 
differentiation and the redistribution of fat deposits from the abdominal to the sub-
cutaneous space may also indirectly improve insulin sensitivity. Improvement of
insulin sensitivity with TZDs results in a decreased demand for insulin secretion,
which may prolong the viability of β-cells. Although the mechanisms by which TZDs
may improve insulin sensitivity are not fully elucidated, observed reductions in FFA 
concentrations may mediated at least part of the effect. There are also preliminary
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reports indicating that TZDs upregulate the production of adiponectin, an adipocyte-
derived protein associated with improved insulin sensitivity.
In addition to their effects on insulin sensitivity, TZDs have demonstrated both direct
and indirect vascular effects, including improved endothelial function, decreased 
vascular inflammation, lowered plasma FFA levels, improved LDL phenotype, and
inhibition of VSMC proliferation. The TZDs have been demonstrated to reduce eleva-
tions in blood pressure and microalbuminuria and to improve fibrinolysis with 
consequent reversal of the procoagulant state. More recently attention has also
been drawn to PPAR-γ independent mechanisms in the vascular wall. There are some
indications that TZDs may reduce atherosclerotic progression in non-diabetic sub-
jects as well. Data evaluating the effects of TZDs on surrogate markers of cardiovas-
cular diseases are more and more available and appear quite promising. The aim of
a main part of this thesis is to focus on the potential role of Thiazolidinediones in
the pathophysiological mechanisms involved in vascular disease.
Chapter 3 is an overview of the metabolic and additional vascular effects of
Thiazolidinediones.
In chapter 4 we investigated the direct vascular effects of pioglitazone on the capacity
of the vasculature to maintain its NO-release, in type 2 diabetic patients, in a double
blind and crossover design. As measurement of NO-activity in the vessel wall, flow-
mediated dilation in the conduit brachial artery was used. We focused on relatively
short-term application of pioglitazone to tease out direct vascular effects from its
indirect metabolic effects. Short-term pioglitazone treatment did ameliorate endo-
thelial dysfunction in conduit arteries irrespective of significant beneficial changes
in plasma levels of insulin, FFA, adiponectin, or CRP in type 2 diabetics, indicating
direct vascular effects of pioglitazone.
We subsequently investigated whether a beneficial effect of TZDs on NO-bioavaila-
bility in type 2 diabetes also translates into better protection of the vessel wall from
inflammatory stimuli.
To this end we investigated in chapter 5, whether diabetic subjects could maintain
NO dominated endothelial function in the presence of increased concentrations of
TNF-α. Therefore we first investigated the effect of TNF-α on endothelium-dependent
vasodilation and secondly the effects of short-term pioglitazone treatment on TNF-α
induced endothelial dysfunction in patients with type 2 diabetes mellitus. Intra-
arterial TNF-α did induce impairment of endothelial function in type 2 diabetes,
indicating an inflammatory endothelial injury while short-term pioglitazone 
treatment blocked this impairment, indicating direct anti-inflammatory effects.
Chapter 8
184
proefschrift_Fabrice  21-12-2005  14:21  Pagina 184
185
General discussion, summary and conclusions
However, in this study the endothelial function did not improve in the resistance
vascular bed (measured with FBF), in contrast to the improvement in the conduit
brachial artery (chapter 4). The heterogeneous role of NO on vascular growth along
the vascular tree (as discussed in chapter 2), may one of the reasons for this difference
in effects on endothelial function.
In addition, we investigated ex vivo whether TZDs changed the properties of mono-
cytes to adhere to the endothelium, or to produce cytokines.
Therefore, we examined in chapter 6, in an ex vivo study, the effects of incubation of
monocytes with TZDs on monocyte-endothelium-adherence under flow conditions.
Monocytes from patients with type 2 diabetes adhered more to endothelium compared
to monocytes from healthy volunteers. Pioglitazone- or troglitazone pre-treatment of
monocytes reduced this monocyte adhesion.
In chapter 7 we studied the cytokine production in whole blood from type 2 diabetes
patients after short-term pioglitazone treatment, in a double blind and crossover
design. However, short-term pioglitazone treatment did not affect TNF-α, IL-6, and 
IL-10 production of monocytes, confirming the results presented in chapter 6, that
pioglitazone does not have direct anti-inflammatory effects on monocytes.
Although the mechanistic studies presented in this thesis add to the current under-
standing of both atherosclerosis and the pharmacologic effects of TZDs, results from
large-scale clinical studies are needed to evaluated the effects on clinical endpoints.
TZDs significantly reduced carotid arterial intima media thickness compared with
placebo. Furthermore a study performed with intravascular ultrasound scanning
showed that pioglitazone reduced neointimal tissue proliferation after coronary
stent implantation in patients with type 2 diabetes mellitus.
Recently the Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROACTIVE)
pioglitazone treatment reduced the relative risk for the combined endpoint death,
myocardial infarction, and stroke with 16%. Compared to placebo, pioglitazone 
reduced HbA1c by 0.5%, the plasma triglyceride concentration by 13.2%, the LDL/HDL
ratio by 5.3%, and the blood pressure by 3 mmHg, while the HDL level increased by
8.9%. Other trials, like Rosiglitazone Evaluated for Cardiac outcomes and Regulation
of Glycemia in Diabetes (RECORD), Carotid Intima Media Thickness in Atherosclerosis
Using Pioglitazone (CHICAGO), and Pioglitazone Effect on Regression of Intra-
vascular Sonographic Coronary obstruction Prospective Evaluation (PERISCOPE), are
planned to report in 2007. The Study of Atherosclerosis with Ramipril and
Rosiglitazone (STARR) is being conducted as a sub-study of the Diabetes Reduction
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Approaches with Ramipril and Rosiglitazone Medications (DREAM) trial and is 
planned to have a follow up from 5 years.
Several issues concerning TZD treatment are yet to be resolved. The apparent paradox
of adipocyte differentiation with weight gain concurring with the insulin-sensitising
effects of TZDs is not completely understood. The TZD-induced decrease in blood
pressure accompanied by an increase in the plasma volume has not been fully
explained but make the TZDs contra-indicated for patients with heart failure. An
important issue that needs to be resolved is the importance of raised cholesterol
levels, in particular raised LDL levels, caused by rosiglitazone. Future research 
may provide answers to these questions, particularly with respect to the role of
PPAR-γ, but also PPAR-α, in vascular pathophysiology. Although the concept of TZDs
is promising, further research and additional long-term clinical trials concerning
cardiovascular endpoints, are needed.
This thesis particularly puts forward the interplay between endothelial dysfunction
and inflammation as biomarkers for cardiovascular disease.
Endothelial function (in the sense of NO-bioavailability) is an important determinant
of vessel wall structure. eNOS exerts a tonic inhibitory influence on aortic growth,
with limited impact on small arteries, in basal and hyperthrophic conditions. This
heterogeneous role of NO on vascular growth may explain the heterogeneity of 
vascular remodeling (eutrophic in the resistance vascular bed and hypertrophic in
the conduit arteries) due to endothelial activation. It may also explain the various
effects of a stimulus on endothelial function, measured in the conduit brachial 
artery with FMD vs. measurements in the resistance vascular bed with FBF.
Furthermore it helps to understand the complicated pathophysiology behind the
clustered risk factors in association with central obesity by linking endothelial dys-
function to insulin resistance. Increase in artery stiffness seems consistent across
the spectrum of worsening glycemic control. Targeting the underlying pathophysio-
logical mechanism of the clustered risk factors in association with central obesity
may be a more logical and beneficial strategy for reduction of cardiovascular morbi-
dity and mortality. Using the gained information of the beneficial metabolic effects
of TZDs as insulin-sensitizers, this thesis reveals also potential direct vascular effects
of TZDs improving insights in the pathophysiology of atherogenesis in insulin resi-
stance. Focussing on endothelial dysfunction, short-term pioglitazone treatment
induced maintenance of NO-release, irrespective of changes in plasma levels of
insulin, FFA, adiponectin, or CRP, indicating a direct vascular effect of TZDs. Intra-
arterial TNF-α induced impairment of endothelial function in type 2 diabetes while
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short-term pioglitazone treatment blocked this impairment, indicating direct anti-
inflammatory effects on the endothelium. TZD-pre-treatment reduced adhesion to
the endothelium of diabetic monocytes. Furthermore, short-term pioglitazone 
treatment did not affect cytokine-production of monocytes. These studies indicate
direct anti-inflammatory effects of pioglitazone on endothelium but not on mono-
cytes.
Studying the effects of TZDs on endothelial function and inflammation may shed
more light on the mechanisms involved in the clustered cardiovascular risk factors.
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Hart- en vaatziekten zijn doodsoorzaak nummer 1 in de Westerse wereld. De term
hart- en vaatziekten omvat alle klinische manifestaties van atherosclerose zoals
perifeer vaatlijden, cerebrovasculaire ziekten en coronair vaatlijden. Bekende risico
factoren zijn dyslipidemie, roken, diabetes mellitus, hypertensie en obesitas. De
pathofysiologie van atherosclerose is gebaseerd op een ‘respons to injury’ principe,
waardoor minder traditionele factoren, zoals endotheeldisfunctie en ontsteking,
een noodzakelijke rol spelen.
Het endotheel is geïdentificeerd als de centrale regulator die ontregelt wordt door
verscheidene risicofactoren waardoor atherosclerose en de daarbij horende compli-
caties kunnen ontstaan. Voornamelijk activatie van het endotheel door risicofactoren
kan endotheeldisfunctie geven. Endotheeldisfunctie is gekarakteriseerd door een 
verschuiving van de processen die zich afspelen in het endotheel richting minder
vasodilaterend, meer ontsteking en meer trombogeen. Mechanismen die betrokken
zijn bij een verminderd vasodilaterend effect zijn, minder NO produktie, oxidatieve
stress en minder produktie van hyperpolarizing factor. Vasoactieve peptiden zoals
Ang-II and ET-1, hypercholesterolemie, onevenwichtige insuline signalling en hyper-
glycemie, samen met opregulatie van adhesie molekulen, produktie van chemokines
zoals MCP-1, en productie van PAI-1, zorgen allemaal samen voor een verminderde
vasodilatatie, de ontsteking en een trombogene toestand. Basaal ontstaat endotheel-
disfunctie door een verschuiving van een gezonde conditie met lage concentraties
NO welke vaatverwijding en/of anti-inflammatoire effecten geeft. Naast vaat-
verwijding, remt NO ook de adhesie van leukocyten aan het endotheel, remt NO de
gladde spiercel-proliferatie en migratie, en vermindert het de vaattonus. In patho-
fysiologische situaties is de NO-beschikbaarheid in vivo echter, door redox signalling
in het geactiveerde endotheel, verminderd door minder NO-productie, toegenomen
NO-afbraak of beiden. Samengevat heeft zulk een pathofysiologische activatie van
het endotheel twee gevolgen:
Allereerst zal dit leiden tot een productie van chemokines en een tot expressie
komen van adhesie-moleculen. Dat heeft weer tot gevolg dat ontstekingscellen door
de vaatwand zullen worden aangetrokken. In fysiologische omstandigheden is dit
systeem er voor de bescherming tegen indringers, maar het kan echter ook door-
slaan bij langdurige endotheel activatie door cardiovasculaire risicofactoren. In de
vaatwand ontstaat nu een inflammatoir fenotype dat weer kan leiden tot athero-
genesis en plaque-rupturen. Het besef dat atherosclerose gebaseerd is op chronische
ontsteking begint bij pathologisch onderzoek waarbij T-lymfocyten en macrophagen
worden aangetoond in de schouder van een atherosclerotische plaque in patiënten
die zijn gestorven door een acute hartaanval. Hierop volgende studies geven steeds
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meer aanwijzingen dat inflammatoire processen betrokken zijn bij atherogenese,
atherosclerose en plaque ruptuur. Het begin van atherosclerose is het migreren van
monocyten van het lumen de vaatwand in, waarbij de monocyten gedreven worden
door een chemische aantrekking welke is ontstaan door beschadiging van het
endotheel. Ondanks het feit dat het precieze pathofysiologische mechanisme hier-
achter nog niet geheel ontrafeld is, is het overduidelijk dat door de centrale rol 
die inflammatie speelt bij het ontstaan van atherosclerose, het remmen van deze
ontstekings-procesen daadwerkelijk als behandeling van atherosclerose een veel-
belovend aspect kan zijn.
Het andere effect, van verminderde NO-beschikbaarheid in het endotheel door 
cardiovasculaire risicofactoren, blijkt de verandering van de vaatwand-structuur.
NO lijkt de gladde spiercel-proliferatie in de vaatwand te remmen. Verminderde NO-
beschikbaarheid zou dan dus een toename van deze gladde spiercel-proliferatie ten
gevolgen hebben. Dit zal dan weer de ontwikkeling tot een atherosclerotische plaque
versnellen, maar ook leiden tot dikkere, van structuur veranderde vaten. Hierdoor
worden de desbetreffende vaten stijver en geven dus onwillekeurig verhoogde druk
op het hart- en vaatstelsel.
Endotheeldisfunctie is geassocieerd met alle vormen van hart- en vaatziekten zoals
hypertensie, coronair vaatlijden, chronisch hartfalen, perifeer vaatlijden, diabetes
en chronisch nierfalen. De mate van endotheeldisfunctie blijkt een prognostische
maat voor cardiovasculaire events. Endotheeldisfunctie is niet alleen geassocieerd
met hart- en vaatziekten maar blijkt ook, als een soort voorbode, een voorspeller
voor cardiovasculaire events. Het behandelen en/of tegengaan van endotheel-
disfunctie lijkt daarmee logischerwijs het risico op hart- en vaatziekten terug te
dringen. Het gaat hier dan om de behandeling van de onderliggende aandoening
die de endotheeldisfunctie veroorzaakt. Maar ook het behandelen van de losse 
componenten, die ieder op zich endotheeldisfunctie veroorzaken, zal helpen.
In hoofdstuk 1 hebben we gekeken naar de hypothese dat endotheelfunctie (obv 
NO-beschikbaarheid) een belangrijke rol speelt in veranderingen van de vaatwand-
structuur. Endotheeldisfunctie, als begin van atherogenese, speelt zich af in de grote
vaten, terwijl er toegenomen vasculaire weerstand ontstaat in de weerstandsvaten
bij essentiële hypertensie. Gepostuleerd kan worden dat deze heterogeniteit best
wel eens te maken zou kunnen hebben met een heterogeen effect van eNOS op 
de proliferatie in grote vaten versus de kleine weerstandsvaten. Inderdaad blijkt
eNOS een tonisch remmende werking te hebben op de groei in de aorta, terwijl er
nauwelijks effect bereikt wordt door eNOS in de kleine weerstandsvaten, zowel 
in basale- als al in hypertrofische toestand. Dit verschil in effect van NO op de 
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vasculaire groei op verschillende plekken in het vasculaire netwerk kan de hetero-
geniteit van vasculaire remodeling, een adaptatie welke geassocieerd is met endo-
theeldisfunctie,verklaren. Ook zou het een verklaring kunnen zijn voor de soms 
verschillende resultaten van endotheelfunctie metingen bij dezelfde stimuli tussen
een FMD-meting van de grote a. brachialis versus een FBF-meting van het onder-
arms-weerstandsvaatbed (zie hoofdstuk 4 en 5).
In dit proefschrift hebben we verschillende aspecten van het zojuist beschreven
model van vaatschade onderzocht bij type 2 diabetes mellitus. Grote bezorgdheid
bestaat bij het wereldwijd enorm toenemen van de prevalentie van diabetes (op dit
moment zo’n 200 miljoen mensen wereldwijd). Een belangrijke rol speelt de enorme
toename van patiënten met insulineresistentie (op dit moment zo’n 400 miljoen
mensen wereldwijd). Deze insulineresistentie is vooral geassocieerd met obesitas,
en daaraan gekoppeld de vrije vetzuur-flux naar andere weefsels dan de adipocyten
(zoal het spierweefsel en de lever). Daarnaast spelen genetische veranderingen, met
name bij Aziatische mensen, een belangrijke rol. Verschillende risico factoren, zoals
glucoseintolerantie, hyperinsulinemie, obesitas, dyslipidemie, hypertensie, maar
ook endotheeldisfunctie en inflammatie, komen vaak samen voor in één patiënt en
resulteren vaak in het ontstaan van klinische diabetes mellitus type 2. Door in 2001
een voor de kliniek goed hanteerbare definitie te formuleren voor dit cluster van
metabole abnormaliteiten, het metabool syndroom genaamd, voorziet de National
Cholesterol Education Program (NCEP) van de VS het grote belang van primaire 
preventie en dus vroege opsporing hiervan. Het klinkt logisch wanneer wordt aan-
genomen dat het totale cardiovasculaire risico voor patiënten die tot het metabool
syndroom behoren gewoon berekend kan worden uit de som van de verschillende
betrokken cardiovasculaire risico factoren samen. Er bestaan echter ook data die
suggereren dat het cardiovasculaire risico voor patiënten behorende tot het meta-
bool syndroom zelfs hoger ligt dan de som der delen. Behandeling van alle tot het
metabool syndroom behorende afzonderlijke pathofysiologische abnormaliteiten
zal zeer zeker leiden tot risicoreductie voor cardiovasculaire events. Het is noodzakelijk
om populatie-studies welke focussen op behandeling van de bekende cardiovasculaire
risico factoren zoals obesitas, hoog plasma LDL cholesterol, hoog trygliceriden gehalte,
laag plasma HDL, hyperglycemie en hoge bloeddruk, te continueren. Deze bekende 
risico factoren zijn namelijk, om het in een metafoor uit te drukken, de uiteinden
van de vasculaire boom. Echter, we moeten ons wel bedenken dat de takken van de
vasculaire boom gedragen worden door de stam. Deze metafoor is bedoeld om aan
te geven dat er een drager bestaat voor alle tot nog toe bekende risico factoren,
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bestaande uit niet-traditionele onderliggende pathofysiologische fenomenen. Deze
pathofysiologische fenomenen zoals endotheeldisfunctie, inflammatie, oxidatieve
stress, stollings-abnormaliteiten en ectopische vetophoping, zijn allen geassocieerd
met insulineresistentie. Het is moeilijk precies te achterhalen wat nu werkelijk de
effecten zijn van insulineresistentie, maar er bestaat duidelijk een significante 
relatie met verhoogd cardiovasculair- en cerebrovasculair risico. Het interessante 
is dat deze relatie stand houdt, zelfs versterkt, naarmate de glycemische controle
verslechtert: van het begin van glucose intolerantie tot de ontwikkeling van klinische
type 2 diabetes mellitus.
Ondanks het feit dat een pathofysiologische constructie logisch lijkt moet toekomstig
onderzoek uitwijzen of we inderdaad pathofysiologisch en klinisch kunnen spreken
van een ‘metabool syndroom’.
Klinisch zou het zinvol zijn wanneer de ernst van insulineresistentie gekoppeld 
zou kunnen worden aan de ernst van vaatstijfheid ontstaan door verminderde 
NO-beschikbaarheid. In hoofdstuk 2 hebben we een cross-sectioneel onderzoek
gedaan om te kijken of er een relatie bestaat tussen vaatstijfheid van de carotis van
2105 patiënten met manifestaties van arterieel vaatlijden en het metabool syn-
droom en hoe deze zich verhoudt tot de relatie van vaatstijfheid van de carotis en
type 2 diabetes mellitus. We kunnen concluderen in lijn met de hypothese dat
naarmate de glycemische control verslechtert, en er dus sprake is van meer insuline-
resistentie, er ook een sterkere relatie bestaat met vaatstijfheid van de carotis in
patiënten met manifestaties van arterieel vaatlijden. De vaatstijfheid is iets ver-
groot bij patiënten met het metabool syndroom en neemt toe naarmate een patiënt
meer componenten van het metabool syndroom heeft. De meeste vaatstijfheid
blijkt echter aanwezig bij patiënten met type 2 diabetes mellitus.
Ondanks uitgebreid onderzoek naar het verband tussen diabetes en de onvermijde-
lijke cardiovasculaire complicaties is het helaas nog niet helemaal duidelijk of de
aggresiever lijkende atherosclerose, ontstaan in een diabetische situatie, ook anders
is dan de atherosclerose die ontstaat in niet-diabetische situatie. Hyperglycemie is
inderdaad een uniek aspect van diabetes. Glucose zelf heeft al zo zijn invloed, maar
ook de alternatieve pathofysiologische consequenties van hyperglycemie spelen
hierin een rol. Advanced glycation endproducts (AGEs), veroorzakers van meer 
plaque instabiliteit, zijn hiervan een voorbeeld. Bij insulineresistentie is er echter
ook sprake van enkele metabole abnormaliteiten zoals hypertensie, hypertriglyceri-
demie, laag HDL gehalte, small dense LDL en meer trombogeniteit, die ook allen
betrokken zijn bij atherosclerose bij niet-diabeten. Zo lijkt het logisch(er) om bij het
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proberen cardiovasculaire complicaties te reduceren, ons te richten op de onder-
liggende pathofysiologische mechanismen van insulineresistentie. De stam van de
vasculaire boom weer in gedachte, zal farmacologische modulatie van het insuline-
resistentie syndroom niet alleen de glycemische controle verbeteren, maar zal ook
gunstige effecten hebben op ontsteking, endotheeldisfunctie, dyslipidemie en
mogelijk nog op andere componenten van het syndroom, zelfs onafhankelijk van
het glucose metabolisme.
De ontdekking van nuclear peroxisome proliferator-activated receptors (PPARs) en
het inzicht in hun werking en daarmee hun rol in verschillende metabole pathways
heeft voor veel meer begrip gezorgd van de onderliggende pathofysiologische
mechanismen van het insulineresistentie syndroom. Thiazolidinedionen (TZDs)
behoren tot de PPAR-γ agonisten, een klasse medicijnen dat uitgebreid heeft aan-
getoond in mens en dier de insuline gevoeligheid (met name in skeletspieren) te
verbeteren. Twee van deze klasse medicijnen, rosiglitazon en pioglitazon, zijn op dit
moment geregisteerd voor patienten met type 2 diabetes mellitus. Een eerdere TZD,
troglitazon, had dezelfde insulinegevoeligheid verbeterende werking, maar is van
de markt gehaald wegens onacceptabele hepatotoxiciteit. Beschikbare TZDs ver-
beteren de insulinegevoeligheid met name in het vetweefsel, en in mindere mate
via het levermetabolisme. Indirecte verbetering van insulinegevoeligheid wordt ook
bewerkstelligd door meer adipocyt differentiatie en de redistributie van vetopslag
van abdominal naar subcutaan. Verbetering van de insulinegevoeligheid door TZDs
resulteert in een verminderde vraag naar insulinsecretie, hetgeen weer de levens-
vatbaarheid van de β-cellen ten goede komt. De precieze mechanismen waarmee
TZDs de insulinegevoeligheid verbeteren is nog niet geheel opgehelderd, maar
daling in de vrije vetzuur concentraties draagt daar zeker aan bij. Sommige studies
beweren ook dat TZDs de produktie van adiponectine, een uit vetweefsel komend
eiwit dat geassocieerd is met verbetering van insulinegevoeligheid, opreguleren.
Naast de effecten op insulinegevoeligheid hebben TZDs ook gedemonstreerd directe
en indirecte vasculaire effecten te hebben. TZDs verbeteren endotheelfunctie,
remmen ontsteking (in de vaatwand), reduceren de vrije vetzuur concentraties,
verbeteren het LDL-profiel en remmen gladde spiercelproliferatie. Ze verlagen
bloeddruk, verminderen de microalbuminemie en verbeteren de fibrinolyse.
Tegenwoordig wordt ook gekeken naar PPAR-γ onafhankelijke mechanismen in de vaat-
wand en lijken TZDs ook atherosclerose te verminderen in niet-diabeten. Er worden
steeds meer veelbelovende data gepubliceerd over de effecten van TZDs op surrogaat-
markers van hart- en vaatziekten. Het doel van een overgroot deel van dit proefschrift is
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na te gaan wat de potenties zijn van het mechanisme van Thiazolidinedionen in de
pathofysiologie van vasculaire ziekte.
Hoofdstuk 3 geeft een overzicht van de metabole en additionele vasculaire effecten
van Thiazolidinedionen.
In hoofdstuk 4 hebben we onderzocht of pioglitazon, direct de endotheelfunctie kan
beïnvloeden door behoud van voldoende NO-productie in type 2 diabetes patïenten.
In een gerandomiseerde, cross-over, placebo-gecontroleerde en dubbel-blinde 
studie, is de NO-activiteit in de vaatwand gemeten middels FMD van de a.brachialis.
Om directe vasculaire effecten te kunnen onderscheiden van de indirecte metabole
effecten hebben we naar een relatief korte behandelingsperiode gekeken. Het blijkt,
dat door het behandelen van patiënten met type 2 diabetes mellitus met pioglitazon
voor een korte tijd, de endotheelfunctie op directe wijze verbetert zonder indirecte
hulp van significante gunstige metabole veranderingen in insuline, vrije vetzuren,
adiponectine of CRP.
Om de gedachte door te trekken, hebben we verder gekeken of dit gunstige effect
van TZDs op de NO-beschikbaarheid in type 2 diabetes, ook te vertalen valt in een
betere bescherming van de vaatwand voor inflammatoire stimuli.
Daarom hebben we in hoofdstuk 5 de twee biomarkers, endotheeldisfunctie en 
inflammatie, gekoppeld en gekeken of diabetici hun NO-gemedieerde endotheel-
functie op peil kunnen houden ondanks een verhoogde concentratie TNF-α. In een
gerandomiseerde, placebo-gecontroleerde en dubbel-blinde studie is onderzocht
of pioglitazon TNF-α geïnduceerde endotheeldisfunctie kan beïnvloeden. Intra-
arteriele infusie van TNF-α geeft een inflammatoire beschadiging van de vaatwand
waardoor endotheeldisfunctie optreedt in type 2 diabetes. Korte-termijn behande-
ling met pioglitazon kan deze geïnduceerde endotheeldisfunctie anti-inflammatoir
blokkeren. Echter, in hoofdstuk 4 hebben we een duidelijke directe endotheel-
functie-verbetering gevonden middels FMD-metingen in de a. brachialis, maar 
vinden we die (nog) niet bij de FBF-meting van het onderarms-weerstandsvaatbed.
De in hoofdstuk 2 beschreven heterogeniteit van NO kan een mogelijke verklaring
zijn voor dit verschil.
Om de mogelijke anti-inflammatoire effecten van TZDs verder te bestuderen heb-
ben we ex vivo onderzocht of TZDs de eigenschappen van adhesie van monocyten
aan het endotheel, of de productie van cytokinen, kunnen beïvloeden.
Daarom is in hoofdstuk 6 ex vivo gekeken naar het adhesie-gedrag van monocyten
van type 2 diabeten op HUVEC onder flow. Het blijkt dat monocyten van patiënten
met type 2 diabetes meer adheren aan endotheel, in vergelijking met monocyten
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van de gezonder vrijwilligers. Pioglitazon- of troglitazon-behandeling van de 
monocyten verminderen echter deze adhesie aan het endotheel. Hoofdstuk 7 is een
ex vivo, gerandomiseerde, cross-over, placebo-gecontroleerde, dubbel-blinde studie
waarbij het effect van kortdurende pioglitazon behandeling op de cytokine-produktie
in volbloed bestudeerd wordt. De conclusie is, dat korte-termijn behandeling met
pioglitazon geen effect heeft op de TNF-α-, IL-6-, of IL-10-produktie van monocyten en
daarmee misschien het idee van hoofdstuk 6 bevestigt dat TZDs geen directe 
anti-inflammatoire effecten op monocyten genereren.
Natuurlijk zijn dit soort fundamentele interventiestudies van belang om meer te
kunnen begrijpen van atherosclerose en de farmacologische effecten van TZDs en
meer te verwachten resultaten van andere studies zullen aan dit inzicht bijdragen.
Op dit moment zijn voornamelijk de effecten van TZDs op surrogaat cardiovasculaire
eindpunten bij patienten bekend. TZDs reduceren significant de arteriële intima
dikte van de carotis, in vergelijking met placebo. Daarnaast blijkt pioglitazon de neo-
intima proliferatie na coronaire stentplaatsing, gevisualiseerd middels intravasculaire 
echografie, te verminderen in patiënten met type 2 diabetes mellitus.
In de recent gepubliceerde Prospective Pioglitazone Clinical Trial in Macrovascular
Events (PROACTIVE) vermindert pioglitazon het relatieve risico op het gecombineerde
eindpunt sterfte, een hartinfarct, of een hersenbloeding, met 16%. Metabole para-
meters veranderen ook ten gunste: HbA1c concentraties werden 0.5% minder, de
plasma triglyceride concentratie daalde met 13.2%, de LDL/HDL ratio met 5.3%, en de
bloeddruk daalde met 3 mmHg, terwijl het plasma HDL-gehalte steeg met 8.9%.
Andere trials, zoals de Rosiglitazone Evaluated for Cardiac outcomes and Regulation
of Glycemia in Diabetes (RECORD), Carotid Intima Media Thickness in Atherosclerosis
Using Pioglitazone (CHICAGO), en Pioglitazone Effect on Regression of Intravascular
Sonographic Coronary obstruction Prospective Evaluation (PERISCOPE), zullen 
allen hun resultaten prijsgeven in 2007. De Study of Atherosclerosis with Ramipril
and Rosiglitazone (STARR) is opgezet als een onderdeel van de Diabetes Reduction
Approaches with Ramipril and Rosiglitazone Medications (DREAM) trial en duurt
5 jaar.
Toch blijven er nog de nodige vraagtekens bestaan voor TZD-behandeling die in de
toekomst opgelost zullen (moeten) worden. De paradox van adipocyt-differentiatie
en de waargenomen gemiddelde gewichtstoename van maximaal enkele kilo’s bij
gebruik van de insuline gevoeligheid verbeterende TZDs is nog niet geheel duidelijk.
Verder is het nog onduidelijk dat TZDs de bloeddruk verlagen terwijl er een expansie
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van het plasmavolume optreedt, waardoor gebruik van TZDs terecht gecontraïndi-
ceerd is bij patiënten met hartfalen. Verder onderzoek zal nog moeten plaatsvinden
naar soms geobserveerde stijging van cholesterolconcentraties, met name het
atherogene LDL. Toekomstig onderzoek zal vele antwoorden vinden op deze en meer
vragen. Zeker zal het belang van PPAR-γ, maar ook PPAR-α in de vasculaire patho-
fysiologie ontrafeld worden. Het concept van de TZDs is zeer veelbelovend, maar
laten we nog enkele jaren van onderzoek, -misschien leidend tot nog betere farma-
cologische behandelingsstrategieën-, en de resultaten van meer lange-termijn 
klinische trials op cardiovasculaire eindpunten afwachten.
In dit proefschrift zien we met name het samenspel tussen de belangrijke biomar-
kers voor hart- en vaatziekten: endotheeldisfunctie en inflammatie.
Endotheelfunctie (de mate van NO-beschikbaarheid) is een belangrijke factor voor
de vaatwandstructuur. Inderdaad blijkt eNOS een tonisch remmende werking te
hebben op de groei in de aorta, terwijl er nauwelijks effect bereikt wordt door eNOS
in de kleine weerstandsvaten, zowel in basale- als al in hypertrofische toestand. Dit
verschil in effect van NO op de vasculaire groei op verschillende plekken in het
vasculaire netwerk kan de heterogeniteit van vasculaire remodeling (eutrofisch in
het weerstandvaatbed en hypertrofisch in de geleidingsvaten), een adaptatie welke
geassocieerd is met endotheeldisfunctie, verklaren. Ook zou het een verklaring 
kunnen zijn voor de soms verschillende resultaten van endotheelfunctie metingen
bij dezelfde stimuli tussen een FMD-meting van de grote a. brachialis versus een
FBF-meting van het onderarms-weerstandsvaatbed.
Verder kan het helpen de gecompliceerde pathofysiologie achter het geclusterd
voorkomen van met obesitas geassocieerde risicofactoren beter te begrijpen, door
endotheeldisfunctie te koppelen aan insulineresistentie: naarmate de glycemische
control verslechtert, en er dus sprake is van meer insulineresistentie, bestaat er ook
een sterkere relatie met vaatstijfheid van de carotis in patiënten met manifestaties
van arterieel vaatlijden. De vaatstijfheid is iets vergroot bij patiënten met het
metabool syndroom en neemt toe naarmate een patiënt meer componenten van
het metabool syndroom heeft. De meeste vaatstijfheid blijkt echter aanwezig bij
patiënten met type 2 diabetes mellitus.
Het lijkt logisch(er) om bij het proberen cardiovasculaire complicaties te reduceren,
ons te richten op de onderliggende pathofysiologische mechanismen van de geclus-
terde met obesitas geassocieerde risicofactoren. Gebruik makend van de kennis 
dat TZDs, als insuline-sensitizers, gunstige metabole effecten hebben, geeft dit
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proefschrift ook een idee van directe vasculaire effecten van TZDs. Dit vergroot niet
alleen de therapeutische mogelijkheden, maar zorgt ook voor meer inzicht in de
pathofysiologie van de atherogenese in insulineresistentie. Het blijkt, dat door het
behandelen van patiënten met type 2 diabetes mellitus met pioglitazon voor 
een korte tijd, de endotheelfunctie op directe wijze verbetert zonder indirecte hulp
van significante gunstige metabole veranderingen in insuline, vrije vetzuren,
adiponectine of CRP.
De gunstige effecten van TZDs op de NO-beschikbaarheid in type 2 diabetes, zijn ook
te vertalen in een betere bescherming van de vaatwand voor inflammatoire stimuli:
intra-arteriele infusie van TNF-α geeft een inflammatoire beschadiging van de vaat-
wand waardoor endotheeldisfunctie optreedt in type 2 diabetes. Korte-termijn
behandeling met pioglitazon kan deze geïnduceerde endotheeldisfunctie anti-
inflammatoir blokkeren. De suggestie wordt gewekt dat dit anti-inflammatoire
effect voornamelijk op het endotheel gericht is, aangezien de in type 2 diabeten ver-
hoogde monocyt-endotheel-adhesie geremd kan worden met TZDs zonder een direct
effect op de monocyt. Ook de cytokinen-productie wordt niet beïnvloed door TZDs.
Het bestuderen van de vasculaire effecten van TZDs op endotheelfunctie en inflamma-
tie zorgt voor meer inzicht in de pathofysiologie achter de geclusterd voorkomende
cardiovasculaire risicofactoren.
Nederlandse samenvatting
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Abbreviations
ACE Angiotensin converting enzyme
Ang-II Angiotensin-II
AT Angiotensin
BH4 Tetrahydrobiopterin
BMI Body mass index (weight in kilograms divided by the square height in meters)
CETP Cholesterolestertransferprotein
cGMP cyclic Guanosine monophosphate 
CRP C-reactive protein
DM2 Diabetes mellitus type 2
EC Endothelial cells
EDHF Endothelium derived hyperpolarizing factor
EDRF Endothelium derived relaxing factor = NO
eNOS endothelial Nitric oxide synthase
E-selectin Endothelial-leucocyte adhesion molecule
ET-1 Endothelin-1
FBF Forearm blood flow
FFA Free fatty acids
FMD Flow-mediated dilation
GLUT 4 Glucose transporter 4
HDL High-density lipoprotein 
HUVEC Human Umbilical Vein Endothelial Cells
ICAM-1 Intracellular adhesion molecule-1
IL-6 Interleukin-6
L-NAME NG-nitro-L-arginine methyl ester 
L-NMMA NG-monomethyl-L-arginine 
LPL Lipoprotein lipase 
LPS Lipopolysaccharide/ endotoxin 
MCP-1 Monocyte chemotactic protein-1
MNC Mononuclear cells
MetSyn Metabolic syndrome
NADPH Nicotamine adenine dinucleotide phosphate 
NF-kB Nuclear factor-kB
NO Nitric oxide
ox-LDL Oxidized low density lipoprotein
PAI-1 Plasminogen activator inhibitor
PPAR Peroxisome proliferator-activated receptors
ROS Reactive oxygen species
TNF-α Tumor necrosis factor-α
tPA tissue Plasminogen activator
TZDs Thiazolidinediones
VCAM-1 Vascular cell adhesion molecule-1
VLDL Very low-density lipoprotein
VSMC Vascular smooth muscle cells
vWF von Willebrand factor
proefschrift_Fabrice  21-12-2005  14:21  Pagina 203
proefschrift_Fabrice  21-12-2005  14:21  Pagina 204
CURRICULUM VITAE
proefschrift_Fabrice  21-12-2005  14:21  Pagina 205
proefschrift_Fabrice  21-12-2005  14:21  Pagina 206
207
Curriculum Vitae
Curriculum Vitae
Fabrice Marcel Anne Clément Martens was born on the 1th of January 1974 in Delft,
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A year later he switched to the University of Utrecht. During his medical training he
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(Norway), and a fellowship of Dermatology at the Royal Perth Hospital, Sir Charles
Gairdner Hospital and the Princess Margeret Children Hospital, all in Perth
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vessel-wall-remodelling at the Université de Montréal (Canada), under supervision
of prof. P. Moreau. In this period his first performance at an international meeting
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Hypertension), Milan.
Fabrice Martens obtained his Medical Degree in January 2001 and started the work
described in this thesis at the department of Vascular Medicine of the University
Medical Center Utrecht, under supervision of dr. F.L.J. Visseren and prof. dr. T.J.
Rabelink. During this period he presented on several international meetings: the
Second International Symposium on PPARs, Florence; the 18th Congress of the
International Diabetes Federation, Paris; the XIIIth International Symposium on
Atherosclerosis (International Atherosclerosis Society), Kyoto; the Scientific Sessions
(American Heart Association), Orlando.
In September 2003 he started his 2 year residency Internal Medicine at the
University Medical Center Utrecht under supervision of prof. dr. E.E. van der Wall as
part of his specialisation to cardiologist. In September 2005 he continued his trai-
ning in cardiology at the department of Cardiology at the St. Antonius Hospital
Nieuwegein, under supervision of dr. W. Jaarsma, where he will become cardiologist
in the year 2009.
Fabrice Martens is married to Marieke Volmer and they have an almost 3 month-old
daughter Valerie.
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Dit dankwoord is dan wel het laatste deel van mijn proefschrift, maar wel één van
de belangrijkste delen! Niet in de laatste plaats omdat het dankwoord het meest
gelezen blijkt, maar zeker ook omdat dit dé plek in het proefschrift is waar ik mijn
waardering kan uiten voor diegenen die onmisbaar waren bij het tot stand komen
ervan. Sterker gezegd: zonder onderstaanden was dit proefschrift niet eens werke-
lijkheid geworden....
Dr. F.L.J. Visseren, geachte co-promotor, beste Frank: Frank, onze ontstane relatie is
eigenlijk niet in woorden te vatten, maar ik ga het toch proberen. Ik heb je ooit, toen
nog als vierdejaars medisch student, een presentatie zien geven waarbij ik, gek
genoeg, hoopte ooit nog eens met je in aanraking te komen. De interesse voor het
vakgebied was er al, maar de manier waarop je de dingen uitlegde werkte aansteke-
lijk. Tot mijn stomme verbazing werd ik, ongeveer 3 jaar later, ongevraagd, voor het
in dit boekje beschreven onderzoek, aan jou gekoppeld! Sindsdien ben ik je als een
zeer gewaardeerd leermeester in het onderzoek gaan beschouwen. Jouw werkwijze
ligt me enorm, ik heb zeer veel opgestoken van je ‘netwerken’ en ben jaloers op je
vermogen het belangrijke van het onbelangrijke te onderscheiden. Jij hebt me naar
de plek in de onderzoekswereld gebracht waar ik nu sta; jij hebt mijn ‘tante Betje-
taal’ aangepakt; jij hebt me leren nadenken op verschillende manieren; en jij hebt
vooral vertrouwen getoond, daar waar ik het nodig had. Dit vertrouwen was waar-
schijnlijk ook mogelijk mede doordat wij meer bevriend zijn geraakt dan ik ooit had
kunnen denken. Onze interesses blijken op vele vlakken overeen te komen en is het
niet in het ziekenhuis, dan is het wel thuis, of op de tennisbaan, waar we het nodige
met elkaar delen. Zonder jouw steun was dit proefschrift er helemaal niet geweest.
Ik bedank je er oprecht voor en hoop nog vele jaren met je te mogen samenwerken,
maar ook vele andere aspecten van het leven met je te delen. Ik wens jou en je prachtige
gezin alle goeds.
Prof. Dr. T.J. Rabelink, geachte promotor, beste Ton: Jij bent degene geweest die mij
eind 1997 een cruciale duw in de juiste richting hebt gegeven door me naar Pierre
Moreau te durven sturen. De interesse voor de wetenschap werd hiermee duidelijk
aangewakkerd. Door de manier waarop je met mij meedacht bij een beslissing tussen
de Mayo Clinics en Montréal, door mij (misschien onbewust) te sturen in mijn ‘jonge-
honden-enthousiasme’, maar ook door een zelfde interesse voor het pianospel, was er
vanaf toen al duidelijk sprake van vertrouwen. Allereerst door je onbetwiste weten-
schappelijke kwaliteiten, maar zeker ook door bovengenoemde, wilde ik bewust bij jou
promoveren. Ondanks je overvolle agenda en je onverwachte, maar onvermijdelijke
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Dankwoord
verhuizing naar Leiden, ben je altijd erg betrokken geweest. Mijn dank is groot en ik
ervaar het als een geweldig voorrecht met je te mogen samenwerken.
De leden van de beoordelingscommissie: De hooggeleerde heren H.A. Koomans,
P.A. Doevendans en J.B.L. Hoekstra, en de hooggeleerde dames E.E. van der Wall en 
Y. van der Graaf, dank ik voor de bereidwilligheid zitting te nemen in deze commissie.
Prof P. Moreau, dear Pierre: Your position in this ‘chapter of thanks’ is definitely 
certified. It was you who took me by the hand and guided me step by step towards
enthousiasm for research. Not only did you guide me with your amazing knowledge,
patience and intelligence through research, but also through an important period of
my life; a period of being abroad for so long for the first time, a period where the age
makes you decide in what direction you want to find your future. Not at least did we
find each other also as friends during our canoe-trip and all the other events in-and
outside the Université de Montréal with- and without your beloved Jacinthe and
Eríc. I hope to keep in touch for many years to come and wish you all the best in your
work and with your soon even bigger family!
Jacinthe, getting to know you was a privilege. You always trigger me with your 
interesting ideas and I’m glad that we even have published together. Good luck as
researcher and mom!
Dr. E.J.P de Koning, beste Eelco: Ik heb enorm veel geleerd van je doorzettingsvermogen
en ben je dankbaar voor alle ondersteunende gesprekken over de vaatmetingen.
Tevens moet ik je bedanken voor je altijd kritische aanwijzingen, zeker bij het schrijven
van mijn eerste artikel. Helaas hebben we ook jou moeten missen bij de Vasculaire
Geneeskunde, maar gelukkig weet ik dat de stap naar de US je geen windeieren heeft
gelegd.
Beste Jos, wat had ik zonder jou gemoeten!? Jij hebt me de eerste 2 jaar van het
onderzoek de kneepjes van de vaatmetingen bijgebracht. Met jouw aanwezigheid
was er altijd wat te beleven waardoor de eindeloze meetdagen tot een ware happe-
ning werden. Je trouw, discipline en principes zijn niet te evenaren. Zonder jouw
inzet was het proefschrift nu nooit klaar geweest. Ik hoop echt dat je je plezier in je
werk houdt en altijd die goede vader blijft voor je meiden thuis. Thanks!
Colleagues and friends around the Université de Montréal: I also want to thank all
the people I worked with during my stay at the laboratory of Pierre. Also mentioning
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my friends I had during my stay in Montréal is inevitable! To avoid forgetting anybody
I will not mention names, but hopefully the ones who deserve it the most can 
appreciate it this way. Thanks!
Alle (ex-) collega’s van de Vasculaire Geneeskunde: zo’n fantastisch onderzoeks-
team krijgen we nooit meer bij elkaar. Ik hoop dat iedereen zijn geluk vindt en dat
het successen regent. Arno (gefeliciteerd met je ‘dr’; je wordt beloond voor je harde
werken; bedankt voor je geweldige hulp en gezelligheid in ons kamertje en dat we
nog vele jaren als collega’s door het leven mogen), Albert (succesvol klinisch chemicus
en altijd aardig), Arash (succes met je onderzoek en dat we in de toekomst maar 
collega’s worden), Ben (het af en toe met een glimlach binnenlopen was genoeg),
Berthil (we doen nog onderzoek; vergeet de bal niet hoog te blijven opgooien bij 
serveren), Carolien (ook in Leiden ben je verzekert van succes door je discipline en
gedrevenheid; zet ‘m op met publiceren), Cindy (ik bewonder jouw sterkte en geloof
enorm; ben jaloers op je wetenschappelijke kwaliteiten; maar wens je bovenal vanaf
nu alle geluk, ook in de liefde), Dao (our research-relationship already started in
Montreal where I was astonished by your capability to oversee all different subjects
in ones; we guided each other through wonderful, but also difficult times; it’s a
shame that your stay in the Netherlands was not what we hoped for but I wish you
all the best in the future with research, your girl, and in the Pharmacy), Despina (ik
ken niemand met zo’n opgewektheid), Hetty (heel erg bedankt voor het delen van je
expertise), Jeroen (gefeliciteerd met je ‘dr’; ook jij wordt beloond voor je harde werken),
Jobien (met jou is de samenwerking heel speciaal; als principiele en kritische dame
houdt je Frank en mij scherp; hopelijk continueert de samenwerking; veel succes
met jouw proefschrift en veel plezier met je gezinnetje), Joke (door Jobien en Frank
heb ik jou ontmoet, als tellig van het Julius Centrum. Ondanks onze zeer korte
samenwerking viel mij jouw stoïcijnse rust waarachter vele kwaliteiten schuil gaan
meteen op. Bedankt voor het mogelijk maken van het artikel van hoofdstuk 2 en
nogmaals gefeliciteerd met jouw ‘dr-schap’), Judith (naast heel wat overspiegelingen
hebben we ook samen heel wat werk verricht en ben ik je dankbaar voor je eindeloos
klinische werklust; ik hoop van harte dat je je ware plek gauw zult vinden), Karin
(zonder jouw aanwezigheid was er heel wat minder leven in de brouwerij geweest),
Laura ( jouw precisie en gedrevenheid moet je koesteren, dankzij deze kwaliteiten
heb ik heel wat extra data kunnen gebruiken; heel erg bedankt), Livio (zonder jouw
relativisme en enorm brede ervaring door een mega aantal interesses, wordt het
leven saaier), Lonneke (‘our lay-out queen’ en altijd in voor een wijntje), Maarten ( jij
houdt tenminste de ‘Vascu Boys’ nog hoog; succes met jouw promotie), Peter (succes
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met je promotie; ik verneem graag je resultaten met Pio), Petra (dat jij nu later in de
lijst staat heeft alleen met het alfabet te maken, want je hebt een speciaal plekje in
mijn hart veroverd tijdens al onze uren als buren), Ronald (bedankt voor het vrij
maken van de weg die ik moest gaan), Tjeerd (succes in Duitsland).
Geesje Dallinga-Thie, Anton-Jan van Zonneveld, Jan-Dirk Banga, Jaap-Jan Zwaginga en
Marianne Verhaar ben ik zeer erkentelijk voor hun begeleiding met hun opbouwende
kritiek en hun onmisbare suggesties.
‘Mijn’ studenten Jan Westerink, Jeroen vd Hilst en Femke Lutgendorf moet ik bedanken
voor het vertrouwen dat ze in me gesteld hebben. Ik heb jullie hulp zeer prettig 
gevonden. Ik weet dat jullie allemaal goed terecht zijn gekomen en dat dat ook wel was
gebeurd zonder onze samenwerking.
De dames van U-man Research (in memoriam): hartelijk dank voor de zeer prettige
samenwerking.
Uiteraard mogen de participerende patienten niet ontbreken in dit dankwoord.
Alhoewel de intentie is om voor jullie bestwil onderzoek te doen, kan ik niet ontkennen
dat daar soms wel heel veel voor doorstaan moet worden. Heel erg bedankt voor 
het door jullie gestelde vertrouwen en de discipline om het gehele onderzoek mee te
werken.
De overgang van onderzoek naar de kliniek is lastig, maar dankzij de steun van al
mijn collega’s Interne in het UMCU was het voor mij nauwelijks een probleem.
Mijn huidige collega’s Cardiologie in het St. Antonius Ziekenhuis te Nieuwegein wil
ik bedanken voor de gelegenheid die ze me gegeven hebben om eerst te promoveren;
dat de komende jaren nog veel collegiaal goeds brengen!
Mijn goede vrienden wil ik zeker niet vergeten en ze allen enorm bedanken voor
hun interesse en steun bij het tot stand komen van dit proefschrift. Jullie moesten
eens weten wat sommige opmerkingen voor een werkdrift met zich mee hebben
gebracht.
Bob, onze vriendschap gaat terug naar het hele begin van onze studie, zelfs nog voor
we samen in Utrecht aan de slag gingen. Zonder de innige verbondenheid op de
Koekoek was onze studie Geneeskunde heel wat minder leuk, leerzaam en interessant
geweest. Je bent al die tijd een stimulator geweest en ook nu jezelf al tot de ‘dr-wereld’
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behoort zie ik dat als een te volgen goed voorbeeld. Er is niets zo typerend aan onze
relatie dan dat jij ditzelfde zei op onze bruiloft. Ik denk dan ook dat het je op je lijf
geschreven is om míjn paranimf te zijn. Fantastisch dat je zo nauwkeurig een deel
van dit manuscript hebt nagekeken en voorzien van zeer goed commentaar; je kunt
zo verder als co-promotor! Dank hiervoor!
Lieve papa en mama, zonder jullie had ik dit nooit bereikt. Jullie hebben me altijd
alle kansen gegeven, maar me ook gewezen op het belang en de consequenties van
bepaalde keuzes. Een betere thuishaven had ik me niet kunnen wensen en jullie
steun naar dit succes is onmisbaar. Ik weet dat ik jullie niet méér kan bedanken dan
met het gelukkig zijn met wat ik bereik, maar ik hoop, dat daarbovenop, jullie het
gevoel van trots ook projecteren op jullie zélf; per slot van rekening zijn júllie diegenen
die me altijd gestimuleerd hebben. Door dit proefschrift onder andere aan jullie op te
dragen hoop ik dat jullie je even opnieuw zo voelen als bij de geboorte van jullie
kleindochter! ;-)
Lieve Alexander, zoals je zo mooi op onze bruiloft verwoordde dat je je nooit zorgen
hebt hoeven maken om mij, zo denk ik dat je er ook vanuit ging dat het me wel zou
lukken te promoveren. Laat ik je bedanken voor je immense vertrouwen en je
meteen ook weer uit de droom helpen door je te vertellen dat ik zelf de nodige twijfels
heb gehad. Alleen ook mede door jouw steun en interesse is het me inderdaad gelukt.
Ik ben dan ook blij dat je me tot de laatste minuut van deze promotie wilt bijstaan en
wil je speciaal bedanken door je als mijn paranimf te kiezen. Fantastisch dat je zo
nauwkeurig een deel van dit manuscript hebt nagekeken en voorzien van zeer goed
commentaar! Dank hiervoor!
Lieve Marieke, hoewel ik jou eigenlijk pas halverwege het werk voor dit proefschrift
ontmoette, lijkt het of we toch de hele bevalling samen hebben gedaan. Jouw directe
steun, interesse, medeleven, vertrouwen en geduld werkten stimulerend en waren
zelfs onmisbaar. Eigenlijk zijn we samen bezig geweest met twee bevallingen tegelij-
kertijd en moet ik met enige jaloezie, maar zeker ook enorme trots toegeven, dat de
bevalling waar jij het hardst voor hebt gewerkt verreweg het mooiste resultaat heeft
opgeleverd. Het is onmogelijk dat resultaat te overtreffen met hetgeen ik bij míjn
bevalling heb weten te fabriceren! Uit liefde en met trots draag ik dan ook mijn proef-
schrift op aan mijn allerliefste dames.
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the vascular tree “treatment from trunk-to-end-sites”
Datum en tijd
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Ter plaatse na afloop van de promotie
Paranimfen
Alexander Martens
06 - 51 50 89 98
vis_42@hotmail.nl
Bob Scheffer
06 - 24 65 72 29
rch.scheffer@tiscali.nl
Fabrice Martens
Wulverhorstlaan 14
3525 EC Utrecht
fabrice.martens@wolmail.nl
Fabrice M.A.C. Martens
Vasoreactivity, Inflammation and 
vascular effects of Thiazolidinediones 
in Insulin resistance
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